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Abstract 
Membranoproliferative glomerulonephritis (MPGN) and C3 glomerulopathy (C3G) are 
rare diseases that associate with dysregulation of the alternative pathway (AP). The 
earliest abnormalities associated with these diseases were C3 nephritic factor and also 
rare genetic variants in the gene CFH that caused factor H (FH) deficiency. Since then, 
other acquired and genetic abnormalities in AP have been reported in MPGN and C3G. 
The aim of this project was to screen cohorts of MPGN and C3G for such abnormalities. 
Screening for rare sequence variants in genes encoding proteins involved in AP activity in 
two cohorts revealed a low prevalence of genetic abnormalities. Compared to the 
prevalence of C3 nephritic factor and autoantibodies to complement proteins, it was clear 
that the predominant abnormalities in these cohorts were acquired. 
Though few, rare genetic variants identified in CFH were studied in functional studies. 
The first was identified in a case of familial MPGN in the N-terminal domain of CFH. 
Functional studies included surface plasmon resonance and haemolytic assays to study a 
mutant protein in the setting of a short fragment comprising the N-terminal domain of 
FH. This initial study confirmed loss of function in a familial variant and formed the basis 
for further studies. 
In studies of eight other variants identified in MPGN and C3G and two other diseases that 
share complement risk factors, only two variants were likely to be functionally significant 
as demonstrated by complete loss of function. This highlights the need for such studies to 
correctly identify important variants. The significant functional effects initially identified 
in studies using short fragments were then confirmed in studies using full length protein. 
The significance of rare genetic variants in CFH needs to be considered even though 
MPGN and C3G are largely an autoimmune phenomenon. 
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Chapter 1 - Introduction 
The complement system comprises an integrated network of proteins that forms part of the 
innate immune system. The ability of the complement system to discriminate between foreign 
and host cells is critical to maintain health. Dysregulation of the alternative pathway of 
complement leads to damage of host cells and is associated with several renal diseases. 
Greater understanding of this pathway and the abnormalities that lead to dysregulation of the 
alternative pathway can improve treatment and prognosis in these diseases. The focus of this 
thesis is the identification and study of abnormalities of the complement system in these 
complement-mediated renal diseases. 
 
1.1 The Complement System 
The complement system comprises three activation pathways that generate C3b via C3 
convertases. These lead to amplification of complement and activation of the terminal 
pathway. Host cells are protected from complement by a number of regulatory proteins. A 
simplified overview highlighting the interplay between complement activation pathways, the 
amplification loop and terminal pathway and a number of regulatory proteins is summarised 
in Figure 1 (Walport, 2001a; Walport, 2001b; Ricklin et al., 2010). 
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Figure 1 The complement system 
Adapted from Oxford Textbook of Medicine, 6th Edition. The activation pathways generate C3b leading to amplification of 
complement via the C3 convertase, C3bBb. This leads to generation of a C5 convertase (C3bBbC3b), which cleaves C5 and 
activates the terminal pathway. Circulating and membrane-bound proteins can regulate complement at the level of the 
amplification loop and also inhibit MAC. Eculizumab is the only licensed complement inhibitor drug available. It inhibits the 
cleavage of C5. FB=complement factor B, FH=complement factor H, FI=complement factor I, MAC=membrane attack 
complex. 
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1.1.1 Classical Pathway 
The classical pathway (CP) is activated by antibody-antigen immune complexes binding to 
C1q. In a calcium-dependent process, C1q binds C1r and C1s and cleaves C4 into its subunits 
C4a and C4b and cleaves C2 into C2a and C2b. Both C4a and C2b are released, leaving C2a 
to bind to C4b to form the C3 convertase of the classical pathway (C4bC2a). This convertase 
then cleaves C3 into C3a and C3b (Wallis et al., 2010). 
 
1.1.2 Lectin Pathway 
The lectin pathway is activated by carbohydrate residues present on the cell surfaces of 
certain pathological organisms including bacterial and fungal organisms. These are 
recognised by proteins collectively known as pattern recognition molecules such as mannose-
binding lectin (MBL). MBL then aggregates with MBL-associated serine protease (MASP) to 
form a complex that then cleaves C2 and C4 resulting in the formation of C4bC2a and the 
generation of C3b (Wallis et al., 2010). 
 
1.1.3 Alternative Pathway 
The alternative pathway (AP) is the most ancient of the three complement pathways and is 
continually active due to ‘tickover’. Tickover is a process in which C3 spontaneously 
hydrolyses leading to a structural change exposing the thio-ester domain of C3, in the form 
C3(H2O) (Pangburn et al., 1981). C3(H2O), structurally similar to C3b, binds complement 
factor B (FB) to form an intermediate proconvertase (C3b(H2O)B) that is cleaved by 
complement factor D (FD) to form an initial C3 convertase (C3b(H2O)Bb) that cleaves C3 
into C3a and C3b and deposits small amounts of C3b onto cell surfaces. On host cells, this 
initial surface bound C3b is inactivated by regulatory proteins. 
Surface bound C3b on foreign cells binds FB to form a proconvertase (C3bB) which is 
cleaved by FD, to form the surface bound C3 convertase of the AP (C3bBb) (Forneris et al., 
2010). Surface bound C3bBb is a short-lived complex with a half-life of about 90s (Pangburn 
and Muller-Eberhard, 1986). C3bBb can be stabilised by properdin (Fearon and Austen, 
1975). C3bBb cleaves C3 and releases C3b to complete an efficient amplification loop thus 
increasing the density of C3b deposition. Eventually, C3b binds C3bBb to form a C5 
convertase (C3bBbC3b).  
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1.1.4 Regulators of the AP C3 convertase 
Regulators of C3bBb are present on the surface of host cells and in the fluid phase. 
Complement factor H (FH) is a regulator of C3bBb in the fluid phase that can be recruited to 
host surfaces via recognition domains (Schmidt et al., 2008a). The membrane-bound 
regulators include membrane co-factor protein (CD46, MCP) (Seya and Atkinson, 1989), 
decay accelerating factor (DAF, CD55) (Kim and Song, 2006) and complement receptor 1 
(CR1, CD35) (Khera and Das, 2009). 
C3bBb decay can be accelerated by FH, CR1 or DAF (Hourcade et al., 2002). Inactivation of 
C3b into iC3b by complement factor I (FI) results in a degradation product that is unable to 
bind FB (Lambris et al., 1996). The FI-mediated proteolysis of C3b requires a co-factor, such 
as FH, CD46 or CR1. C4-binding protein (C4BP) can also bind C3b and act as a co-factor for 
FI-mediated inactivation of C3b (Blom et al., 1999). 
 
1.1.5 Terminal complement pathway 
The formation of C3bBbC3b results in the cleavage of the complement component C5 and 
activates the terminal pathway. This results in the release of the anaphylatoxin C5a into the 
circulation. Meanwhile, C5b binds C6, C7, C8 and C9 to form the membrane attack complex 
(MAC) and initiate cell lysis (Bubeck, 2014). Regulators of this pathway include CD59, a 
membrane-bound protein that prevents polymerisation of C9 in the formation of MAC 
(Farkas et al., 2002). Eculizumab, the only licensed complement inhibitor approved for 
clinical use, binds C5 and prevents its cleavage by C3bBbC3b (Rother et al., 2007). 
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1.2 Membranoproliferative Glomerulonephritis and C3 Glomerulopathy 
Membranoproliferative glomerulonephritis (MPGN), dense deposit disease (DDD), C3 
glomerulonephritis (C3GN) and CFHR5 nephropathy are rare renal diseases that associate 
with dysregulation of the AP. These classifications are based upon pathological appearances 
on renal biopsy. The diseases DDD, C3GN and CFHR5 nephropathy are collectively known 
as C3 glomerulopathy (C3G). 
 
1.2.1 MPGN 
Membranoproliferative glomerulonephritis (MPGN) is a pathological term describing a 
pattern of glomerular injury seen on light microscopy. It is characterised by mesangial 
expansion, cellular proliferation and double contouring of basement membrane (Sethi and 
Fervenza, 2012). It is associated with immunoglobulin (Ig) and complement deposition. The 
classification of MPGN was historically based upon the position of electron dense deposits 
relative to the glomerular basement membrane. Three types of MPGN were defined in this 
manner, type 1 (subendothelial), type 2 or DDD (intramembranous) and type 3 
(subendothelial and subepithelial) (Anders and Thoenes, 1975). Type 1 and type 3 MPGN 
typically stained positive for Ig and complement on immunofluorescence whereas type 2 
MPGN typically stained for complement only. Low C3 levels associate with all types of 
MPGN. Associations with low C4 and a C3 nephritic factor, suggestive of a different 
underlying causes of a low C3 via classical pathway and alternative pathway activation 
respectively, do not exclusively associate with individual types of MPGN, 1, 2 or 3 (Rennke, 
1995) (Table 1). 
A revised classification (Sethi and Fervenza, 2011) of MPGN based on the presence or 
absence of Ig on immunofluorescence was suggested. In MPGN, the presence of Ig (an 
immune-complex MPGN or IC-MPGN) would suggest complement deposition via the 
classical pathway and prompt the clinician to search for an underlying secondary cause 
(Table 2). The absence of Ig would be suggestive of a disorder of AP regulation leading to 
complement deposition such as the presence of a C3 nephritic factor (Masani et al., 2014). 
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 MPGN Type 1 MPGN Type 2 MPGN Type 3 
Position of 
Electron Dense 
Deposits 
Sub-endothelial Intramembranous 
Sub-endothelial and 
sub-epithelial 
C3 deposition Present Present Present 
Ig deposition Typically present Often absent Typically present 
Low complement 
levels 
Usually C3 and C4 
Sometimes low C3 only 
Usually low C3 only 
Usually C3 and C4 
Sometimes low C3 only 
C3 Nephritic 
Factor 
Sometimes present Usually Present Sometimes present 
Table 1 Historical classification of MPGN 
Clinical and pathological characteristics of MPGN type 1, 2 and 3 are summarised. 
 
1.2.2 C3 Glomerulopathy 
In 2007, a new pathological entity of primary glomerulonephritis with isolated C3 deposits 
was identified (Servais et al., 2007). Abnormalities of AP were identified in this group of 
patients and not restricted to those who had an MPGN pattern of glomerular injury. This led 
to the introduction of the term C3 glomerulopathy. C3G was initially defined as ‘glomerular 
pathology characterized by C3 accumulation with absent or scanty immunoglobulin 
deposition’ (Fakhouri et al., 2010a). This classification has evolved since its initial 
introduction and the most recent interpretation was described in the C3 glomerulopathy 
consensus report (Pickering et al., 2013). The introduction of the term was to alert the 
clinician to a group of diseases in which dysregulation of the AP was likely. DDD, C3GN 
and CFHR5 nephropathy are all forms of C3G. 
 
 
7 
 
Autoimmune diseases Infections Paraproteinemias 
Systemic lupus Hepatitis B 
Monoclonal gammopathy of 
undetermined significance 
Sjogren’s syndrome Hepatitis C 
Waldenstrom 
macroglobulinaemia 
Rheumatoid arthritis Endocarditis Chronic lymphocytic leukaemia 
Mixed connective tissue disease Shunt infections Low-grade B-cell lymphoma 
 Visceral abscesses Cryoglobulinaemia type 1 and 2 
 Leprosy Immunotactoid glomerulopathy 
 Malaria 
Monoclonal Ig deposition 
disease 
 Schistosomiasis Fibrillary glomerulopathy 
 Mycoplasma  
Table 2 Secondary causes of MPGN 
Adapted from Masani et al (Masani et al., 2014). Chronic circulating antigen from numerous causes is thought to result in 
classical pathway activation and the appearance of immune-complexes in MPGN (type 1, 3 or immune-complex MPGN). 
 
According to the C3G consensus report, a diagnosis of C3G should be considered if there is 
dominant C3 deposition, where dominant is defined as C3 intensity ≥2 orders of magnitude 
more than any other immune reactant on a scale of 0 to 3 (including 0, trace, 1+, 2+, 3+) 
(Pickering et al., 2013). The presence of Ig staining on biopsy does not exclude C3G 
(Pickering et al., 2013; Hou et al., 2014). Light microscopy may show one of several patterns 
of glomerular injury, but usually membranoproliferative glomerulonephritis or mesangial 
proliferative glomerulonephritis (Hou et al., 2014). 
Dense deposit disease (DDD) is a term defined by the laminar electron dense deposits within 
the glomerular basement membrane and was and considered a form of MPGN (type 2) 
(Habib et al., 1975). However, only 25% of cases with DDD have an MPGN pattern of 
glomerular injury (Fogo and Kashgarian, 2005; Walker et al., 2007). The most common 
pattern of glomerular injury is mild mesangial cell hypercellularity in approximately 45% of 
cases of DDD. Other patterns of injury include a crescentic pattern (approximately 18%) or 
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an acute proliferative and exudative pattern (12%) (Walker et al., 2007). DDD is currently 
considered a form of C3G and not a form of MPGN. Cases of C3G that do not fulfil the 
diagnostic criterion for DDD are termed C3GN. 
CFHR5 nephropathy is a distinct form of C3GN (Gale et al., 2010). Two large families of 
Cypriot patients with renal disease had distinct characteristics of persistent microscopic 
haematuria and synpharyngytic macroscopic haematuria. Biopsy appearances were consistent 
with C3GN and MPGN. Further genetic studies identified an internal duplication of exons 2 
and 3 of CFHR5 in affected family members. This led to the expression of a novel FHR5 
protein. This inherited form of C3GN was subsequently reported in a total of 91 patients from 
16 pedigrees of Cypriot descent (Athanasiou et al., 2011). CFHR5 nephropathy has since 
been identified in a family of non-Cypriot descent (Medjeral-Thomas et al., 2014a). 
 
1.2.3 Overlap of MPGN and C3G 
The classification and aetiology of MPGN and C3G overlap (Sethi et al., 2012b). Patients 
with an MPGN pattern of glomerular injury can also have C3G, defined by dominant C3 
deposition. In cases of MPGN without dominant C3 deposition, an underlying secondary 
cause should first be considered. This is applicable to patients with IC-MPGN and those 
previously classified as MPGN type 1 or 3. The possibility of an underlying abnormality of 
AP can then be considered in cases of C3G and types of MPGN in which no secondary cause 
can be found (Figure 2). In this thesis, I shall refer to cohorts that include either of these 
pathological entities as MPGN/C3G, in which abnormalities of AP should be considered. 
 
1.2.4 Epidemiology of MPGN/C3G 
All forms of MPGN/C3G are rare. The exact incidence of MPGN is unknown but is in the 
order of 1- 4 cases per million (West, 1992; Briganti et al., 2001). The incidence of C3G in a 
recent study was estimated at 1-2 cases per million (Medjeral-Thomas et al., 2014b) and 
similar for DDD (Appel et al., 2005). These diseases, especially DDD are a disease of 
childhood and young adulthood (Servais et al., 2012; Medjeral-Thomas et al., 2014b). 
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1.2.5 Clinical Features of MPGN/C3G 
Patients with MPGN/C3G have similar clinical features (excepting CFHR5 nephropathy as 
described above). Presenting features include proteinuria, haematuria and renal failure 
(Servais et al., 2012; Medjeral-Thomas et al., 2014b). Renal failure is progressive and 40% 
of patients develop end-stage renal disease (ESRD) at 10 years (Cansick et al., 2004; Servais 
et al., 2012; Medjeral-Thomas et al., 2014b). Recurrence in transplantation is common in all 
types, ranging from 30-40% in MPGN type 1 to 80-90% in DDD (Braun et al., 2005). Plasma 
C3 levels are often low (Varade et al., 1990; Servais et al., 2012; Medjeral-Thomas et al., 
2014b; Iatropoulos et al., 2016). Several extra-renal manifestations also associate with 
patients in these cohorts and are described section 1.4.5. 
 
 
Figure 2 Current overview of MPGN and C3 Glomerulopathy 
Once secondary causes (table 3) have been excluded, an abnormality of AP should be considered in MPGN and C3G. In 
these overlapping conditions, C3 deposition is usually present. MPGN is shown in dashed circle and includes IC-MPGN (Ig 
and C3 deposition - Green) and C3G (Dominant C3 deposition). C3G is shown in large circle (pink) any can associate with 
an MPGN pattern of glomerular injury. Specific forms of C3G include C3GN, DDD and CFHR5 nephropathy. 
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1.3 Complement Abnormalities in MPGN/C3G 
A number of abnormalities of AP that have been described in MPGN/C3G are summarised in 
Figure 3. Uncontrolled activation of the AP in the fluid phase due to C3 nephritic factor 
(Spitzer et al., 1969) and FH deficiency have been associated with MPGN for over 30 years 
(Levy et al., 1986). In recent studies, the C3 nephritic factor remains a common finding in 
patients with MPGN/C3G, especially those with DDD (Servais et al., 2012; Zhang et al., 
2012). Autoantibodies against other complement components (Strobel et al., 2010; Goodship 
et al., 2012) have also been described. 
Studies describing rare genetic variants in genes encoding proteins of the AP have been 
reported in cohorts of MPGN/C3G. The prevalence of rare genetic variants in CFH, CFI or 
CD46 was 17.9% in a French cohort of MPGN/C3G patients (Servais et al., 2012). In cohorts 
screened for rare genetic variants in CFH, CFI, CD46, C3 and CFB, the prevalence ranged 
from 18% in an Italian cohort of MPGN/C3G (Iatropoulos et al., 2016) to 43.3% in an 
American cohort of C3G (Bu et al., 2015). Individual complement abnormalities have not 
been associated with a greater risk of adverse outcomes (Servais et al., 2012; Medjeral-
Thomas et al., 2014b) although the absence of a C3 nephritic factor or a rare genetic variant 
in an Italian cohort did have a higher risk of progression to ESRD (Iatropoulos et al., 2016). 
These abnormalities and others are described in more detail below. 
 
 
Figure 3 Abnormalities of alternative pathway in MPGN/C3G 
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1.3.1 Complement Factor H 
Complement factor H (FH) is a single chain, 155kDa glycoprotein that is organised into 20 
repetitive subunits called short consensus repeats (SCR) each of ~ 60 amino acids (Ripoche et 
al., 1988). FH regulates the AP in the circulation and on cell surfaces via regulatory and 
recognition domains that are localised to specific SCRs shown in Figure 4 (Schmidt et al., 
2008b). In order to regulate AP, FH binds C3b and acts as a co-factor for the FI-mediated 
proteolytic cleavage of C3b into iC3b and accelerates the decay of the C3bBb. These 
regulatory effects of FH are mediated via its N-terminal domains (SCR1-4) (Wu et al., 2009). 
 
 
Figure 4 The CFH gene, FH and FHL-1 
The schematic of the CFH gene is taken from (Rodriguez de Cordoba et al., 2004). FH is encoded by the gene, CFH, shown 
above comprising 23 exons. FHL-1 is an alternatively spliced protein, encoded by CFH. Exons 1-9 are common to both 
proteins. Exon 10 encodes a C-terminal 4 amino acid tail and a stop codon. Exons 11-23 encode FH only. 
 
The regulatory functions of FH can be recruited to host surfaces via binding domains in 
SCR6-8 and the C-terminus of FH in SCR19-20. Differences in these two binding domains 
for glycosaminoglycans (GAGs), polyanions and C3b infer specificity of these regions to 
different host tissues (Clark et al., 2013). The domain in SCR6-8 has specificity for Bruch’s 
membrane within the eye (Clark et al., 2013). The domain in SCR19-20 has specificity for 
tissues bearing GAGs and sialic acids, localising FH to the glomerular endothelium via a 
second main C3b binding site (Ferreira et al., 2009; Morgan et al., 2011). Furthermore, FH 
appears to be able to bind to C3b simultaneously via SCR1-4 and SCR19-20 (Morgan et al., 
2011). 
Functional studies of disease-associated genetic variants in CFH have a predilection to these 
three domains (Sanchez-Corral et al., 2002; Ferreira et al., 2009; Wong et al., 2014; Yu et al., 
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2014; Recalde et al., 2015). Two domains in particular SCR1-4 and SCR19-20 are the focus 
of functional studies that I will be describing later in this thesis. 
Interactions of FH to other proteins have previously been identified and include the lipid 
peroxidation product malondialdehyde (Weismann et al., 2011), C-reactive protein (Sjoberg 
et al., 2007), pentraxin  3 (Kopp et al., 2012), adrenomedullin (Pio et al., 2001), as well as 
necrotic cells (Sjoberg et al., 2007). Furthermore, proteins that bind FH have been 
synthesised by micro-organisms allowing them to hijack FH and evade the activity of the 
complement system. The number of organisms that have developed these strategies is vast 
and includes Streptococcus (Horstmann et al., 1988) and Meningococcus (Malito et al., 
2013). 
A lack of FH leads to uncontrolled activation of AP in the fluid phase (Thompson and 
Winterborn, 1981) and associates with a phenotype that includes MPGN or C3G in both 
human (Levy et al., 1986; Dragon-Durey et al., 2004; Servais et al., 2007) and animal studies 
(Hegasy et al., 2002; Pickering et al., 2002). Screening of cohorts of MPGN/C3G identifies 
rare genetic variants in CFH in 4-16.2% of patients (Servais et al., 2012; Bu et al., 2015; 
Iatropoulos et al., 2016). In some cases but not all, these associate with low FH levels. In 
other cases, where FH levels are normal, functional testing of a variant is required to confirm 
their significance in disease (Kavanagh and Anderson, 2012). 
Functional studies of rare genetic variants identified in CFH in MPGN/C3G are rare and 
include the study of the significant disease-associated variants delK224 (Licht et al., 2006) 
and R1210C (Recalde et al., 2015). A detailed discussion of rare genetic variants in 
MPGN/C3G forms part of chapter 5 of this thesis. 
Common single-nucleotide polymorphisms (SNPs) in CFH have been studied in cohorts of 
MPGN/C3G (Table 3). In DDD, the Y402H polymorphism (Abrera-Abeleda et al., 2006; 
Abrera-Abeleda et al., 2011; Servais et al., 2012) associates with an increased risk of disease. 
Conversely, the V62I polymorphism was shown to be protective against DDD (Pickering et 
al., 2007; Iatropoulos et al., 2016). 
Risk haplotypes in CFH (Pickering et al., 2007) (Table 4) also associate with disease. The H1 
haplotype that carries the at–risk Y402H SNP in DDD associates with an increased risk of 
DDD (Abrera-Abeleda et al., 2006; Pickering et al., 2007). The H2 haplotype that carries the 
protective SNP V62I was shown to be protective in DDD (Pickering et al., 2007). 
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These two SNPs that associate with increased risk of disease have been functionally studied. 
The V62 variant is less effective in co-factor activity compared to I62 resulting in greater AP 
activity (Tortajada et al., 2009; Pechtl et al., 2011). The Y402H variant does not associate 
with any effect on AP activity (Francis et al., 2012) but there is an effect on tissue 
recognition within Bruch’s membrane (Clark et al., 2010; Clark et al., 2013). 
 
SNP Amino Acid Change Db SNP identifier MAF (%) 
c.-331C>T N/A rs3753394 26.21 
c.184G>A V62I rs800292 22.12 
c.1204T>C Y402H rs1061170 38.22 
c. 2016A>G Q672Q rs3753396 17.32 
c.2808 G>T E936D rs1065489 17.52 
Table 3 Common SNPs defined in CFH haplotypes 
Db SNP = Single Nucleotide Polymorphism Database, MAF = minor allele frequency, % = percentage values taken from 1 
http://www.1000genomes.org/ for non-coding or 2European-American population of evs.gs.washington.edu. for coding 
regions. N/A = not applicable. 
 
 c.-331C>T c.184G>A c.1204C>T c. 2016A>G c.2808 G>T Frequency (%) 
HI C G C A G 22.8 
H2 C A T A G 26.6 
H3 T G T G T 19.2 
H4 C G T A G 16.7 
H5 T G C A G 7.5 
H6 C G T G T 3.9 
Table 4 Common CFH haplotypes (H1 to H6) 
Frequency of CFH haplotypes (%) percentage values taken from (Pickering et al., 2007) 
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1.3.2 RCA Gene Cluster 
The CFH gene is within the regulators of complement activation (RCA) gene cluster on 
chromosome 1q32 (Rodriguez de Cordoba et al., 2004) and encodes the 20 SCR FH protein 
and an alternatively spliced gene product FHL-1 (Figure 4). FHL-1 is identical to the first 7 
SCRs of FH before the alternatively spliced transcript translates into a C-terminal 4 amino 
acid tail and the introduction of a stop codon, leading to the truncated protein (Figure 4). 
A number of other genes within this cluster arose as a series of genetic duplications resulting 
in the formation of several genes that have a high sequence homology to CFH, known as 
CFH-related (CFHR) genes 1-5 (Figure 5). They encode the FH-related (FHR) proteins 1-5. 
The characteristics of FHL-1 and the FHR proteins are summarised in Table 5. Estimations of 
serum concentration of the FHR proteins are consistently lower than those of FH (Timmann 
et al., 1991; Heinen et al., 2009; Skerka et al., 2013). 
 
 
Figure 5 CFH and CFHR genes 
Adapted from (Heinen et al., 2006). Coloured boxes represent regions of sequence duplication. 
 
The N-terminal regulatory domains of FH are shared by FHL-1 but not the FHR proteins. The 
roles of FHL-1 and the FHR proteins are not completely known though a role for FHL-1 in 
maintaining health within Bruch membrane has been postulated (Clark et al., 2014). 
Although the FHR proteins do not contain the regulatory domains of FH, some studies report 
complement regulatory activity for FHR3 and FHR4 (Hellwage et al., 1999) and FHR5 
(McRae et al., 2005). Other possible complement regulatory roles have been suggested via 
inhibition of C3 convertase by FHR2 (Eberhardt et al., 2013) and FHR5 (McRae et al., 2005) 
and C5 convertase by FHR1 (Heinen et al., 2009). 
  
    
1
5
 
 SCRs 
Glycosylated 
forms 
Size (kDa) Suggested complement regulatory roles Reference 
FHR1 5 2 
1β - 42 
1α - 37 
Regulates C5 convertase (Heinen et al., 2009) 
FHR2 4 2 
24 
28 
Regulates C3 convertase (Eberhardt et al., 2013) 
FHR3 5 4 35-56 Weak co-factor activity (Hellwage et al., 1999) 
FHR4 
4A 9 
4B 5 
2 
4A 86 
4B 45 
Weak co-factor activity 
Stabilises C3 convertase 
(Hellwage et al., 1999; 
Hebecker and Jozsi, 2012) 
FHR5 9 1 62 
Weak co-factor  and decay activity 
Regulates C3 convertase 
(McRae et al., 2005) 
Table 5 Characteristics of FHR proteins 
Not shown in this table is that FHR 1,2 and 5 have been identified in serum in dimeric form. Studies of these proteins suggest a complement de-regulatory role (Goicoechea de Jorge et al., 
2013).  
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More recent studies suggest that the FHR proteins may compete with FH for C3b binding and 
prevent the regulatory activities of FH on surface-bound C3b (Goicoechea de Jorge et al., 
2013). SCR1 and 2 of FHR1, 2 and 5 have a very high degree of sequence homology (Figure 
6) and share a structure that allows dimerization. These studies show that these FHR proteins 
exist in dimeric form. The avidity of these dimeric forms of FHRs enables them to act as 
competitive antagonists, preventing the normal regulatory function of FH and therefore 
‘deregulating FH’ (Goicoechea de Jorge et al., 2013). 
Due to the high degree of sequence homology, the CFH-CFHR gene region is prone to 
genomic abnormalities such as genetic rearrangements, insertions and deletions (Lupski and 
Stankiewicz, 2005). One frequently observed abnormality is the CFHR3/1 gene deletion. The 
allele frequency of the CFHR3/1 gene deletion ranges from 0% to 54.7% depending upon the 
geographical location of the cohort studied (Holmes et al., 2013). The allele frequency in the 
United Kingdom of the CFHR3/1 deletion has reported between 6.3% and 18.4% (Zipfel et 
al., 2007; Holmes et al., 2013). In the largest study of a UK cohort of 505 patients, this 
frequency was 17.3% (Moore et al., 2010). 
 
Figure 6 FH, FHL-1 and FHR proteins have a high degree of sequence homology 
Coloured ovals denote regulatory and recognition domains of FH. Percentages shown within ovals indicate degree of 
homology shared with corresponding SCR of FH depicted directly above. FHR4 is a 9-SCR protein shown on two rows. In 
boxed inset, percentages along lines indicate degree of shared homology between SCR1 and 2 of FHR1, 2 and 5. 
 
A number of genomic abnormalities in this region have been described in familial cases of 
C3G (Table 6). In all cases, the genomic abnormality resulted in the formation of a larger 
CFHR gene resulting in FHR proteins with additional SCRs. Functional study of dimeric 
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forms of abnormal FHR proteins demonstrated an enhanced ability to compete with FH 
resulting in enhanced deregulation of FH as a possible mechanism of disease. (Goicoechea de 
Jorge et al., 2013; Tortajada et al., 2013). In the case of the FHR212FHR5 hybrid protein, 
functional studies showed evidence of stabilisation of C3bBb in the presence of the hybrid 
FHR212FHR5 protein resulting in complement activation in the fluid phase (Chen et al., 
2014) and most recently a possible role in binding properdin (Chen et al., 2015). 
Rare genetic variants in CFHR5 have also been reported in C3GN and include C269R 
(Besbas et al., 2014) and N216P (Sethi et al., 2012a). The functional significance of either 
variant has yet to be determined. 
 
Abnormal FHR 
protein 
Phenotype Effect Reference 
FHR212FHR5 DDD Stabilises C3bBb 
(Chen et al., 2014; Chen et al., 
2015) 
FHR512FHR5 CFHR5 nephropathy De-regulates FH 
(Gale et al., 2010; Goicoechea de 
Jorge et al., 2013) 
FHR512FHR12 C3GN Not known (Zhang et al., 2013b) 
FHR11234FHR1 Low C3 De-regulates FH (Tortajada et al., 2013) 
FHR312FHR1 C3GN De-regulates FH 
(Malik et al., 2012; Goicoechea de 
Jorge et al., 2013) 
Table 6 Abnormal FHR proteins described in C3G 
 
1.3.3 Complement Factor I 
Complement Factor I (FI) is a glycoprotein, 88kDa in size. It is a serine protease that cleaves 
the α-chain of C3b and C4b. Cleavage of the α-chain of C3b irreversibly inactivates C3b and 
prevents its entry into the amplification loop of the AP, and requires co-factors that include 
FH (Pangburn et al., 1977) and CD46 (Liszewski et al., 1991). It is composed of a heavy 
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chain and a light chain – the active catalytic site is contained within the light chain (Roversi 
et al., 2011). 
In studies of MPGN/C3G, a total of 10 rare genetic variants in CFI have been reported in four 
cohorts of MPGN/C3G (Table 7) (Servais et al., 2012; Sethi et al., 2012a; Bu et al., 2015; 
Iatropoulos et al., 2016). Not all variants lead to impairment of FI levels or function. The 
significance of some variants is unknown. 
 
Variant Disease Effect Reference 
c.1-4C>T C3GN Unknown (Iatropoulos et al., 2016) 
G57D DDD Unknown (Iatropoulos et al., 2016) 
G119R MPGN1 Low FI levels 
(Bienaime et al., 2010; Servais et al., 2012; 
Kavanagh et al., 2015) 
A240G C3GN Impaired Secretion (Nilsson et al., 2010; Servais et al., 2012) 
G261D C3GN Normal function 
(Nilsson et al., 2007; Servais et al., 2012; Sethi 
et al., 2012a) 
I306S C3GN Normal function (Servais et al., 2012) 
C309R MPGN1 Low FI levels (Servais et al., 2012) 
C327R MPGN1 Low FI levels (Servais et al., 2012) 
Not stated* C3GN 
DDD 
Unknown (Bu et al., 2015) 
Table 7 Rare CFI variants in MPGN and C3G identified in literature 
MPGN1 = MPGN type 1, * two variants not stated in paper. 
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1.3.4 Membrane Co-factor Protein - CD46 
Membrane-cofactor protein (CD46) is a cell surface bound regulator of complement and 
comprises a transmembrane domain and 4 extracellular SCRs. Like FH, it acts as a co-factor 
for the FI-mediated proteolytic cleavage of C3b but it does not have any decay activity 
(Liszewski et al., 1991). 
Rare genetic variants in CD46 have rarely been reported in MPGN/C3G and include the 
variants K66N (Iatropoulos et al., 2016) and V181M (Servais et al., 2012). 
Common SNPs (Table 8) and haplotypes (Table 9) in CD46 have been studied in cohorts of 
MPGN/C3G. The intronic SNP c.-652G was protective in MPGN and C3GN. This 
association was also observed in cases of MPGN type 1 and C3GN, in which the haplotype 
CD46AAGGT that was observed more frequently, whist the haplotype CD46GAGGT was 
observed less frequently (Servais et al., 2012). These findings were not observed in a later 
study (Iatropoulos et al., 2016). In this later study, the SNPs c.-366A>G and c. *4070T>C 
were observed more frequently in IC-MPGN than controls (Iatropoulos et al., 2016). In the 
same later study, the SNP c.-366A was observed more frequently in DDD compared to 
controls (Iatropoulos et al., 2016). 
 
SNP Db SNP identifier MAF (%) 
c.-652A>G rs2796267 39.1 
c.-366A>G rs2796268 36.4 
IVS9 -78G rs1962149 29.3 
IVS12 +638G rs859705 31.7 
c.*4070T>C rs7144 34.7 
Table 8 SNPs that define common CD46 haplotypes 
Db SNP = Single Nucleotide Polymorphism Database, MAF – minor allele frequency % percentage values taken from 
http://www.1000genomes.org/. 
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 -652G>A -366A>G IVS9 -78G IVS12 +638G *4070T>C Frequency 
CD46 1 A A G G T 0.5 
CD46 2 G G A A C 0.25 
CD46 3 G A G G T 0.12 
CD46 4 A G A A C 0.09 
Table 9 Common CD46 haplotypes 
Frequency of CD46 haplotypes taken from (Servais et al., 2012.) 
 
1.3.5 Components of the AP C3 Convertase - C3 and FB 
Complement component C3 is a 186kDa protein that comprises an α- and β- subunit. It is 
cleaved by C3 convertases, releasing a 9kDa anaphylatoxin, C3a and undergoes 
conformational change to C3b thus exposing the thioester domain and allowing binding to 
cell surfaces (Janssen et al., 2006). Complement factor B (FB) is a 90kDa protein that 
comprises 3 SCR domains, a Von Willebrand type A domain (VWA) and a serine protease 
domain (Milder et al., 2007). FB binds to C3b to form C3bB. A linker region between the 
SCR domains and the VWA domain is then cleaved by FD, releasing Ba and resulting in the 
formation of C3bBb, the key molecule in the amplification loop of AP (Forneris et al., 2010). 
Key regulators of this interaction include FH, FI and CD46. FH accelerates the natural decay 
of C3bBb. FH and CD46 act as co-factors for the FI-mediated proteolytic cleavage of the α-
chain of C3b. 
Detailed functional studies of several familial rare genetic variants in C3 in MPGN/C3G have 
been described. In a case of familial DDD, the variant Δ923-924 does not undergo 
conformational change to C3b but does form a C3 convertase that is resistant to decay by FH 
(Martinez-Barricarte et al., 2010). In a report of familial C3GN, the variant I756T results in 
defective C3b inactivation by FI in setting of co-factors CR1 and FH (Chauvet et al., 2015). 
Rare genetic variants have also been described in cohorts of MPGN/C3G in C3 (Table 10) 
and CFB (Table 11), and includes the S367R variant in CFB in 1 familial case of C3GN 
(Imamura et al., 2015). Most of these variants have not been functionally studied. 
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Variant Reference 
R148Q R161W1 A443S L1100P L1318R  (Bu et al., 2015) 
V86I R505C V619M G637R R1042Q K1051M2 
(Iatropoulos et al., 2016) 
S1063N R1303H R1320Q D1362N C1518R D1625H 
Table 10 Rare C3 variants in MPGN and C3G identified in literature 
Most rare variants in C3 in MPGN/C3G have not been functionally studied.  1 functionally significant, 2 not-functionally 
significant (Schramm et al., 2015). 
 
Several common SNPs in C3 and CFB have been studied in MPGN/C3G (Table 12). The 
SNPs, R102G (Finn and Mathieson, 1993; Abrera-Abeleda et al., 2011) and P314L in C3 are 
associated with DDD (Abrera-Abeleda et al., 2011). Functional studies of the SNPs in CFB, 
R32W and R32Q have been described (Marinozzi et al., 2014) but no significant association 
with MPGN/C3G was identified (Iatropoulos et al., 2016). 
 
1.3.6 Complotypes 
Increased AP activity has been demonstrated in functional studies for the SNPs R102G in C3 
and R32Q in CFB and I62V in CFH (Heurich et al., 2011). The effect of inheriting a 
combination of SNPs that conferred greater AP activity was studied. C3, FB and FH were 
depleted from serum and replaced with purified C3, FB and FH of specific polymorphic 
variants in a series of sheep erythrocyte haemolytic assays. It was found that using purified 
C3, FB and FH of the most active variants C3 102G, FB 32R and FH 62V, the haemolytic 
activity was 6x greater than if the less active variants C3 102R, FB 32Q and FH 62I were 
used (Heurich et al., 2011). Therefore inheriting certain polymorphisms or a complotype can 
lead to a more active complement system and may explain the association of some SNPs in 
MPGN/C3GN (Harris et al., 2012). 
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Variant Reference 
I242L1 (Bu et al., 2015) 
D279E2 (Bu et al., 2015) 
S367R3 (Imamura et al., 2015) 
G161R (Iatropoulos et al., 2016) 
H451R (Iatropoulos et al., 2016) 
R679W (Iatropoulos et al., 2016) 
Table 11 Rare CFB variants in MPGN and C3G identified in literature 
1had enhanced formation of C3 convertase but no evidence of enhanced haemolytic activity (Marinozzi et al., 2014), 2the 
D279G mutation was gain of function (Hourcade et al., 1999) (Marinozzi et al., 2014), 3familial. 
 
Gene SNP 
Amino acid 
change 
Db SNP ID MAF (%) 
C3 c.304C>G R102G rs2230199 20.9 
C3 c.941C>T P314L rs1047286 20.5 
CFB c.94C>T R32W rs641153 9.8 
CFB c.95G>A R32Q rs12614 8.7 
Table 12 Common polymorphisms in C3 and CFB associated with disease 
MAF = minor allele frequency, % = percentage values taken from http://evs.gs.washington.edu/ 
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1.3.7 C3 Nephritic Factor 
The earliest evidence of a C3 nephritic factor resulting in dysregulation of complement in 
MPGN was described in 1969 (Spitzer et al., 1969). A circulating factor in the serum was 
found to increase cell lysis in the fluid phase. This was later discovered to be IgG that 
stabilised C3bBb by 10-fold (Daha et al., 1976; Daha et al., 1977) now known as C3 
nephritic factor. There is a strong association of C3 nephritic factor with DDD, MPGN and 
C3GN and is prevalent in up to 80% of DDD and 50% of MPGN and C3G (Servais et al., 
2012; Zhang et al., 2012). There is also a genetic association of C3 nephritic factor with the 
C3 polymorphism, R102G (Finn and Mathieson, 1993). C3 nephritic factors are not specific 
to MPGN and C3G and have been observed in APL (Sissons et al., 1976) and in normal 
individuals (Gewurz et al., 1983). 
 
1.3.8 Autoantibodies to C3b and FB 
Autoantibodies to FB have been described in DDD. In one patient, these were shown to 
stabilise C3bBb, causing C3 consumption and terminal pathway activation (Strobel et al., 
2010). No functional data are available in a further report in which three DDD patients with 
autoantibodies to FB are described (Zhang et al., 2012). Autoantibodies to C3b and FB in the 
same patient were described in two cases of DDD. These patient lacked C3 nephritic factor 
but the antibodies enhanced C3bBb activity (Chen et al., 2011). 
 
1.3.9 Autoantibodies to FH 
Autoantibodies to FH have also been described in patients with MPGN/C3G. These bind 
predominantly to the N-terminal domain of FH (Goodship et al., 2012; Zhang et al., 2012). 
The prevalence of autoantibodies to FH was 11% in a MPGN/C3G cohort (Blanc et al., 
2015). In this cohort, patients with autoantibodies to FH did not associate with homozygous 
deletion of CFHR3/1. These autoantibodies associated with C3 nephritic factor in children 
and monoclonal gammopathy in adults (Blanc et al., 2015). The association of autoantibodies 
to FH and monoclonal gammopathy had been previously described in case reports (Meri et 
al., 1992; Zand et al., 2013). 
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1.4. Other Diseases Associated with MPGN/C3G 
1.4.1 Atypical Haemolytic Uraemic Syndrome 
Haemolytic uraemia syndrome (HUS) comprises the clinical trial of microangiopathic 
haemolytic anaemia, thrombocytopaenia and acute kidney failure (Kavanagh and Goodship, 
2011). Most cases are due to Shiga-like toxin. The remainder of cases of HUS are termed 
atypical. The incidence of atypical HUS (aHUS) in the United Kingdom is estimated to be 
0.2/million population (Sheerin et al., 2015). 
Over 50% of cases of aHUS are caused by abnormalities within the AP (Kavanagh et al., 
2013). Morbidity and mortality rates are high with 36% to 48% of children and 64% to 67% 
of adults dying or reaching ESRD within 3-5 years (Noris et al., 2010; Fremeaux-Bacchi et 
al., 2013; Kavanagh et al., 2013). The adverse clinical course of patients with aHUS can be 
stratified from extensive cohort studies (Table 13). Prognosis is best in patients with rare 
genetic variants in CD46. Risk of recurrence in renal transplantation is also high except in 
those with a rare genetic variant in CD46 and low anti-FH titres (Le Quintrec et al., 2013). 
Penetrance of disease is only 50% for CFH, CFI CD46 and CFB and slightly lower for C3 
(Bresin et al., 2013). Other factors required for the development of aHUS include inheritance 
of a risk haplotype (Esparza-Gordillo et al., 2005; Fremeaux-Bacchi et al., 2005) and a 
trigger. The more common triggers include diarrhoea (Sellier-Leclerc et al., 2007) and 
pregnancy (Fakhouri et al., 2010b). 
 
1.4.2 Genetic Abnormalities of the Complement System in aHUS 
Rare genetic variants in CFH are found in a quarter of all cases of aHUS (Noris et al., 2010; 
Fremeaux-Bacchi et al., 2013). The majority of disease-associated variants are localised to 
the C-terminal domain of CFH (Noris and Remuzzi, 2009). The consequence of many of 
these variants is impaired cell surface recognition and has been confirmed for a large number 
of variants in functional studies (Sanchez-Corral et al., 2002; Jokiranta et al., 2005; Ferreira 
et al., 2009) that includes the C-terminal R1210C variant mentioned in section 1.3.1 
(Sanchez-Corral et al., 2002; Recalde et al., 2015). Variants that lead to FH deficiency also 
associate with aHUS (Dragon-Durey et al., 2004). 
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Gene or subgroup Frequency in 
aHUS 
Risk of death or ESRD at 1st 
episode or within 1 year 
Risk of recurrence after renal 
transplant 
CFH 20-30% 50-70% 75-90% 
CFI 4-10% 50% 45-80% 
CD46 5-15% 0-6% <20% 
C3 2-10% 60% 40-70% 
CFB 1-4% 50% 100% 
Autoantibodies to FH 6% 30-40% Yes, if high Ab titre 
Table 13 Complement abnormalities in aHUS - Prevalence and prognosis 
Adapted from (Loirat and Fremeaux-Bacchi, 2011). Ab = antibody. 
 
Functional studies of aHUS-associated variants outside of the C-terminal domain of CFH are 
limited. Several functionally significant N-terminal variants in CFH have been described 
(Pechtl et al., 2011). The importance of functional studies in CFH was confirmed in the study 
of the polymorphic variants I890/L1007. No effect on FH regulatory function could be 
demonstrated in co-factor assays in the fluid phase or in haemolytic assays on the cell surface 
(Tortajada et al., 2012). The remaining aHUS-associated rare variants without functional 
studies should be termed variants of uncertain significance (VUS) (Kavanagh and Anderson, 
2012). 
A number of genetic deletions within the CFH-CFHR gene cluster associate with aHUS. The 
CFHR3/1 deletion in homozygosity associates strongly with the presence of autoantibodies 
against FH in aHUS cohorts (Moore et al., 2010). 
Abnormal FH/FHR hybrid (Venables et al., 2006; Maga et al., 2011; Francis et al., 2012; 
Challis et al., 2015) or FHR1/FH ‘reverse’ hybrid proteins (Eyler et al., 2013; Valoti et al., 
2015) have been described resulting from genetic deletions from within the CFH-CFHR gene 
cluster. These are shown in Figure 7. Functional studies have confirmed the significance of 
several of these hybrid proteins (Francis et al., 2012; Challis et al., 2015; Valoti et al., 2015). 
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Figure 7 FH hybrid proteins and FHR1 ‘reverse’ hybrids in aHUS 
Adapted from Challis et al. Coloured ovals represent complement control protein (=CCP, synonymous with short consensus 
repeat and SCR) .from either FH, FHR3 or FHR1. 
 
Rare genetic variants in CFI are found in 4-10% of cases of aHUS (Fremeaux-Bacchi et al., 
2004; Kavanagh et al., 2005). These are all heterozygous and cluster in the light chain. Most 
result in a secreted protein. Functional studies of a number of these variants have been shown 
to result in loss of complement regulation of AP and CP (Kavanagh et al., 2008). 
Rare genetic variants in CD46 are found in 5-15% of cases of aHUS. Variants mostly result 
in a failure to express CD46 on the surface of peripheral blood mononuclear cells (Richards 
et al., 2007). Functional studies have confirmed loss of function of several secreted variants 
(Richards et al., 2003; Caprioli et al., 2006). 
Rare variants in C3 and CFB are uncommon in aHUS cohorts, and are found in only 2-10% 
and 1-4% of patients respectively. Nonetheless, detailed functional studies of rare genetic 
variants in C3 and CFB have been described in several series. These studies have identified a 
number of different molecular mechanisms (Table 14) that ultimately result in over activation 
of AP. 
Most rare genetic variants in C3 lead to gain-of-function due to loss of binding to FH, CD46, 
or occasionally CR1 and subsequent loss of co-factor activity and impairment of inactivation 
of C3b by FI (Fremeaux-Bacchi et al., 2008; Martinez-Barricarte et al., 2015; Schramm et 
al., 2015). In a familial case of aHUS, gain-of-function of a variant in C3 was due to 
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enhanced FB binding and convertase formation has been previously described (Lhotta et al., 
2009). 
Rare genetic variants in CFB lead to gain of function by enhanced convertase formation and 
resistance to convertase decay by complement regulators (Goicoechea de Jorge et al., 2007; 
Marinozzi et al., 2014). 
Two variants (Y832X and C1136W) led to impaired secretion of C3 and haploinsufficiency 
(Fremeaux-Bacchi et al., 2008). Their role in disease has not yet been elucidated. 
 
C3 variant CFB variant 
Reduced co-factor binding by FH, CD46 or CR1 Enhanced C3bB formation 
Reduced co-factor activity C3bBb resistant to decay acceleration 
Enhanced FB binding and convertase formation  
Table 14 Mechanisms of pathogenicity of C3 and CFB variants in aHUS 
 
1.4.3 Autoantibodies to Complement Proteins in aHUS 
Autoantibodies to FH have been detected in approximately 10% of patients with aHUS 
(Dragon-Durey et al., 2005; Loirat and Fremeaux-Bacchi, 2011). These autoantibodies bind 
predominantly to the C-terminal domain of FH, corresponding to the location of the majority 
of rare variants in CFH in aHUS (Jozsi et al., 2007). However, autoantibodies to FH 
identified in a study of nineteen patients by Blanc et al did not bind exclusively to the C-
terminal domain of FH suggesting that their pathological role may extend beyond the 
impairment of cell-surface recognition (Blanc et al., 2012). The development of 
autoantibodies to FH in aHUS appears to be associated with homozygous deletion of 
CFHR3/CFHR1 (Jozsi et al., 2008; Moore et al., 2010). 
Autoantibodies to FI were described in one series of 3 patients out of 175 patients with aHUS 
(Kavanagh et al., 2012). The autoantibodies were bound to circulating FI to form immune 
complexes but there was only a modest effect on complement regulation in functional studies. 
Autoantibodies to FI were found in a similar proportion of patients in a more recent study 
(Jozsi et al., 2014). A pathogenic role for these autoantibodies also remains unclear. In this 
study, one patient with an autoantibody to C3b was also described (Jozsi et al., 2014). Again, 
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a direct pathogenic role was uncertain. Recently, screening of a cohort of 89 patients for 
autoantibodies to CD46, CD35, CD55 and CD59 was performed (Watson et al., 2015). No 
autoantibodies were identified to these surface-bound regulators. 
 
1.4.4 Acquired Partial Lipodystrophy 
Acquired partial lipodystrophy (APL) is the loss of subcutaneous tissue and is usually limited 
to the upper half of the body (Eisinger et al., 1972; Misra et al., 2004). APL has been 
described in association with DDD (Duvall-Young et al., 1989; Finn and Mathieson, 1993). 
A shared risk factor between DDD and APL is C3 nephritic factor (Sissons et al., 1976; Finn 
and Mathieson, 1993; Misra et al., 2004). In one study, 22% of cases of APL developed 
MPGN after a median of 8 years (Misra et al., 2004). A role of C3 nephritic factor in 
adipolysis and fat cell loss has been previously described (Mathieson et al., 1993; Williams, 
1997). The distribution of fat loss is thought to be dependent upon FD, expressed in 
adipocytes in a distribution that mimics the pattern of fat loss observed in APL (Mathieson et 
al., 1994).  
 
1.4.5 Drusen and Age-related Macular Degeneration 
Drusen are a hallmark of early age-related macular degeneration (AMD), an important cause 
of blindness worldwide (Hageman et al., 1999). Both drusen (Duvall-Young et al., 1989) and 
AMD (Montes et al., 2008; Savige et al., 2016) have been described in patients with DDD. 
Drusen found in patients with glomerulonephritis are abundant in complement proteins and 
were of similar composition to those found in AMD (Mullins et al., 2001). Furthermore, 
AMD and DDD shared the common polymorphism Y402H in CFH as a genetic risk factor, 
first described in AMD in 2005 (Edwards et al., 2005; Haines et al., 2005). Since then 
additional common polymorphisms and rare variants in several genes encoding proteins 
within the AP have now been described in AMD. These genes include C3 (Yates et al., 2007; 
Seddon et al., 2013), CFB (Gold et al., 2006), CFH (Boon et al., 2008; Montes et al., 2008; 
Raychaudhuri et al., 2011; Duvvari et al., 2015; Triebwasser et al., 2015) and CFI (Kavanagh 
et al., 2015). That complement genetic risk factors are common to AMD and MPGN/C3G is 
fascinating and may benefit our understanding of the complement system and these diseases. 
One notable example of such a risk factor is the rare genetic variants R1210C in CFH that is 
found in AMD, MPGN/C3G and aHUS (Recalde et al., 2015). 
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1.5 Treatments of MPGN/C3G and aHUS 
There are no universally effect treatments for MPGN/C3G. The only double blind 
randomised control trial in this group of patients was performed in 1992 (Tarshish et al., 
1992). Eighty children (with MPGN type 1, 2 and 3) were randomised to receive 40mg/m2 of 
prednisolone on alternate days. In this study, long-term treatment with prednisolone did 
appear to improve the outcome of patients with MPGN. Other studies suggest some benefit 
from the use of cyclophosphamide, mycophenolate mofetil (MMF) and the combination of 
aspirin and dipyridamole (Table 15). Other treatments used in MPGN or C3G have been 
described in case reports and include the use of rituximab (Marques et al., 2014; Farooqui et 
al., 2015; Giaime et al., 2015), soluble CR1 (Zhang et al., 2013a) and plasma exchange 
(PEX) (Habbig et al., 2009). 
PEX had been considered the ‘gold-standard’ in the management of aHUS (Ariceta et al., 
2009; Taylor et al., 2010). The rationale for use included the replacement of defective 
complement regulators and hyper-functional complement components. It remains an 
important treatment in the initial management of aHUS (Scully and Goodship, 2014) and also 
in the ongoing management of aHUS in countries where Eculizumab is not available. 
1.5.1 Eculizumab 
Eculizumab is a recombinant, humanised, monoclonal antibody directed against C5 (Rother 
et al., 2007) (Figure 1). It binds C5 thus preventing its cleavage by C3bBbC3b into C5a and 
C5b, therefore inhibiting the terminal pathway. 
Eculizumab has replaced PEX as the gold-standard in the management of aHUS in adults 
(Legendre et al., 2013; Licht et al., 2015) and children (Greenbaum et al., 2016). Eculizumab 
is given in the treatment of aHUS in the native kidney and also to prevent recurrence of 
aHUS following renal transplantation (Wong et al., 2013). Current controversies in the use of 
Eculizumab include the optimal duration of therapy (Ardissino et al., 2015). 
The benefit of Eculizumab in MPGN/C3G is less clear. There is a growing list of case reports 
describing the possible benefit of Eculizumab in MPGN/C3G but these reports are subject to 
publication bias. One small study by Bomback et al of 6 patients reported variable outcomes 
in a heterogeneous cohort of C3GN and DDD in both native and transplanted kidneys 
(Bomback et al., 2012). Future studies of a well-characterised cohort of MPGN/C3G are 
required, such as the Eculizumab in Primary MPGN (EAGLE) trial currently underway 
(Eculizumab in Primary MPGN - Full Text View - ClinicalTrials.gov, 2016). 
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Treatment Study Type Outcome Reference 
Prednisolone Double-blind randomised control trial in children with MPGN 
(42, type 1, 14, type 2, 17, type 3 and 7, non-typable disease) 
The rate of treatment failure was lower in patients 
receiving steroids (40%) compared to controls 
(55%). 
After a median of 13 years, a higher proportion of 
patients had stable renal function in the group 
receiving steroids (61%) compared to controls 
(12%). 
(Tarshish et al., 1992) 
Cyclophosphamide Single arm study, 19 patients (concurrent prednisolone use) Renal failure and progression in 1 patient only (Faedda et al., 1994) 
MMF 5 patients receiving MMF and Prednisolone vs 6 controls (no 
treatment) 
Improvement in proteinuria in treatment group (Jones et al., 2004) 
Retrospective cohort of C3GN 
22 patients receiving MMF and Prednisolone 
Renal function and renal survival better in patients 
receiving MMF (and prednisolone) compared to 
those receiving other regimens 
(Rabasco et al., 2015) 
Aspirin and 
dipyridamole 
18 patients with MPGN and nephrotic syndrome randomised to 
treatment (10 patients) vs control (8 patients) 
Improvement in proteinuria in treatment group (Zauner et al., 1994) 
40 patients with MPGN type 1, double-blind randomised control 
trial (21 treatment, 19 control) 
Less progression to ESRD in treatment group in 
initial study but re-analysis showed no benefit. 
(Donadio et al., 1984; 
Donadio and Offord, 1989) 
Table 15 Studies of treatments in MPGN/C3G 
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1.6 Summary 
Acquired and genetic abnormalities of the AP have been described in several renal 
phenotypes. The earliest associations were in MPGN. More recently, the term C3G has been 
introduced. These terms describe a cohort of patients in whom abnormalities of the AP may 
be found. Patients with MPGN/C3G often have low C3 levels. The most prevalent 
abnormality in these patients is the C3 nephritic factor; an autoantibody that stabilises C3bBb 
resulting in over activity of AP in the fluid phase. Additional abnormalities, including 
autoantibodies to FH and rare genetic variants in genes encoding proteins within the AP have 
also been identified. Functional studies of these abnormalities also demonstrate over activity 
of AP. 
Previous detailed studies of AP abnormalities in aHUS led to clinical trials and the successful 
use of Eculizumab in aHUS. Further studies in cohorts of MPGN/C3G are required to clarify 
the role of these abnormalities, in terms of pathogenicity and their influence on the clinical 
course of disease. 
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1.7 Aims of Thesis 
I have several main aims in this thesis. 
1. I will identify and determine the prevalence of acquired and genetic abnormalities of 
AP in two cohorts of MPGN/C3G 
2. I will study a rare genetic variant in the regulatory domain of FH to solve a long-
standing conundrum and explain a case of familial MPGN 
3. I will determine the range of functional effects of rare genetic variants in the 
regulatory domain of CFH associated with MPGN/C3G and other diseases 
4. I will undertake functional studies using full length FH to confirm the effects of 
previous functional tests performed in the regulatory domain of FH. 
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Chapter 2 – Methods 
2.1 Screening for Complement Abnormalities in MPGN and C3G Cohorts 
The study was approved by Newcastle and North Tyneside 1 Research Ethics Committee, 
and informed consent was obtained in accordance with the Declaration of Helsinki. 
 
2.1.1 Cohort Selection  
Two cohorts for study of patients with MPGN/C3G were identified. Patients from paediatric 
renal units based in 10 UK hospitals were recruited for study in a prospective paediatric 
cohort (Table 16). Patients presented with haematuria, proteinuria and/or abnormal renal 
function and were investigated in their local paediatric renal unit. A diagnosis of MPGN, 
DDD or C3GN was made by the local pathology service following renal biopsy. All 
paediatric renal units were invited by the study investigators Professor Tim Goodship and Dr. 
Sally Johnson since 2011 to recruit patients with a diagnosis of MPGN, DDD or C3GN into 
the registry for rare renal disease (RaDaR) and the national study of MPGN. Patients 
consented to clinical data collection from the registry, and collection of pre-existing renal 
biopsy material and whole blood for DNA and serum storage (Figure 8). Following 
recruitment, I had access to the list of patients and oversaw the acquisition of data and 
subsequent analysis from clinical data registry, central pathology review, autoantibody 
screening and genetic screening. I will refer to this cohort as the RaDaR (prospective) cohort. 
 
Alder Hey Children’s Hospital Leeds General Infirmary 
Birmingham Children’s Hospital Queen’s Medical Centre 
Bristol Royal Hospital for Children Royal Hospital for Sick Children 
Evelina Children’s Hospital Royal Victoria Infirmary 
Great Ormond Street Hospital University Hospital of Wales 
Table 16 Paediatric renal units recruiting to RaDaR 
 34 
 
 
Figure 8 Flowchart of patient recruitment and sample acquisition for RaDaR 
 
Patients were referred to Professor Tim Goodship or Dr. David Kavanagh at the Newcastle 
specialist centre for complement-mediated renal disease with a diagnosis of MPGN, DDD or 
C3GN by clinicians requesting specialist testing for complement abnormalities. Data was 
entered onto a central database of patients with complement–mediated renal diseases and was 
collected by me for analysis of complement abnormalities in a retrospective adult and 
paediatric cohort. I will refer to this as the Newcastle (retrospective) cohort. 
 
2.1.2 Central Pathology Review 
A central pathology review was conducted for patients in the prospective cohort study. 
Original slides or digital images were reviewed by Professor Terry Cook, an expert in the 
pathological diagnosis of MPGN/C3G. Immunofluorescence images and/or reports, and 
electron microscopy images and/or reports were also acquired for review. Following review a 
diagnosis given based upon the C3G consensus report (Pickering et al., 2013). 
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2.1.3 Clinical Data 
Clinical data from patients in the RaDaR cohort was entered by research nurses at local 
centres into the RaDaR database. The database was exported into an Excel spreadsheet by Dr. 
Fiona Braddon for analysis by me. Clinical data from patients in the Newcastle cohort was 
sent by the referring clinician at time of referral. Additional data was available if requested by 
Prof Tim Goodship or Dr. David Kavanagh. The data in the Newcastle MPGN database was 
analysed by me. 
 
2.1.4 Complement Protein Analysis 
Serum samples from patients in the RaDaR cohort study were tested for C3, C4, FH and FI in 
the laboratory at Newcastle Hospitals NHS Foundation trust. Serum samples from patients in 
the retrospective cohort study were also tested for C3, C4, FH and FI in the laboratory at 
Newcastle Hospitals NHS Foundation trust. Complement levels were analysed by me. 
 
2.1.5 Autoantibodies to Complement Components 
Serum samples from patients in the RaDaR cohort were screened for autoantibodies to 
complement proteins. Dr. Kevin Marchbank undertook screening for autoantibodies using an 
enzyme-linked immunosorbent assay (ELISA) to FH, FI, CD46, C3b, FB, CD35, CD55, 
CD59, FHR1, FHR2, FHR3, FHR4 and FHR5. Further analysis was performed for patients 
that were positive for autoantibodies to FH. Characterisation of epitope binding to fragments 
of FH was also performed in patients who had an autoantibody to FH. Descriptions of ELISA 
testing are in the references indicated in Table 17. Minor modifications were made to the 
protocol for screening for autoantibodies to FH for the study of proteins not referenced. C3b 
and FB were obtained from CompTech and were also coated onto 96-well plates at 5μg/ml. 
FHR2, 3 and 4 were expressed in mammalian cell lines and coated onto 96-well plates at 
5μg/ml. FHR1 and FHR5 were expressed in mammalian cell lines and coated onto 96-well 
plates at 1μg/ml. FH SCR1-7 was expressed in mammalian cell lines and coated onto 96-well 
plates at molar equivalence to FH. 
Serum samples from patients in the retrospective cohort were screened for autoantibodies to 
FH only. In a case of familial MPGN, detailed characterisation of autoantibodies against FH 
was also performed. Specificity of the autoantibodies to FH was tested using western blotting 
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(Goodship et al., 2012; Wong et al., 2014). Characterisation of epitope binding to fragments 
of FH was also performed (Wong et al., 2014). 
I undertook some of the screening for autoantibodies to FHR3 and FHR4. Flexible 96-well 
plates were filled with 50µL of coating buffer, pH 7.6 (AbD Serotec) containing 5µg/ml of 
purified FHR3 or FHR4 proteins (generated by Dr. Kevin Marchbank in mammalian cell 
culture) and incubated for 16 hours at 4°C. Plates were washed three times with 200µL of 
PBS containing 0.01% Tween 20 (Sigma) followed by blocking with 200µL ultrablock (AbD 
Serotec) for 45 minutes at 25°C. A duplicate plate was set up with block solution as a 
background binding control. After blocking, 50µL of 2% serum in PBS/0.01% Tween 20 was 
loaded in triplicate onto both plates and incubated for 1-2 hours. Plates were washed three 
times with 200µL of PBS containing 0.01% Tween 20 followed by blocking with 200µL 
ultrablock for 45 minutes at 25°C. 50µL of goat anti-human IgG HRP (Stratech Scientific 
UK) at 1:4000 dilution with PBS containing 0.01% Tween 20 was added to each well and 
incubated for 1 hour at 25°C. Plates were washed three times with 200µL of 
PBS/0.01%Tween 20. 50µL of tetramethyl benzidine standard kinetic solution (AbD serotec) 
was then added to each well for 7 minutes prior to the reaction being stopped using 10% 
sulphuric acid. Absorbance at 450nm (A450) was measured using a SpectraMax 190 plate 
reader (MDS Analytical Technologies Limited). Triplicate data were analysed and mean 
ultrablock readings were subtracted from mean FHR readings to control for non-specific/false 
positive readings. Rabbit polysera (1:100000) for each FHR protein and goat anti-rabbit-HRP 
(1:10000) was used as a loading control. No positive control from a patient was available for 
use. 
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Protein Reference 
FH1, 2, 3 (Goodship et al., 2012) 
FH SCR1-41,, 3 (Pechtl et al., 2011) 
FH SCR6-81, 3 (Schmidt et al., 2008b) 
FH SCR8-151, 3 (Herbert et al., 2012) 
FH SCR16-181, 3 (Morgan et al., 2011) 
FH SCR19-201, 3 (Ferreira et al., 2009) 
FI1 (Kavanagh et al., 2012) 
CD461 (Watson et al., 2015) 
CD351 (Watson et al., 2015) 
CD551 (Watson et al., 2015) 
CD591 (Watson et al., 2015) 
Table 17 Screening for autoantibodies to complement proteins 
Screening for autoantibodies to different proteins was performed in the 1RaDaR, 2Newcastle cohort and 3familial MPGN. 
Screening for autoantibodies to C3b, FB, FHR1-5 and FH SCR1-7 was performed for patients in the RaDaR cohort, and 
with small modifications to the FH protocol. 
 
2.1.6 Genetic Studies in RaDaR and Newcastle Cohort 
Screening for rare genetic variants in C3, CFB, CFH, CFI and CD46 was performed for both 
the RaDaR and Newcastle cohorts using sequencing offered by the Northern Molecular 
Genetics Service in Newcastle upon Tyne during the course of the study. The techniques 
included Sanger sequencing and Next Generation Sequencing. In all cases, all coding exons 
of C3, CFB, CFH, CFI and CD46 were sequenced. Exons that failed to sequence and all rare 
variants that were identified using Next Generation Sequencing were sequenced again using 
Sanger sequencing. Sanger sequencing of intronic sequences was also performed to identify 
common polymorphisms associated with risk haplotypes for patients in the RaDaR cohort. 
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Multiplex-ligation dependent probe amplification (MLPA) was used to screen for copy 
number variation (CNV). This was undertaken by the Northern Molecular Genetics Service. 
Screening for CNV in CFH, CFHR3, CFHR1, CFHR2 and CFHR5 was performed for 
patients in the prospective cohort using a proprietary kit from MRC Holland 
(www.mlpa.com; SALSA MLPA kit P236-A1 ARMD). GeneMarker software (Version 1.90) 
was used to calculate dosage quotients for all MLPA experiments. I undertook analysis of the 
data provided. Exons included in this analysis are summarised (Table 18) 
 
CFH CFHR3 CFHR1 CFHR2 CFHR5 
CFH exon 1 CFHR3 exon 1 CFHR1 exon 3 CFHR2 exon 1 CFHR5 exon 1 
CFH exon 2 CFHR3 exon 2 CFHR1 exon 5 CFHR2 exon 2 CFHR5 exon 2 
CFH exon 3 CFHR3 exon 3 CFHR1 exon 6 CFHR2 exon 3 CFHR5 exon 3 
CFH exon 4 CFHR3 exon 4  CFHR2 exon 4  
CFH exon 6 CFHR3 exon 6    
CFH exon 11     
CFH exon 12     
CFH exon 13     
CFH exon 18     
CFH exon 23     
Table 18 Exons tested in MLPA for copy number variation 
Screening was performed in Northern Molecular Genetics Service using SALSA MLPA kit P236-A1 ARMD. 
 
2.1.7 Defining Rare Genetic Variants 
The Exome Variant Server website (evs.gs.washington.edu/) is a population database, 
containing whole exome data generated from the NHLBI GO Exome Sequencing Project 
(ESP6500). The dataset contains exomes from 2203 African American and 4300 European 
American unrelated individuals. A rare genetic variant was defined as occurring at a 
frequency of <1% in a control cohort. The exome variant server was chosen for this purpose. 
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Rare genetic variants were modelled on the crystal structure of C3b in complex with FB 
(C3b:FB-2XWJ), C3b in complex with FH SCR 1-4 (C3b:FH1-4-2WII) and FH SCR19-20 in 
complex with C3d (C3d:FH19-20-3OXU) from .PDB files available from 
http://www.rcsb.org/pdb/home/home.do using Pymol (Schrödinger, Inc). 
The minor allele frequency of exonic SNPs in CFH, C3 and CFB was determined from the 
NHLBI GO Exome Sequencing Project (ESP6500). The minor allele frequency of intronic 
SNPs in CFH and CD46 was determined from a previously screened cohort of UK and 
French controls (Fremeaux-Bacchi et al., 2005). 
The effect of rare genetic variants on function was modelled in-silico using two online 
prediction software programs. Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and 
Provean (http://provean.jcvi.org/index.php) are both online prediction software programs that 
predict the effects a variant would have on a protein. Polyphen-2 reports the likely effect as 
benign, possibly damaging or probably damaging (Figure 9). Provean reports the likely effect 
as deleterious or neutral (Figure 10). These were discussed in the setting of the functional 
studies that were performed for some of the rare genetic variants identified. 
 
2.1.8 Statistics 
Clinical data was summarised in box and whisker plots, and demonstrate median values, 
quartiles, 10th and 90th percentiles and outliers. Comparison between multiple groups was 
performed using ANOVA or Kruskal-Wallis tests. Comparison between two groups was 
performed using t tests or Mann-Whitney test. Odds Ratio and Fisher’s Exact test was used 
for proportional data. Statistical analysis and graphs were prepared using SigmaPlot®. 
Additional graphs were prepared using GraphPad Prism 6 (GraphPad Software) or Microsoft 
Excel®. 
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Figure 9 In-silico prediction of functional effects of variants using PolyPhen-2 
Screenshot of prediction of effect of R83S variant using PolyPhen – (Polymorphism Phenotyping). Numbering entered into 
prediction software does not include the leader sequence. This is an in-silico tool used to predict the possible effects of a 
non-synonymous SNP. It reports a prediction based upon data held in two datasets, HumDiv and HumVar. The first data set 
HumDiv defines known disease-causing alleles as deleterious and variants that are different between human and other 
mammals, classed as benign. The second dataset HumVar defines known disease-causing alleles classed as deleterious and 
common variants (MAF>1%) as benign. The HumDiv score was preferred due to improved accuracy and higher true 
positive prediction rates (Adzhubei et al., 2010). 
 
 
Figure 10 In-silico prediction of functional effects of variants using Provean 
Screenshot of prediction of effect of R83S variant using Provean – (Protein Variation Effect Analyser). Numbering entered 
into prediction software does not include the leader sequence. This is an in-silico tool used to predict the possible effects of a 
non-synonymous SNP and also short sequences of genetic insertions or deletions. The algorithm used in Provean to predict 
the effect of amino acid substitutions has a prediction accuracy that is similar to Polyphen-2 (Choi et al., 2012). 
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2.2 Molecular Biological Techniques 
Rare genetic variants in the N-terminal domain of FH were selected for study in structural 
and functional studies. A wildtype and mutant protein in the setting of FH SCR1-2 was 
expressed for the structural studies of the R83S variant in familial MPGN in chapter 4. 
Wildtype and mutant proteins in the setting of FH SCR1-4 were expressed for the functional 
studies of N-terminal variants identified for study in chapter 4 and chapter 5. 
The pPICZαB vector, in E. coli and Pichia pastoris clones containing cDNA encoding SCR1-
2 of FH (residues 19-142) previously used in the structural study of FH in the setting of 
SCR1-2 of FH (Hocking et al., 2008) were obtained from Dr Kavanagh. The pPICZαB 
vector, in E coli and Pichia pastoris clones containing cDNA encoding SCR1-4 of FH 
(residues 19-263) with a C-terminal 6xHIS tag and N-terminal myc-tag previously used in the 
functional study of FH in the setting of SCR1-4 of FH (Pechtl et al., 2011) were obtained 
from Dr Kavanagh. Plasmid DNA of the pPICZαB vector containing cDNA encoding both 
the 2 SCR and 4 SCR FH fragments were also obtained from Dr. Kavanagh and used as a 
DNA template for site-directed mutagenesis. The pPICZαB vector in E.coli containing cDNA 
encoding the mutant S159N SCR1-4 was a gift from Professor Alan Wright, University of 
Edinburgh. 
 
2.2.1 pPICZαB Vector and KM71H 
The pPICZαB vector for use in Pichia pastoris (both ThermoFisher Scientific) contains a 
5’AOX promotor region that allows for methanol induced expression of protein and an α-
factor signal sequence that allows secretion of protein. It also has a Sac I restriction site to 
linearise the plasmid and a Zeocin™ resistance gene that allows for selection of clones in 
E.coli and the KM71H strain of Pichia pastoris (Figure 11). Further advantages in using 
Pichia pastoris as an expression system include its ease to make high-yields of protein in an 
easily scalable manner. The importance of expressed protein that is correctly folded is 
important and functional wildtype protein was confirmed in previous studies using this 
technology (Pechtl et al., 2011). 
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Figure 11 pPICZαB vector used for expression of FH fragments in Pichia pastoris 
Taken from pPICZα Manual, Invitrogen. 
 
2.2.2 Site-directed Mutagenesis 
High performance liquid chromatography purified specific primers (Appendix 1 - Table 54) 
were designed and ordered from Integrated DNA Technologies. Primer pairs were used for 
the introduction of each rare genetic variant as a point mutation into plasmid DNA of the 
pPICZαB vector containing cDNA encoding either the 2 SCR or 4 SCR FH fragments. Site-
directed mutagenesis was performed using QuikChange II XK Site-Directed Mutagenesis Kit 
(Stratagene). 
Sample reactions were prepared by the addition of 5µL of a proprietary 10x reaction buffer, 
1µL of DNA template (~50ng/µL), 1.25µL forward mutagenesis primer (~100ng/µL), 
1.25µL reverse mutagenesis primer (~100ng/µL) and 1µL of dNTP mix in a final volume of 
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50µL dH2O. 1µL of PfuUltra HF DNA polymerase (2.5U/µL) was then added to each sample 
reaction before cycling for 1 minute at 95°C, then 18 cycles for 50 seconds at 95°C, for 50 
seconds at 60°C and for 7.5 minutes at 68°C before a final 7 minutes at 68°C. 
Following mutagenesis, residual template DNA was digested by incubating the products of 
mutagenesis with 1μL of Dpn I (10U/µL) for 1 hour at 37°C. The mutagenesis product was 
then stored at 4°C until ready for transformation into E. coli competent cells. 
 
2.2.3 Transformation of Mutated DNA into E.coli Competent Cells 
2µL of the Dpn I-treated mutated DNA template was added to 45μL of thawed XL-1 Blue 
competent cells (Stratagene) and incubated for 10 minutes on ice. The mixture was then 
‘heat-shocked’ for 45 seconds at 42°C before incubation for 2 minutes on ice. 500μL of low 
salt LB broth (Appendix 2) (prewarmed to 42°C) was then added to the competent cells. The 
mixture was incubated at 37°C for 1 hour. 450µL and 50µL of transformed cells were then 
inoculated onto low salt LB agar (Appendix 2) plates containing 25µg/ml Zeocin™ 
(Invivogen). Successfully transformed clones containing pPICZαB and a Zeocin™ resistance 
gene were identified following incubation for 16 hours at 37°C. 
 
2.2.4 Extraction of Plasmid DNA – Small Scale 
Clones containing mutated cDNA for FH SCR1-2 or SCR1-4 in the vector pPICZαB were 
picked and cultured in 5ml of LB broth (Appendix 2) containing 25µg/ml Zeocin™. Cultures 
were incubated at 37°C for 16 hours with shaking at 225rpm. Cells were then pelleted by 
centrifugation at 6800xg for 3 minutes at 25°C and the supernatant was removed. Plasmid 
DNA was then extracted from the cell pellet using QIAprep Spin Miniprep Kit (QIAGEN). 
The bacterial cell pellet was resuspended in 250µL of Buffer P1 containing 100µg/ml RNase. 
To this, 250µL of Buffer P2 was added and the mixture inverted 10 times. The mixture was 
incubated for 5 minutes during which time lysis of cell membrane occurred. The lytic 
reaction was stopped by the addition of 350µL of chilled Buffer N3 and the mixture inverted 
10 times before centrifugation for 10 minutes at 13200xg. The supernatant was then applied 
to the QIAprep spin column before centrifugation for 60 seconds. The spin column was 
washed with 500µL Buffer PB and 750µL Buffer PE with a 60 second centrifugation step 
after each wash. Finally, the DNA was eluted by the addition of 60µL Buffer EB, incubation 
for 1 minute, followed by centrifugation for 1 minute to collect the eluted DNA.  
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2.2.5 Determining Concentration of Plasmid DNA 
DNA was quantified using a NanoDrop 8000 (Thermo Scientific) at 260nm. 
 
2.2.6 Sequencing of Plasmid DNA in pPICZαB Vector 
20μL of plasmid DNA (~50ng/μL) and 20μL of sequencing primer (10pmol) (forward and 
reverse) (Appendix 1 - Table 55) were sent for Sanger sequencing at GATC Biotech. The 
sequencing data was checked using Sequencher (Genecodes). 
 
2.2.7 Extraction of Plasmid DNA – Large Scale 
Clones containing the correctly mutated cDNA for FH SCR1-2 or SCR1-4 in the vector 
pPICZαB were picked and initially cultured in 5ml of LB broth containing 25µg/ml Zeocin™ 
for 8 hours. The initial culture was then added to 500ml of LB broth containing 25µg/ml 
Zeocin™ for 16 hours. Cultures were incubated at 37°C with shaking at 225rpm. Cells were 
then pelleted by centrifugation at 6000xg for 15 minutes at 4°C. The supernatant was 
discarded and plasmid DNA was then extracted from the cell pellet using QIAprep Spin 
Maxiprep Kit (QIAGEN) The cells were resuspended in 10ml of Buffer P1 containing 
100µg/ml RNase and mixed. To this, 10ml of Buffer P2 was then added and inverted to lyse 
the cells, then incubated for 5 minutes at 25°C. 10ml of chilled Buffer P3 was then added and 
the lysate was transferred to the QIAfilter Cartridge and incubated for 10 minutes. The lysate 
was then filtered through the QIAfilter Cartridge and collected in a QIAGEN-tip equilibrated 
with 10ml of Buffer QBT. The QIAGEN-tip was then washed with 60 ml of Buffer QC. The 
DNA was then eluted with 15ml Buffer QF and collected. To precipitate DNA, 10.5ml of 
isopropanol was then added to the eluted DNA, mixed and centrifuged at 15000xg for 30 
minutes at 4°C. The supernatant was carefully decanted. The DNA pellet was then washed in 
5ml of ethanol and centrifuged at 15000xg for 10 minutes. The ethanol was removed and the 
DNA pellet was allowed to air dry. The DNA pellet was resuspended in 500µL of dH2O and 
quantified. Bidirectional Sanger sequencing was performed to confirm fidelity. DNA was 
stored at 4°C prior to linearization and transformation into KM71H cells. 
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2.2.8 Linearisation of Plasmid DNA and Phenol-chloroform Extraction 
100µg of correctly mutated cDNA for FH SCR1-2 or SCR1-4 in the vector pPICZαB was 
linearised by adding to 1.4µL 100x BSA (Promega) and 14µL 10x reaction buffer (Promega) 
and 2µL Sac I (Promega) in a final volume of 140µL with dH2O and incubated for 16 hours 
at 37°C. 
Protein was then removed by phenol:chloroform extraction. An equal volume of 
phenol:chloroform, isoamyl alcohol 25:24:1 saturated with 10mM Tris pH 8.0, 1mM EDTA 
(Sigma) was added to the linearised DNA and vortexed. The mixture was centrifuged at 
16800xg for 2 minutes. The aqueous phase was removed and added to an equal volume of 
phenol:chloroform, isoamyl alcohol 25:24:1 saturated with 10mM Tris pH 8, 0 1mM EDTA 
and vortexed again. Following centrifugation at 16800xg for 2 minutes, the aqueous phase 
was removed and added to an equal volume of chloroform (Sigma) in order to remove the 
phenol. The mixture was vortexed and centrifuged at 16800xg for 2 minutes. The aqueous 
phase was removed and to it, 0.1 volume of 3M sodium acetate pH 5.2, 2.5 volumes of 100% 
ethanol was added, vortexed and placed for 1 hour at -80°C. The mixture was then 
centrifuged at 16800xg for 20 minutes at 4°C and the supernatant was removed. 1ml of cold 
70% ethanol was then added, centrifuged at 16800xg for 10 minutes and the supernatant 
removed. The DNA pellet was allowed to dry and then resuspended in 10µL dH2O. 
 
2.2.9 Transformation of KM71H 
Wildtype KM71H cells (Invitrogen) were revived from -80°C stocks on YPD agar (Appendix 
2) plates and incubated for 72 hours at 30°C. A single clone was picked and cultured in 5ml 
of YPD media (Appendix 2) for 24 hours at 30°C. 100µL of the initial culture was sub-
cultured in 250ml of YPD media for ~18 hours at 30°C until it had an optical density at 
600nm of 1.3-1.5. 
The cells were centrifuged at 1500xg for 5 minutes at 4°C, and washed twice, each time by 
resuspending in 250ml ice-cold sterile water and centrifuged at 1500xg for 5 minutes at 4°C. 
After the second wash, cells were resuspended in 10ml of ice-cold 1M sorbitol and 
centrifuged at 1500xg for 5 minutes at 4°C. After this final wash, the cells were resuspended 
in 400µL of ice-cold 1M sorbitol. 
For the electroporesis, 80µl of the KM71H cells were mixed with 10µg of linearised plasmid 
DNA in 10µl sterile water and transferred to an ice cold 0.2cm electroporation cuvette 
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(Biorad). The cuvette was incubated for 5 minutes on ice. Electroporesis was performed at 
1500V, 200 Ω, and 25uF using a gene pulser (Biorad). 
Following electroporesis, the cells were incubated for 1 hour at 30°C before 50µL, 200µL 
and 250µL aliquots of transformed cells were streaked onto 2 sets of YPD agar plates 
containing 100µg/ml and 300 µg/ml of Zeocin™ respectively. The plates were then incubated 
for ~72 hours at 30°C until the appearance of clones. 
 
2.3 Protein Expression 
2.3.1 Small Scale Test Expression of Transformed Pichia Clone 
Successful clones of transformed KM71H with pPICZαB following electroporesis were 
picked and cultured in 10ml of BMG (Appendix 2) for 48 hours at 30°C with agitation at 
225rpm. After 48 hours, the cells were pelleted at 1500xg for 5 minutes and resuspended in 
3.3ml of BMM (Appendix 2) and incubated at 30°C with agitation at 225rpm. Further 
methanol was added at 24 and 48 hours to a final concentration of 0.5%. After a total 72 
hours, some of the cell culture was inoculated onto YPD agar containing 100µg/ml Zeocin™ 
to enable stocks of successful clones to be kept. The remaining cells were pelleted at 1500xg 
for 5 minutes at 4°Cand the supernatant was collected for analysis. Samples were taken and 
detection of protein expression was determined by SDS-PAGE followed by staining with 
Coomassie blue (Figure 12) and/or Western blotting. Samples were then concentrated prior to 
SDS-PAGE and Western blotting if protein could not initially be detected. 
 
2.3.2 Separation of Protein Samples by SDS-PAGE 
Protein samples (20µL) were prepared for sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) by the addition of 5µL of Pierce™ Lane Maker Non-Reducing 
or Reducing sample buffer (both ThermoFisher Scientific), and incubated for 5 minutes at 
95°C. TGX Mini-Protean Pre-Cast gels (Biorad) and Mini-Protean Tetra Vertical 
Electrophoresis Cell (Biorad) were set up using 1x running buffer (100mM Tris, 100mM 
Glycine, 0.1% SDS, pH 8.3) after dilution from 10x Tris/glycine/SDS running buffer 
(Biorad). 4-15% gradient gels were used for the analysis of recombinant and purified protein 
samples. 25μL of sample was loaded per well and 5μL of a molecular weight ladder 
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(Appendix 3 Table 56) was loaded into one lane of each gel. Samples were then separated by 
SDS-PAGE at 190V. 
Products of fluid-phase co-factor assay (section 2.5.5) were separated on a 10% gel. 
Detection of proteins in serum is described separately (section 2.4.9). 
Following electrophoresis, the protein bands were visualised by Coomassie staining or 
Western blotting. 
 
2.3.3 Coomassie Staining 
Following separation of protein samples by SDS-PAGE, the gel was washed 3 times in dH2O 
for 5 minutes. The gel was then incubated in 25ml of Bio-Safe™ Coomassie Stain (Biorad) 
for 30 minutes before destaining with dH2O. The destained gel was then scanned using HP 
Scanjet G4050 (Hewlett Packard). 
 
 
Figure 12 Representative small scale test expression of protein 
Following transformation of KM71H and initial culture of successful clones, protein expression was induced using 
methanol. In this figure, protein expression is detected following separation of supernatant from small scale test expressions 
on 4-15% gradient SDS-PAGE under non-reducing conditions. The clone of FH SCR1-2 containing the R83S mutation was 
successfully transformed into the KM71H strain of Pichia pastoris. Clones #1-#4 all show a band at 15kDa consistent with a 
2 SCR protein and comparable to the previously transformed WT FH SCR1-2. A pPICZαB empty vector (containing no 
cDNA for FH) was also transformed into KM71H. No band could be seen at a size of 15kDa for the empty vector. 
 
2.3.4 Western Blotting 
Mini-Protean Tetra Vertical Electrophoresis Cell (Biorad) was set-up for transfer of protein 
from TGX Mini-Protean Pre-Cast gels to nitrocellulose membrane (Invitrogen) by Western 
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blotting. Gels were transferred at 100V for 60 minutes in a transfer buffer (12mM Tris base, 
96mM Glycine, pH 8.3, 20% methanol), pre-chilled to 4°C. The membrane was washed 3 
times with dH2O and then blocked for 1 hour at 25°C or 16 hours at 4°C in 5% milk powder 
(Marvel) in TBST (50mM Tris-HCl, pH 7.4, 150mM NaCl and 0.05% Tween 20). The 
membrane was then incubated in 5% milk power in TBST containing a primary antibody for 
1 hour at 25°C. This was followed by a further incubation step in 5% milk powder in TBST 
containing a secondary antibody for 1 hour at 25°C. The membrane was washed 3 times in 
TBST for 5 minutes following each incubation step. The selection of respective primary and 
secondary antibodies and their dilutions are summarised (Appendix 3, Table 57). 
The membrane was then incubated in SuperSignal™ West Pico Chemiluminescent Substrate 
(Thermo Scientific) for 1 minute prior to exposure onto Carestream® Kodak® X-Omat LS 
film (Sigma) in a hypercassette (Amersham Biosciences) for sufficient time for bands to 
develop. The film was then developed in a Konica SRX-101A Tabletop Processor (Konica 
Minolta Medical). 
Alternatively, following incubation with chemoluminescence, the image was captured using 
BioSpectrum 500 Imaging System (UVP) and analysed using VisionWorks®LS Analysis 
Software (UVP). 
 
2.3.5 Cryopreservation of successful clones 
Single clones were cultured in 5ml YPD for 16 hours at 30°C with agitation of 225rpm. Cells 
were frozen at -80°C in YPD media containing 15% glycerol. 
 
2.3.6 Expression of FH SCR1-2 Clone using 15N Media 
Expression of FH SCR1-2 using 15N-media was performed for structural studies using NMR. 
WT and R83S FH SCR1-2 clones of KM71H were picked and cultured in a starter culture of 
10ml BMG for 24 hours and transferred into a larger culture of 300ml BMG containing 15N-
ammonium sulphate (Appendix 2) as the sole nitrogen source. After a period of 24 hours of 
growth, cells were pelleted by centrifugation at 1500xg for 5 minutes and resuspended in a 
total of 3L of BMG containing 15N-ammonium sulphate for a period of 48 hours. The cells 
were then pelleted and resuspended in a total of 1L of BMM containing 15N-ammonium 
sulphate (Appendix 2) as the sole nitrogen source to induce protein expression. Methanol was 
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added to a final concentration of 1% after 24 and 48 hours. After a total of 72 hours of protein 
expression, the cells were pelleted by centrifugation at 1500xg for 15 minutes and the 
supernatant collected for protein purification. Culture of Pichia pastoris in shaker flasks was 
at 30°C and agitation of 225rpm throughout. 
 
2.3.7 Expression of FH SCR1-4  
Expression of FH SCR1-4 was performed for functional studies. WT and mutant FH SCR1-4 
clones of KM71H were picked and cultured in an initial starter culture of 20ml BMG for 48 
hours before transfer into an intermediate culture of 200ml for a further 48 hours at 30°C 
with agitation at 225rpm in shaker flasks. The intermediate culture was then added to 1.2L of 
fermentation basal salts medium (Appendix 2) supplemented with 4.35ml/L PTM1 trace salts 
(Appendix 2) for culture in a BioFlo®/CelliGen®115 Fermentor/Bioreactor (New 
Brunswick). 0.1% Antifoam A (Sigma) was also added to prevent foaming prior to 
inoculation and during fermentation when foaming was observed in the fermentor vessel. 
Biocommand software® (New Brunswick) was used to optimise cell growth and protein 
expression during the fermentation process described below. The dissolved oxygen (DO) 
level measured by Mettler Ingold dO2 Probe, InPro 6800 (New Brunswick Scientific) prior to 
inoculation was set to 100% and monitored. During cell culture DO levels falling as a result 
of cell growth and oxygen consumption. In order to maintain DO levels at a set-point of 30%, 
the agitation was programmed to increase from a minimum of 200rpm to a maximum of 
800rpm in response to DO levels falling below 30%. Monitoring of DO levels during the 
initial cell growth phase and subsequent induction of protein expression allowed careful 
evaluation of glycerol and methanol use as a source of carbon respectively so that the carbon 
source was limiting. 
Metabolism from cell growth also resulted in a fall in pH. The pH was monitored by Mettler 
Ingold pH Probe (New Brunswick Scientific) and maintained at 5.0 by the automated 
addition of 50% ammonium hydroxide that also provided a constant nitrogen source. 
Temperature was monitored and target temperature was maintained by the 
Fermentor/Bioreactor by a heating blanket and the flow of cold water within cooling 
elements within the fermentor vessel. 
Following inoculation of the 200ml intermediate culture to the fermentation basal salts 
medium, the culture in the Fermentor/Bioreactor was allowed to grow at 30°C with an initial 
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agitation of 200rpm. No glycerol was added to the culture at this time. The glycerol in the 
initial media was metabolised by Pichia during cell growth resulting in an initial fall in DO 
from 100%. As growth and oxygen consumption continued, DO levels would fall to a set-
point of 30% resulting in the increase in agitation to maintain DO levels of 30%. This initial 
phase is summarised in Figure 13. 
 
Figure 13 Monitoring of oxygen consumption during fermentation using Biocommand software 
Screenshot from Biocommand® software representative of first 12 hours of Pichia culture in the fermentor. Y-axis indicates 
agitation (red), dissolved oxygen (blue), pH (pink), base feed (green), glycerol feed (brown) and temperature (purple). Pump 
3 shown above was not used. X-axis represents time in hours. Calibration of dissolved oxygen (DO) was set to 100% 
immediately prior to inoculation of intermediate cell culture at time 0. Setpoint of DO was set to 30%. As the cell culture 
metabolises the available glycerol in the initial fermentation basal medium, oxygen is consumed and DO falls to the setpoint 
of 30%, at which point agitation increases to maintain DO at 30%. No glycerol is added until evidence of exhaustion of 
glycerol (indicated by sudden rise in DO – not shown in this example) to ensure it is the limiting factor during subsequent 
growth. Metabolism of Pichia also leads to a fall in pH. Base (in this case 50% ammonium hydroxide) is automatically 
added). Temperature during the initial glycerol growth phase is maintained at 30°C throughout. 
 
Once the initial glycerol was exhausted, oxygen consumption would fall resulting in a sudden 
‘spike’ in DO. At this point, the addition of glycerol was commenced at an initial rate of 
0.5ml/min to allow continued cell growth. The DO set-point of 30% was maintained with 
increasing agitation as the metabolic rate of the culture increased with increasing cell mass. 
As the cell mass increased, the rate of glycerol was doubled if there was evidence of a fall in 
metabolic rate as determined by a sudden rise in DO or fall in agitation until a total of 36 
hours of growth in the Fermentor/Bioreactor. 
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After 36 hours, no further glycerol was added. Given that the carbon source was limiting, 
there was a resultant ‘spike’ in DO. The cell culture was allowed to starve for a minimum of 
4 hours ensuring that glycerol had completely exhausted as indicated by a rise in DO to 100% 
before the addition of methanol. Using methanol only as a limiting carbon source maximised 
the induction of the AOX1 promoter and protein expression during this induction phase. 
Maintaining the concentration of methanol at a basal amount also avoided the risk of toxicity 
due to elevated concentrations of methanol in the order of 1-2%. 
After this time, the culture was cooled to 15°C to minimise degradation of subsequent protein 
expression and an initial volume of 100% methanol (supplemented with 12ml of PTM1 trace 
salts per litre) was added to a final concentration of 0.75% of the culture media to induce 
protein expression. Again, the DO was allowed to fall and the agitation was set to increase to 
a maximum of 800rpm to maintain a basal DO of 30%. After ~12 hours, and when there was 
evidence that the carbon source was limiting as observed by a DO ‘spike’, further methanol 
was added at 0.5ml/min. As the cell culture adapted to the utilisation of methanol, as seen by 
a further ‘spike’ in DO, the rate of methanol was doubled. 
After 72 hours of protein expression, the cells were pelleted at 6000xg for 15 minutes and the 
supernatant collected for protein purification. During initial purification, it was noted that 
upon cooling supernatant to 4°C, the formation of crystals prevented sample loading during 
nickel affinity purification. The addition of potassium hydroxide to the cell culture to a pH of 
7.4 prior to pelleting was an early modification to the protocol that allowed purification of 
protein. 
 
2.3.8 Tissue Culture of OX24 Hybridomas 
The OX24 antibody, a monoclonal to FH SCR5 was produced by a B-cell hybridoma cell line 
(Sigma). Hybridomas were cultured at 37°C and 5% CO2 using Roswell Park Memorial 
Institute (RPMI) medium. RPMI media was supplemented with 10% low immunoglobulin 
foetal calf serum, 2mM L-glutamine, 0.1units/mL penicillin, 0.1mg/mL streptomycin, 1mM 
non-essential amino acids, 1mM sodium pyruvate (all PAA Laboratories) and 50µM β- 
mercaptoethanol (Sigma). A supernatant containing secreted OX24 was obtained following 
centrifugation of the cell suspension at 300xg for 2 minutes. The supernatant was stored at -
20°C until purification. 
  
 52 
 
2.4 Protein Purification 
2.4.1 Cation Exchange 
Cation exchange was used for the purification of WT and R83S FH SCR1-2 expressed using 
15N-ammonium sulphate as the sole nitrogen source. Supernatant containing FH SCR1-2 was 
diluted 1:5 in a binding buffer (250mM formic acid pH 4) and loaded onto a crude column 
filled with 5ml of SP Sepharose Fast Flow (GE Healthcare) equilibrated with binding buffer 
at 4°C. Supernatant containing unbound protein was collected in a flow-through. Once all of 
the supernatant had passed over the column, a further 5 column volumes of binding buffer 
was used to remove non-specific binding in a wash step. Bound FH SCR1-2 was eluted by 
the addition of 5 column volumes of an elution buffer (250mM formic acid pH4 and 1M 
NaCl). 
Following cation exchange, the expressed protein (both WT and R83S) could be seen in 
elution fractions 1-3. The expressed protein was visualised following 4-15% gradient SDS-
PAGE under non-reducing conditions as a 15kDa band as predicted and a smaller band 
suggestive of degradation (Figure 14) that would require further purification. 
 
 
Figure 14 Initial purification step of 15N FH SCR1-2 
FH SCR1-2 was purified using cation exchange. WT and R83S FH SCR 1-2 were expressed using 15N- ammonium sulphate 
as a sole nitrogen source. The expressed protein can be seen following separation on 4-15% gradient SDS-PAGE at 15kDa 
under non-reducing conditions with evidence of a degradation product in the initial supernatant. The expressed protein and 
degradation product are seen in the elution fractions following batched cation exchange of the available supernatant. 
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2.4.2 Nickel Affinity Purification 
Nickel affinity chromatography was used to purify FH SCR1-4 (WT and all mutant proteins) 
expressed in KM71H. Proteins were histidine-tagged therefore allowing rapid purification on 
a HISTrap FF Crude pre-packed column (GE Healthcare). A 5ml HIS-Trap crude column 
was equilibrated with a binding buffer (40mM sodium phosphate pH 7.4, 500mM NaCl and 
20mM imidazole). Following protein expression, the culture media was centrifuged at 
6500xg at 4°C. The supernatant was collected and prepared for purification by the addition of 
an equal volume of 2x binding buffer (80mM sodium phosphate, pH7.4, 1000mM NaCl and 
40mM imidazole). The sample was loaded onto the equilibrated column at a rate of 2ml/min 
using an ÄKTA purifier (GE Healthcare). After the sample had loaded, weakly bound protein 
was removed in a wash step using 25ml of binding buffer. Non-specific binding was removed 
in an additional wash step using 25ml of a binding buffer containing 40mM imidazole instead 
of 20mM. 
Protein was eluted by applying an elution buffer (40mM sodium phosphate pH 7.4, 500mM 
NaCl and 500mM imidazole) at a rate of 2ml/min. The eluted protein was collected in 5ml 
elution fractions. Fractions containing protein were analysed by SDS-PAGE to confirm the 
presence of protein (Figure 15). 
 
Figure 15 Purified R83S FH SCR1-4 following elution from nickel-affinity column 
Representative gel following 4-15% gradient SDS-PAGE under non-reducing conditions showing the presence of a protein 
~25kDa at the expected size for a FH SCR1-4 protein. In this example, R83S FH SCR1-4 has been eluted in fractions 1 and 
2. Previously purified WT FH SCR1-4 is shown for reference. 
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2.4.3 Size Exclusion Chromatography 
Size exclusion chromatography was used to remove any aggregates or degradation products 
following initial purifications steps. A 16/200 or 26/200 Superdex column (GE Healthcare) 
was equilibrated in 4 column volumes of buffer using an ÄKTA purifier (GE Healthcare). 
The buffer was chosen depending upon the functional assay for which the protein was 
required. A maximum volume of 5ml or 10ml of purified protein depending on whether the 
16/200 or 26/200 Superdex column was used, was prepared using a 0.22µm filter and was 
loaded onto each column respectively using a superloop (GE Healthcare). Buffer was applied 
to the column for 1 column volume at a rate of 0.5ml/min. Elution fractions were collected 
and those containing protein as visualised on the chromatogram were analysed by SDS-
PAGE to confirm the presence of protein. A representative chromatogram and corresponding 
bands on SDS-PAGE is shown (Figure 16). 
 
Figure 16 Representative trace of size-exclusion 
R83S FH SCR1-4 was eluted from HIS-Trap FF column and loaded onto a 26/200 Superdex column. Protein was eluted 
using PBS. Chromatogram (blue trace) is a measure of absorbance at 280nm and the peak shown is evidence of protein 
elution. In this representative example, the peak was visible at a retention volume just under 150ml. Elution fractions 
corresponding to the peak were separated on a 4-15% gradient SDS-PAGE that confirmed the presence of a protein free of 
aggregates and degradation at ~25kDa under non-reducing conditions. 
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2.4.4 Reverse Phase Chromatography 
WT and R83S FH SCR1-2 expressed in 15N-media was purified using cation exchange 
followed by size exclusion. Unfortunately, due to the small difference in size between the 
intact protein and degradation product shown previously in Figure 14, size exclusion did not 
separate the intact protein to homogeneity. In order to separate the intact protein from the 
degradation product, reverse-phase chromatography was used. 
WT and R83S FH SCR1-2 in 50mM potassium phosphate pH 7 was applied to a Discovery 
BIO Wide Pore C5 column (Sigma) equilibrated with 2.5 column volumes of a binding buffer 
(dH2O with 0.05% tri-fluoroacetic acid). Protein was eluted using an elution buffer 
(acetonitrile with 0.05% tri-fluoroacetic acid) over a gradient of 0-100% over 20 minutes. 
The elution fractions containing protein were analysed by 4-15% SDS-PAGE confirming 
separation of intact protein from the degraded protein as shown in Figure 17. 
 
 
Figure 17 Final purification step of FH SCR 1-2 (WT and R83S) using reverse phase chromatography 
WT and R83S FH SCR1-2 were loaded onto Discovery BIO Wide Pore C5 column and eluted using acetonitrile with 0.05% 
tri-fluoroacetic acid. Chromatogram (black trace) is a measure of absorbance at 280nm. Peaks are evidence of protein 
elution. Elution fractions corresponding to peaks were separated on 4-15% gradient SDS-PAGE and confirmed the 
separation of two similarly sized proteins, consistent with a larger intact protein at ~15kDa and a smaller degraded 
fragment, under non-reducing conditions. 
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2.4.5 Purification of OX24 using a Protein G Column 
Protein G is a cell surface protein of Group G Streptococci that can bind mouse 
immunoglobulin of all sub-classes. Prepacked HiTrap Protein G HP column (Sigma) contains 
protein G and was used to purify OX24, a mouse monoclonal immunoglobulin. Supernatant 
containing OX24 antibody was prepared using a 0.22µm filter immediately prior to loading 
onto a HiTrap Protein G HP column equilibrated with 5 column volumes of a binding buffer 
(20mM sodium phosphate pH 7.0) using an ÄKTA purifier at 4°C. The column was washed 
with 5 column volumes of binding buffer. Bound protein was eluted using an elution buffer 
(0.1M glycine-HCl pH 2.7) and collected in 500µL fractions and immediately neutralised 
with 80µL 1M Tris pH 8.0. The elution fractions containing protein were analysed on 4-15% 
gradient SDS-PAGE under reducing conditions (Figure 18). 
 
 
Figure 18 Purification of OX24 antibody 
OX24 antibody binds to Protein G and was eluted using 0.1M glycine-HCl, pH 2.7 (green trace). The conductivity (brown 
trace) falls as the elution buffer is loaded onto the column and reflects the lower conductivity of the elution buffer. 
Chromatogram (blue trace) is a measure of absorbance at 280nm and the peak shown is evidence of protein elution. Elution 
fractions corresponding to the peak were separated on 4-15% gradient SDS-PAGE confirmed the separation of a ~160kDa 
band under reducing conditions into 2 smaller bands at ~ 50kDa and 25kDa, consistent with the elution of an 
immunoglobulin visible as a single protein and its heavy and light chains. 
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2.4.6 Generation of an Immunoaffinity Column 
HiTrap NHS-activated HP (Sigma) is a prepacked column containing NHS-activated 
Sepharose™ High Performance and is designed for the covalent coupling of ligands 
containing primary amino groups. An affinity column can be generated by covalently 
coupling purified monoclonal antibody onto agarose beads activated by N-
hydroxysuccinimide (NHS). Thereafter, the column with bound immunoglobulin can be used 
to capture a target antigen by immunoaffinity chromatography. 
Purified antibody was buffer exchanged into a coupling solution (0.2M sodium carbonate and 
0.5M NaCl, pH 8.3) and concentrated to 10mg/ml. 6ml of HCl was used to wash out 
isopropanol, used to maintain activity of the1 ml HiTrap NHS-activated HP column prior to 
first use. 1ml of purified antibody was then loaded onto the column and incubated for 30 
minutes at 25°C. 6ml of Buffer A (0.5M ethanolamine and 0.5M NaCl, pH 8.3) and 6ml of 
buffer B (0.1M sodium acetate and 0.5M NaCl, pH 4) were alternately loaded onto the 
column to deactivate excess active groups for a total of 3 times each. The column was 
incubated for 30 min at 25°C following the second application of buffer A. 
Three immunoaffinity columns were generated. One was using a monoclonal antibody to FB 
(JC-1), a kind gift from Professor Claire Harris, Cardiff University. One was a monoclonal 
antibody specific to SCR5 of FH (OX24), generated by tissue culture of OX24 hybridomas. 
One was a monoclonal antibody specific to the common polymorphic variant, 402Y on SCR7 
of FH (MBI6), a kind gift from Professor Claire Harris, Cardiff University. 
 
2.4.7 Preparation of Serum Samples 
Freshly drawn whole blood was allowed to clot for 30 minutes at 25°C and centrifuged at 
3000rpm for 15 minutes. Serum was removed and prepared using a 0.22µm filter and pooled. 
 
2.4.8 Depletion of Serum of FB and FH 
A 1ml HiTrap NHS HP column with bound monoclonal antibody to FB (JC-1) and a 1ml 
HiTrap NHS HP column with bound monoclonal antibody to FH (OX24) were equilibrated 
with PBS in series. Freshly prepared and filtered serum (up to 5ml at a time) was applied to 
the columns via a superloop using ÄKTA purifier to sequentially deplete FB and FH from 
serum at 0.5ml/min. Fractions of serum depleted of FB and FH (ΔBΔHNHS) containing peak 
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absorbance were analysed to confirm the removal of FB and FH. Fractions were then pooled 
and stored in 500µL aliquots before use in sheep erythrocyte haemolysis assays. 
 
2.4.9 Detection of Proteins in Serum. 
For the detection of proteins in serum, serum samples were diluted 1:100 in dH2O and 
prepared for SDS-PAGE by the addition of 5x non-reducing buffer (Thermoscientific). Tris-
glycine gels (Novex) and the XCell SureLock Mini-Cell (Novex) were set up using 1x 
running buffer (25mM Tris base, 192mM Glycine and 0.1% SDS pH 8.3) diluted from 10x 
Tris/Glycine SDS (Invitrogen). Diluted serum samples and 5μL of Precision Plus Protein™ 
Dual Color Standard (Biorad) were loaded into individual wells. Samples were separated by 
SDS-PAGE at 125V for 90 minutes. 
XCell SureLock Mini-Cell was set up for gel transfer of Novex Tris-glycine gels onto a 
nitrocellulose membrane. Following SDS-PAGE, the protein was transferred to nitrocellulose 
membrane at 25V for 90 minutes in transfer buffer, pre-chilled to 4°C. The membrane was 
then blocked for 1 hour at 25°C in 5% milk powder in TBST. The membrane was then 
incubated in 5% milk power in TBST containing a primary antibody for 1 hour at 25°C 
followed by a 5% milk powder in TBST containing a secondary antibody for 1 hour at 25°C. 
The membrane was washed 3 times in TBST for 5 minutes following each incubation step. 
The selection of respective primary and secondary antibodies are summarised (Appendix 3, 
Table 57). The membrane was then incubated in SuperSignal™ West Pico Chemiluminescent 
Substrate and exposure onto Carestream® Kodak® X-Omat LS film as previously described. 
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2.4.10 Confirmation of depletion of serum 
Fractions of serum depleted of FB and FH were tested using Western blot to confirm that FB 
and FH had been removed. Western blot analysis confirmed that serum was depleted of FB 
and FH (Figure 19). A sample of serum prior to FB and FH depletion and purified FB and FH 
were used as positive controls. 
 
Figure 19 Confirmation of serum depletion of FB and FH 
A 1ml HiTrap NHS HP column with bound antibody to FB (JC-1 column) and a 1ml HiTrap NHS HP column with bound 
antibody to FH (OX24 column) were equilibrated with PBS in series. Serum is loaded onto the columns in series. 
Conductivity (green trace) falls indicating differences between PBS and serum alongside a chromatogram (dark blue trace) 
that shows absorbance at 280nm representing the passage of serum through the column. The ‘JC-1’ and ‘OX24’ columns 
contain monoclonal antibody to FB and FH respectively and therefore capture and remove FB and FH from serum. 
Fractions (black arrows) containing serum following passage of the JC-1 and OX24 column were collected and analysed to 
confirm the depletion of FB and FH by Western blotting. Serum (1:100), before and after FB and FH depletion, and purified 
FB and FH were separated on 6% SDS-PAGE under non-reducing conditions. Incubation with goat anti-FH (1:14000) and 
goat anti-FB (1:2000) primary antibody and rabbit anti-goat HRP (1:3000) as a secondary antibody was used to detect FB 
and FH. FB and FH were detected in serum (NHS). Fractions of depleted serum(ΔBΔHNHS) show no evidence of FB and 
only traces of FH. A pair of bands visible at ~30kDa are likely to be FHR1. 
 
 60 
 
2.4.11 Purification of FB and FH from immunoaffinity column 
A 1ml HiTrap NHS HP column with bound antibody to FB and a 1ml HiTrap NHS HP 
column with bound antibody to FH, generated in section 2.4.6 were used to purify FB or FH 
from serum. Freshly prepared serum was loaded onto a HiTrap NHS HP column with bound 
antibody using an ÄKTA purifier, equilibrated with 5 column volumes of binding buffer 
(PBS). The column was washed with a further 5 column volumes of binding buffer before 
elution of protein using an elution buffer (0.1M glycine-HCl, pH 2.7) (Figure 20). The eluted 
protein was collected in 500µL fractions and immediately neutralised with 80µL 1M Tris, pH 
8. Fractions containing eluted protein were pooled, gel-filtered into PBS and concentrated. 
 
Figure 20 Purification of FB from serum 
Representative chromatogram of elution from the ‘JC-1’ column’. Cyan line indicates conductivity. As it falls, demonstrating 
the transition of PBS to 0.1M Glycine pH 2.7 in the column. Chromatogram (blue trace) is a measure of absorbance at 
280nm and the peak shown is evidence of protein elution. Elution fractions corresponding to the peak were separated on 4-
15% gradient SDS-PAGE under non-reducing conditions. Bands at <100kDa can be seen, at the size expected for FB. 
 
2.4.12 Purification of 402Y FH from Serum 
A 1ml HiTrap NHS HP column with bound antibody to 402Y FH (MBI6), generated in 
section 2.4.7 was used to purify 402Y-specific FH from serum in the study of a FH/FHR3 
hybrid protein. Freshly prepared serum was loaded onto a HiTrap NHS HP column with 
bound antibody on an ÄKTA purifier, equilibrated with 5 column volumes of binding buffer 
(PBS). The column was washed with a further 5 column volumes of binding before elution of 
protein using an elution buffer (PBS containing 0.05% diethylamine, pH 11.5) (Figure 21). 
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The eluted protein was collected in 500µL fractions and immediately neutralised with 80µL 
1M Tris, pH 7. Fractions containing eluted protein were pooled and gel-filtered into PBS and 
concentrated for testing in functional assays. 
 
Figure 21 Purification of 402Y-specific FH 
Representative chromatogram of elution of FH from the ‘MBI-6’column. Donor control serum was loaded onto the column. 
UV chromatogram (blue trace) a measure of absorbance at 280nm and the peak shown is evidence of protein elution. 
Elution fractions corresponding to the peak were separated on 4-15% gradient SDS-PAGE under non-reducing conditions. 
Bands between 100 and 150kDa can be seen, consistent with FH. 
  
2.4.13 Heparin Affinity Chromatography 
Heparin chromatography was used to determine the differences in heparin binding between a 
hybrid FH/FHR3 protein and WT FH. HiTrap Heparin HP (GE Healthcare) is a prepacked 
column containing Heparin Sepharose™ High Performance. FH or hybrid FH/FHR3 protein 
purified from serum was loaded onto a 1ml HiTrap Heparin HP following equilibration with 
a binding buffer (10mM sodium phosphate, pH 7). The column was washed following sample 
loading with 5 ml of binding buffer before elution of protein using an elution buffer (10mM 
sodium phosphate, pH 7 and 1M NaCl) on a gradient. The salt concentration at peak elution 
was determined from the chromatogram. 
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2.4.14 Quantification of Protein 
The absorbance of protein (A280) was determined using a NanoDrop 8000 (Thermo Scientific) at 
280nm. 
The concentration of a protein was determined using a formula (Figure 22) based on A280 and 
extinction coefficient of a protein determined using www.Expasy/Protparam. Extinction co-
efficient values for different proteins are shown (Appendix 4, Table 58). 
 
 
Figure 22 Formula to determine concentration of a protein 
 
2.4.15 Buffer Exchange  
Following protein purification, size-exclusion chromatography (as described in section 2.4.3) 
was used to gel-filter purified proteins into a suitable buffer for functional studies. 
Alternatively, Vivaspin concentrators (Sartorius) were used to buffer exchange samples.  
 
2.4.16 Concentration of Protein Samples 
Concentration of purified protein samples in the correct buffer to an adequate concentration 
for functional studies was performed using Vivaspin concentrators.  
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2.5 Structural and Functional Analysis of Expressed Proteins 
2.5.1 NMR Studies 
Purified samples of SCR1-2 (WT and R83S) expressed by me using 15N-ammonium sulphate 
as the sole nitrogen source were freeze-dried by Dr. Andy Herbert and resuspended at 20mM 
potassium phosphate pH 7 with added 10% D2O. The sample was loaded onto a Bruker 
Avance III spectrometer fitted with a TCI cryogenic probe for nuclear magnetic resonance 
(NMR) spectroscopy. Two-dimensional 1H-15N-heteronuclear single quantum coherence 
(HSQC) spectra were acquired at 37°C and analysed by Dr Andy Herbert. 
In this analysis, resonance assignments were determined where possible by comparison with 
the previously assigned WT FH SCR1-2 spectrum (Hocking et al., 2008). Chemical shift 
differences between the WT FH SCR1-2 and R83S FH SCR1-2 proteins were determined 
using the CcpNmr Analysis Suite of Programs. Normalized log values of the chemical shift 
differences were entered into the B factor field of the Protein Data Bank file (2RLP) and 
plotted onto cartoon representations of the representative structure of WT FH SCR1-2 using 
Pymol. 
 
2.5.2 Immobilisation of C3b for SPR Studies 
The surface of a CM5 chip can be activated for standard amine coupling by the addition of N-
hydroxysuccinimide (NHS) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), allowing covalent binding of a ligand containing primary amino 
groups. This allows the analysis of protein-protein interactions between an analyte and the 
bound ligand using surface plasmon resonance (SPR). 
The amount of ligand to be bound as measured by resonance units (RU) was determined by 
the ratio of molecular mass of the ligand (C3b) and the analyte (FH SCR1-4) as a multiple of 
the maximum number of RU to be measured during flow of the analyte. For binding studies, 
maximal RU chosen was 100, so ~600 RU of C3b was immobilised. 
C3b was immobilised to a CM5 biosensor chip by standard amine coupling on a Biacore 
X100 (GE Healthcare). C3b (CompTech) was diluted to 5µg/ml in an immobilisation buffer 
(50mM sodium acetate pH 5). The surface of a CM5 biosensor chip (GE Healthcare) was 
prepared for standard amine coupling by the injection of a freshly prepared mixture of NHS 
and EDC (both GE Healthcare) in equal volumes over both flow cell surfaces for 540 seconds 
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at 10µL/min. Serial injections of 5µg/ml C3b were performed onto flow cell 2 only for 10-20 
seconds at a time at 10µL/min until the desired amount of C3b was detected on the surface of 
flow cell 2. The active sites were then blocked by an injection of ethanolamine (GE 
Healthcare) for 540 seconds at 10µL/min (Figure 23). 
 
Figure 23 Immobilisation of C3b by standard amine coupling 
Blank substracted sensorgram (Flow cell 2 – Flow cell 1) showing activation of surface of CM5 chip by the addition of 
NHS/EDC over flow cells 1 and 2. This is followed by the flow of C3b on flow cell 2 only and results in an incremental rise 
in baseline, due to immobilisation of C3b on the surface of the CM5 chip. Finally, injection of ethanolamine over both flow 
cells blocks active sites. 
 
2.5.3 Testing Affinity of FH SCR1-4 to C3b 
Wildtype and mutant FH SCR1-4 were gel-filtered into a HEPES-buffered running buffer 
(HBS-EP+) (10mM HEPES-buffered saline, 3mM EDTA and 0.05% surfactant P20) and 
concentrated. Wildtype and R83S FH SCR1-4 samples were injected over both flow cells for 
90 seconds followed by a dissociation time of 600 seconds. Flow cells were regenerated 
using 2 x 45 second injections of 1M NaCl (Figure 24). A steady state was achieved within 
seconds of the injection of FH SCR1-4. A range of at least 5 different concentrations of FH 
SCR1-4 including at least one duplicate injection was performed. In experiments comparing 
R53C, D90G, G69E, Q81P, D130N, S159N, A161S and M162V and wildtype, FH SCR1-4 
samples were injected over both flow cells for 45 seconds followed by a dissociation time of 
100 seconds. The steady-state response was plotted against concentration of FH SCR1-4. An 
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affinity curve was generated using Biacore T200 Evaluation software (GE Healthcare) and 
the affinity constant (KD) determined for mutant proteins and compared to wildtype 
performed on the same immobilised C3b. 
 
Figure 24 Initial single cycle of binding of FH SCR1-4 to immobilised C3b 
FH SCR1-4 is injected over the surface of immobilised C3b. A senogram shows the rapid association and acheivement of 
steady state binding between FH SCR1-4 and C3b. At the end of FH injection, there is rapid dissocation. The spike at the 
end of FH injection is an artefact of refractive index changes of different buffers. Due to the rapid dissocation to baseline, 
the period of dissociation and the number of regneration steps was reduced to shorten assay time. 
 
2.5.4 Testing Decay Activity in Real-time Using SPR 
In initial experiments testing R83S, R53C and D90G, FB (CompTech) and FD (CompTech) 
were buffer exchanged into a HEPES-buffered running buffer supplemented with magnesium 
(HBS-P+Mg) (HEPES-buffered saline containing 0.5% (v/v) surfactant P20 and 1mM 
MgCl2) and concentrated. A mixture of 500µM FB and 60µM FD in HBS-P+Mg was 
injected over both flow cells of immobilised C3b on the surface of a CM5 biosensor chip for 
120 seconds, forming an on-chip C3bBb. C3bBb was allowed to decay for 210 seconds. FH 
SCR1-4 (wildtype or mutant), also in HBS-P+Mg was then injected for 45 seconds and 
acceleration of C3bBb decay was visualised in real time. The surface was regenerated by the 
injection of 2µM FH SCR1-4 for 45 seconds followed by 1M NaCl for 45 seconds. 
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In experiments testing decay activity of G69E, Q81P, D130N, S159N, A161S and M162V vs 
wildtype, FB and FD (CompTech) were diluted to 250µM FB and 30µM FD in HBS-P+Mg 
and was injected over both flow cells to form an on-chip C3bBb. 
In experiments testing decay activity of all variants except R83S vs wildtype, sensograms 
were normalised from baseline prior to injection of FB and FD (0%) to the binding stability 
reading (100%) after injection of FB/FD. Overlaying sensograms from mutant and wildtype 
injections of FH SCR1-4 are shown and representative of decay acceleration for at least 2 
different experiments. A representative sensogram is shown in Figure 25. 
 
Figure 25 Decay of on-chip C3 convertase 
C3bBb was formed by the injection of FB and FD in a HEPES-buffered running buffer supplemented with magnesium onto 
immobilised C3b on the surface of CM5 biosensor chip on Biacore X100. Sensograms for wildtype (solid line) and a buffer 
(dotted line) are shown in overlay. Following 210 seconds of natural dissociation of C3bBb, the first injection of WT FH 
accelerates C3bBb decay whereas buffer does not. At the second (regeneration) injection of FH, remaining C3bBb following 
initial buffer injection completely decays.A further regeneration step takes place with the injection of NaCl. 
 
2.5.5 Testing Co-Factor Activity of FH in the Fluid Phase 
A mixture of 3µL C3b (5.68μM), 4.5µL FI (114nM) and 5µL FH SCR1-4 (750nM) or 5μL of 
FH or FH/FHR3 (150nM) in a final volume of 15µL PBS were incubated for 30 minutes 
before the reaction was terminated by the addition of 15µL Laemmli 2x reducing sample 
buffer (Sigma). A positive and negative control was set up by the addition of 5μL of FH 
(6.45μM) (CompTech) and 5μL of PBS respectively. The products of reaction were 
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visualised following 10% SDS-PAGE and staining with Coomassie blue or by transfer to 
nitrocellulose membrane and Western blotting. For Western blotting (Appendix 3 - Table 57), 
the α- and β-chains of C3b were detected using rabbit polyclonal C3 primary antibody 
(Abcam) (1:5000) and goat anti-rabbit HRP secondary antibody (Abcam) (1:5000) followed 
by chemoluminescence. Evidence of co-factor activity was visualised by the loss of the α’-
chain and appearance of the α1-chain (Figure 26). 
In the study of the R83S mutant protein, a mixture of 3µL C3b (5.68μM), 4.5µL FI (114nM) 
and 5µL FH (750nM) in a final volume of 15µL PBS were incubated for 15, 30, 60 and 120 
minutes before the reaction was terminated by the addition of 15µL 2x Laemmli 2x reducing 
sample buffer. Co-factor activity was visualised following 10% SDS-PAGE and Western 
blotting by the loss of the α’-chain and appearance of the α1-chain. The image was captured 
using BioSpectrum 500 Imaging System (UVP) and the intensity of the bands quantified 
using VisionWorks®LS Analysis Software (UVP) and normalised to the β-chain. 
 
 
Figure 26 Inactivation of C3b in a fluid phase co-factor assay 
In this represenative figure, C3b formed of α’- and β-chain are held together by disulphide bonds. In the presence of FI and 
a co-factor, FH, inactivation of C3b to iC3b via proteolytic cleavage of the α’-chain occurs, forming α1 and α2 chains. 
Under reducing conditions, the α- and β-chains are separated on 10% SDS-PAGE and transferred onto nitrocellulose 
membrane. Bands are visualised using rabbit anti-goat (1:5000) and goat anti-rabbit–HRP (1:5000) as primary and 
secondary antibody respectively follwed by enhanced chemoluminescence. Loss of the α’-chain and appearance of the α1 
and α2 chains indicate intact co-factor activity of FH. 
 
2.5.6 Generation of C3b-coated Sheep Erythrocytes 
Sheep erythrocytes in Alsever’s solution (TCS Biosciences) were washed 3 times in 
complement fixation diluent (CFD) (Oxoid) by centrifugation at 2000rpm for 5 minutes. 
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Washed sheep erythrocytes were sensitised by incubation with rabbit anti-sheep RBC stroma 
(Sigma) (1:4000) at a final concentration of 2% erythrocytes in CFD for 30 minutes at 37°C. 
Sensitised sheep erythrocytes (EA) were then washed 3 times in CFD by centrifugation at 
2000rpm for 5 minutes and resuspended at a final concentration of 2%. C3b was then 
deposited on the surface of EA by the addition of 1 volume of 4% ΔBΔHNHS and 6µg/ml 
Ornithodoros moubata complement inhibitor (OMCI) (Kind gift from Varleigh Immuno 
Pharmaceuticals) in CFD and an equal volume of 2% EA and incubated for 20 minutes at 
37°C (Figure 27). EA-coated with C3b (EA-C3b) were then washed 3 times in AP buffer 
(5mM sodium barbitone, pH 7.4, 150mM NaCl, 7mM MgCl2 and 10mM EGTA) and 
resuspended at a final concentration of 2% for decay and co-factor experiments. 
 
 
Figure 27 Generation of sheep EA-C3b 
Sheep E is sensitised by the addition of Sheep E and anti-sheep RBC stroma in a complement fixation diluent that contains 
calcium and magnesium ions permitting classical pathway activity. The cells are washed and sensitised sheep E (sheep EA) 
are added to ΔBΔHNHS and OMCI. OMCI is added to prevent cell lysis by serum. C3b deposits on the surface of Sheep E by 
the classical pathway. The depletion of FB from serum stops C3bBb formation at this stage. Cells are then washed into AP 
buffer for functional tests. Subsequent testing in both AP buffer (containing EGTA that chelates calcium ion) and PBS 
supplemented with EDTA (that chelates calcium and magnesium ions) prevents further classical pathway activation in the 
remainder of the protocol. 
 
2.5.7 Testing Decay Activity of FH on the Surface of Sheep Erythrocytes 
C3bBb was formed on the surface of sheep erythrocytes by the addition of 50µL of 40μg/ml 
FB and 0.2μg/ml FD diluted in AP buffer to 50µL of EA-C3b for 15 minutes at 37°C. C3bBb 
formation was then stopped by the addition of PBS containing 250µM EDTA pH 7.4 at a 
1:20 dilution. C3bBb decay was then commenced by the addition of a concentration range of 
FH (wildtype or mutant) in triplicate, diluted in 50µl PBS for 15 minutes at 25°C. Lysis was 
then instigated as measure of remaining of C3bBb by the addition of 4% ΔBΔHNHS in PBS 
and incubation for 20 minutes at 37°C (Figure 28). To determine the amount of lysis, cells 
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were pelleted at 1200rpm for 3 minutes and 100µL of supernatant was sampled and the 
absorbance at 420nm (A420) measured on Multiskan Ascent® (Agilent). No lysis controls for 
blank subtraction were set up by the addition of no serum. Maximal lysis was determined by 
A420 from the addition of PBS instead of FH. Mean readings of experiments in triplicate were 
calculated. Total protection from lysis for each concentration of FH was determined by 1-
[mean A420 (FH) – mean A420 (blank)]/A420 (PBS) expressed as a percentage. A sigmoidal 
curve was fitted using SigmaPlot and used to determine the concentration at which FH gave 
50% protection from lysis (IC50). 
 
 
Figure 28 Decay activity on surface of sheep erythrocytes 
C3bBb is formed by the addition of FB and FD on the surface of sheep EA-C3b in AP buffer, permitted by the presence of 
magnesium. Lysis can then be initiated by the addition of ΔBΔHNHS (diluted in PBS containing EDTA) from which C3 is 
cleaved via preformed C3bBb on the surface of sheep erythrocytes. Lysis occurs following the subsequent formation of 
C3bBbC3b and activation of terminal pathway and MAC formation. EDTA chelates both calcium and magnesium ions 
preventing further formation of C3bBb via AP. Lysis is therefore dependent the amount of C3bBb present prior to the 
addition of ΔBΔHNHS. Decay activity of FH can be tested on the surface of Sheep EA-C3b with formed C3bBb. This is 
added to FH that binds to C3b and sialic acids on sheep E. FH decays C3bBb and protects sheep E from lysis.  
 
2.5.8 Testing Co-Factor Activity of FH on the Surface of Sheep Erythrocytes 
Co-factor activity of FH was determined by the addition of 50µL of a concentration range of 
FH (wildtype or mutant) in triplicate, and 2.5µg/ml FI in AP buffer to 50µL of EA-C3b. In 
the experiments for R83S and R53C, co-factor activity was allowed to occur for 8 minutes at 
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25°C (Figure 29). In the experiments for the remainder of mutants, co-factor activity was 
allowed to occur for 15 minutes. After the incubation period, cells were washed 3 times in 
200µL of AP buffer followed by pelleting for at 1200rpm 3 minutes. After the final wash, 
cells were resuspended in 50µL AP buffer. C3bBb was formed on the surface of sheep 
erythrocytes containing intact C3b by the addition of 50µL of 40μg/ml FB and 0.2μg/ml FD 
to 50µL of EA-C3b for 15 minutes at 37°C. Lysis was then instigated as measure C3bBb that 
was able to form by the addition of 4% ΔBΔHNHS and incubation for 20 minutes at 37°C. 
To determine the amount of lysis, cells were pelleted for 3 minutes at 1200rpm and 100 µL of 
supernatant was sampled and the absorbance as 420nm measured (A420). No lysis controls for 
blank subtraction were set up by the addition of no serum. Maximal lysis was determined by 
A420 from the addition of PBS instead of FH. Mean readings of experiments in triplicate were 
calculated. Total protection from lysis for each concentration of FH was determined by 1-
[mean A420 (FH) – mean A420 (blank)]/A420 (PBS) expressed as a percentage. A sigmoidal 
curve was fitted using SigmaPlot and used to determine the concentration at which FH gave 
50% protection from lysis (IC50). 
 
 
Figure 29 Co-factor activity on surface of sheep erythrocytes 
C3bBb is formed by the addition of FB and FD on the surface of sheep EA-C3b in AP buffer. Lysis as before can then be 
initiated by the addition of ΔBΔHNHS. Co-factor activity of FH can be tested on the surface of Sheep EA-C3b. Sheep EA-
C3b is added to FI and FH. FH acts as a co-factor for the FI-mediated proteolytic cleavage of C3b into iC3b and prevents 
C3bBb formation. In turn, this protects sheep E from lysis. 
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Chapter 3 – Complement Abnormalities in Cohorts of MPGN and C3G 
3.1 Introduction 
MPGN and C3G are rare diseases that associate with abnormalities of the AP. Included in 
these cohorts are the distinct phenotypes, IC-MPGN, DDD and C3GN that are characterised 
by their appearances on light microscopy, electron microscopy and immunofluorescence. 
These patients share clinical features that include proteinuria, haematuria and renal failure 
(Servais et al., 2012; Medjeral-Thomas et al., 2014b). Renal failure is progressive and 40% 
of patients develop ESRD at 10 years (Cansick et al., 2004; Servais et al., 2012; Medjeral-
Thomas et al., 2014b). Recurrence in transplantation is common in all subtypes, ranging from 
30-40% in MPGN to 80-90% in DDD (Braun et al., 2005). There are no universally effective 
treatments for these conditions. 
The role of the AP has been described in patients with MPGN/C3G for many years. 
Uncontrolled activation of AP in association with C3 nephritic factor (Spitzer et al., 1969) 
and FH deficiency (Levy et al., 1986) in MPGN has been reported for over 30 years. More 
recently, functional studies of familial rare genetic variants in CFH (Licht et al., 2006) and 
C3 (Martinez-Barricarte et al., 2010; Chauvet et al., 2015) have also been reported. 
Genetic variants in CFH, CFI, CD46, C3 and CFB have been described in several cohorts of 
MPGN/C3G and includes rare genetic variants and common polymorphisms (Servais et al., 
2012; Bu et al., 2015; Iatropoulos et al., 2016). Autoantibodies to FH have been described 
and characterised in cohorts of MPGN/C3G (Goodship et al., 2012; Blanc et al., 2015). 
Furthermore, studies of several large families with C3G have led to the discovery of 
abnormal FHR proteins, arising due to genomic abnormalities within a region of high 
sequence homology (Malik et al., 2012; Tortajada et al., 2013; Zhang et al., 2013b; Chen et 
al., 2014) and includes CFHR5 nephropathy (Gale et al., 2010). Studies of these abnormal 
FHR proteins have suggested a role for FHRs on surface bound C3b resulting in the de-
regulation of FH (Goicoechea de Jorge et al., 2013; Tortajada et al., 2013). 
Further cohort studies to determine the prevalence of these acquired and genetic 
abnormalities of AP are required. Ongoing study of these abnormalities might improve our 
understanding of the factors that determine disease onset and progression. This may allow a 
targeted approach to therapies in MPGN and C3G. 
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3.1.1 Chapter Aims 
In this chapter, I will describe my analysis of two cohorts of patients with MPGN/C3G. 
In a prospective study of a paediatric (RaDaR) cohort recruited from 2011 until July 2014, 
DNA, serum and biopsies were collected. In this study, 
1. I co-ordinated the central review of pathological samples by an expert pathologist 
(Prof Terry Cook) with a special interest in C3G; 
2. I analysed the clinical data that was provided by the RaDaR registry; 
3. I analysed the sequencing and copy number variation data that was undertaken by the 
Northern Molecular Genetics Service and 
4. I analysed the autoantibody data provided by Dr. Kevin Marchbank (and performed 
the screening for autoantibodies against FHR3 and FHR4).  
In a retrospective cohort of patients referred to the Newcastle Complement Genetics Service 
since 2001, 
1. I analysed the autoantibody data performed by Dr. Kevin Marchbank and 
2. I analysed the sequencing data that was undertaken by the Northern Molecular 
Genetics Service. 
Overall, my aim was to describe the prevalence of acquired and genetic abnormalities of AP 
in these cohorts of MPGN/C3G, in which I predict these abnormalities to be present. 
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3.2 Complement Abnormalities in a Prospective Paediatric Cohort of MPGN and C3G 
3.2.1 Clinical Characteristics of a Prospective Paediatric Cohort (RaDaR) 
Patients from 10 paediatric centres were recruited into the National Study of MPGN and 
C3G, a part of RaDaR. A diagnosis from renal biopsy was made by pathologists at local 
centres. Eighty-three patients were recruited between 2011 and July 2014. Central pathology 
review was performed by Professor Terry Cook of available histology, immunofluorescence 
and electron microscopy. Three patients were excluded from any further analysis at this stage 
as no form of glomerulonephritis could be identified on the pathological specimens available. 
A diagnosis of DDD, C3GN or IC-MPGN was made in 64 patients. In a further 8 patients, 
there was immune-complex deposition. Light microscopy review of these patients identified 
features of mesangial expansion and cellular proliferation but insufficient double contouring 
of glomerular basement membrane for a diagnosis of MPGN. These cases have been included 
in this data analysis but treated as a separate group called immune-complex 
glomerulonephritis (IC-GN) (Figure 30). The analysis of patients was performed for 4 sub-
groups – IC-GN, IC-MPGN, DDD and C3GN. 
Patients from all groups presented throughout childhood, ages ranging from 2 years to 15 
(Table 19). The typical presentation of patients in all sub-groups was hypoalbuminaemia 
(Figure 31), proteinuria (Figure 32), and haematuria. Patients with DDD and C3GN presented 
with lower estimated glomerular filtration rate (eGFR) than IC-MPGN (P<0.05) (Figure 33). 
 
Figure 30 Pathological classification of patients in RaDaR cohort 
 74 
 
 IC-GN IC-MPGN DDD C3GN 
Number of patients 8 33 14 25 
Median age at presentation (range) 8 (2-10) 9 (2-15) 9.5 (4-15) 9 (4-15) 
Median albumin at presentation (n)(g/L) 34 (7) 25 (31) 30 (14) 26 (22) 
Median P:Cr (n) (mg / mmol creatinine) 332.3 (5) 546.9 (18) 775.5 (8) 402.0 (17) 
Number of patients with documented haematuria 
(%) 
6 (75.0) 20 (60.1) 10 (71.4) 13 (52.0) 
Median eGFR (ml/min/1.73m2) at presentation (n) 95.5 (4) 125.5 (24) 74 (7) 96 (18) 
Table 19 Clinical characteristics of RaDaR cohort 
n = number of patients for which data available, P:Cr = protein to creatinine ratio, Cr = creatinine, % = percentage of 
total number of patients, eGFR= estimated glomerular filtration rate, determined by Schwartz formula. 
 
Figure 31 Serum albumin at presentation in RaDaR cohort 
A lower limit of normal serum albumin is 35g/L. The differences between groups were not statistically significant. 
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Figure 32 Urinary protein:creatinine at presentation in RaDaR cohort 
An upper limit of normal urinary protein:creatinine is 20mg/mmol creatinine. The differences between groups were not 
statistically significant. 
 
 
Figure 33 Estimated glomerular filtration rate at presentation in RaDaR cohort 
Normal estimated glomerular filtration rate (eGFR) is >90ml/min/1.73m2. eGFR determined by Schwartz formula. eGFR 
was significantly lower in DDD and C3GN compared to IC-MPGN *= P<0.05. 
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3.2.2 Complement Levels in RaDaR Cohort 
At the time of first investigation, 83.6% of patients had a low C3 level. C3 levels were lowest 
in patients with DDD (Figure 34). Over 70% of patients with immune-complex disease (IC-
GN and IC-MPGN) had a low C4, a higher proportion compared to patients with C3 
glomerulopathy (DDD and C3GN) (Figure 35). C3 and C4 levels for individual patients can 
be seen in Figure 36. Patients with low C4 were more likely to have a form of immune-
complex disease than C3 glomerulopathy (Odds Ratio 6.6, P=0.0009) (Table 20). 
 
Figure 34 C3 levels in RaDaR cohort at diagnosis 
Dotted line indicates lower limit of normal C3 (0.68g/L). n = number of patients in sub-group with data available. The 
differences between groups were not statistically significant. 
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Figure 35 C4 Levels in RaDaR Cohort at diagnosis 
Dotted line indicates lower limit of normal C4 (0.18g/L). n = number of patients in sub-group with data available. The 
differences between groups were not statistically significant.. 
 
Figure 36 C3 and C4 levels plotted for individual patients according to disease sub-group at diagnosis 
Dotted lines indicate lower limits of normal complement levels. Filled markers are forms of immune-complex disease. Open 
markers are forms of C3 glomerulopathy. 
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 Immune-Complex Disease C3 Glomerulopathy 
Number of patients with 
Low C4 (%) 
32 (82.1) 11 (40.7) 
Number of patients with 
normal C4 (%) 
7 (17.9) 16 (59.3) 
Table 20 Frequency of patients with low or normal C4 Levels in RaDaR cohort at diagnosis 
Patients with low C4 were more likely to have immune-complex disease than C3 glomerulopathy (Odds Ratio 6.6 
P=0.0009). 
 
C3 and C4 levels were measured on samples at time of recruitment into the RaDaR cohort in 
the laboratory at Newcastle Hospitals NHS Foundation trust. These samples were taken at a 
median duration of 23.4 (IQR 3.0 – 48.1) months from initial diagnosis (Table 21). This 
duration was used as a measure of initial follow-up time in this study. Follow-up in the 
patients with DDD was slightly less than in patients in other sub-groups but not statistically 
significant. C3 and C4 levels at diagnosis and follow-up are summarised in Figure 37 and 
Figure 38. Median C3 levels increased from diagnosis to follow-up in all sub-groups. This 
increase was statistically significant in IC-GN, IC-MPGN and C3GN. Fewer patients at 
follow-up in all sub-groups had low C3, though almost three-quarters of patients with DDD 
still had low C3 at this time. 
 
 Number of Patients Median Follow Up (months) IQR Follow Up (months) 
All 80 23.4 3.0 – 48.1 
IC-GN 8 27.8 3.2 - 57.4 
IC-MPGN 33 35.5 4.3 - 52.9 
DDD 14 10.5 1.1 - 44.3 
C3GN 25 20.0 3.3 - 40.5 
Table 21 Time since diagnosis at time of recruitment of patients into RaDaR 
Follow-up times between groups was not statistically significant. IQR = interquartile range. 
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Figure 37 C3 levels at diagnosis and follow-up 
Dotted lines indicate lower limits of normal complement levels. n = number of patients in sub-group with data available. C3 
levels were significantly higher at follow-up (FU) compared to diagnosis (Dx) in IC-GN, IC-MPGN and C3GN. *=P<0.05 
***=P<0.001. 
 
C4 levels were slightly higher at follow-up compared to diagnosis in the two immune-
complex sub-groups, though half of patients continue to have low C4 levels. None of the 
differences in C4 levels between diagnosis and follow-up were statistically significant. 
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Figure 38 C4 levels at diagnosis and follow-up 
Dotted lines indicate lower limits of normal complement levels. n = number of patients in sub-group with data available. The 
differences between groups were not statistically significant. 
 
3.2.3 C3 Nephritic Factor in RaDaR cohort 
There was a poor return of data for C3 nephritic factor at time of diagnosis from the clinical 
teams. It was available in only 27 cases (33.8%). Using this data only, an estimate of 
prevalence of C3 nephritic factor in this cohort was determined (Figure 39). The prevalence 
of C3 nephritic factor in DDD was 66.7%, 28.6% in IC-MPGN and 33.3% in C3GN. A C3 
nephritic factor at the time of diagnosis was not detected in the available results from patients 
with IC-GN. 
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Figure 39 C3 nephritic factor in RaDaR cohort at diagnosis 
The prevalence of C3 nephritic factor in this cohort was 42.1%, and highest in the DDD group. n = number of patients in 
sub-group with data available. The differences between groups were not statistically significant. 
 
C3 and C4 levels for individual patients are shown in Figure 40 for patients with available C3 
nephritic factor data at diagnosis. In this limited dataset, 18/21 (85.7%) patients had low C3 levels and 
was comparable with the figure of 83.6% of patients described in section 3.2.2. All patients with a low 
C3 nephritic factor at diagnosis had a low C3 level. C3 levels were lower in patients with a C3 
nephritic factor at diagnosis compared those without (P=0.039) (Figure 41). C4 levels were lower in 
patients without C3 nephritic factor though this difference did not reach statistical significance 
(Figure 42). 
In patients in whom C3 nephritic factor data was available, the association of C3 levels with C4 levels 
and the presence of a C3 nephritic factor is shown (Figure 43). Low C3 levels were explained by low 
C4 levels or C3 nephritic factor in 11 patients. Low C3 levels were not explained by low C4 levels or 
C3 nephritic factor in 5 patients. A further two patients (1 IC-MPGN and 1 C3GN) with low C3 levels 
had both low C4 levels and C3 nephritic factor. In the 3 patients that had normal C3 levels, 1 (IC-GN) 
had low C4 levels and 2 (both C3GN) had normal C4 levels (Figure 43). 
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Figure 40 C3 vs C4 levels for individual patients according to C3 nephritic factor status 
Dotted lines indicate lower limits of normal complement levels. 
 
 
Figure 41 C3 levels according to C3 nephritic factor status 
Dotted lines indicate lower limits of normal complement levels. n = number of patients in sub-group with data available. C3 
levels were lower if C3 nephritic factor was present (P=0.039). 
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Figure 42 C4 levels according to C3 nephritic factor status 
Dotted lines indicate lower limits of normal complement levels. n = number of patients in sub-group with data available. The 
differences between groups were not statistically significant. 
 
 
Figure 43 Patients with low C3, low C4 and C3 nephritic factor in RaDaR cohort. 
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3.2.4 Autoantibodies to FH in RaDaR cohort 
Samples of serum at the time of recruitment were screened for the presence of autoantibodies 
to FH by Dr. Kevin Marchbank. These samples were taken at a median follow up time of 
23.4 (IQR 3.0 – 48.1) months after diagnosis. 13/78 (16.7%) of patients were positive for 
autoantibodies to FH (Figure 44). 
 
Figure 44 Raw data for screening for autoantibodies to FH 
Data and Figure prepared by Dr. Kevin Marchbank. RU = response units titrated to standard published in (Goodship et al., 
2012), BDC = blood donor control, line indicates 97.5th percentile. Screening was performed in an initial 81 patients, but 
analysis is of 78 patients that had a diagnosis of IC-MPGN/C3G following central pathology review. 
 
Binding studies to short fragments of FH were performed by Dr. Kevin Marchbank in 
patients that were positive for autoantibodies to FH. Binding to FH SCR1-7, SCR8-15, 
SCR16-18 and SCR19-20 was tested (Figure 45). Predominant binding of each autoantibody 
to FH is summarised in Figure 46. Patients with autoantibodies to FH in this cohort 
predominantly bound to FH SCR1-7. 
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Figure 45 Epitope binding characteristics of autoantibodies to FH in RaDaR cohort 
Data and Figure prepared by Dr. Kevin Marchbank. Positive and negative controls for binding to each fragment are shown 
at the right of the figure. 14 patients with autoantibodies to FH are indicated. Epitope binding is shown for patient 1476 – 
not included in analysis as excluded due to no central pathology review. RU = response units. 
 
  
Figure 46 Predominant binding of autoantibodies to FH 
Epitope binding in patients with autoantibodies to FH was tested against short SCR fragments (1-7, 8-15, 16-18 and 19-20). 
The predominant reactivity was to SCR1-7 in 10 cases out of 13. 
 
The characteristics of the 13 patients with autoantibodies to FH are summarised in Table 22. 
C3 and C4 levels were compared from time of diagnosis and follow-up. C3 nephritic factor 
was identified in 2 patients (15.4%) but data for most patients was not available. 
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Patient Disease Predominant SCR Binding C3 at Dx C4 at Dx C3 at FU C4 at FU C3 Nephritic Factor 
381 C3GN 19 to 20 ↓ ↓ ↓ ↓ Not Known 
398 DDD 1 to 7 ↓ ↔ NR NR P 
429 IC-MPGN 1 to 7 NR NR ↓ ↓ P 
482 DDD 19 to 20 NR NR ↓ ↔ Not Known 
512 IC-MPGN 1 to 7 ↓ ↔ ↓ ↔ Not Known 
539 IC-GN 8 to 15 NR NR ↔ ↔ N/A 
541 C3GN 1 to 7 ↓ ↔ NR NR Not Known 
553 IC-MPGN 1 to 7 ↓ ↓ ↔ ↓ Not Known 
557 C3GN 1 to 7 NR NR ↔ ↓ N/A 
739 IC-GN 1 to 7 ↓ ↓ ↔ ↓ Not Known 
790 DDD 1 to 7 ↓ ↓ ↓ ↓ Not Known 
827 IC-MPGN 1 to 7 ↔ ↓ ↔ ↓ N/A 
845 IC-GN 1 to 7 ↔ ↓ ↔ ↓ N/A 
Table 22 Disease association and complement profile of patients with autoantibodies to FH in RaDaR cohort 
SCR = short consensus repeat, Dx = diagnosis, FU = follow-up, NR = no result, ↓ = below normal range, ↔ = within normal range, Not known = C3 levels were low but no C3 nephritic 
factor data available, P = positive, N/A = C3 levels were normal, C3 nephritic factor testing not applicable in the clinic. 
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3.2.5 Autoantibodies to other complement components in RaDaR cohort 
Screening of patient serum at time of recruitment was also performed for autoantibodies to 
FI, CD46, CD35, CD55, CD59, FHR1, FHR2, FHR3, FHR4 and FHR5 for 81 serum samples 
available in the RaDaR cohort. Screening for antibodies against C3b and FB was performed 
in 80 samples. I performed screening for autoantibodies against FHR3 and FHR4. Screening 
for all other autoantibodies was performed by Dr. Kevin Marchbank. The raw data was 
summarised by Dr. Kevin Marchbank and presented in Figure 47 to Figure 49. 
Data was plotted in response units using a previously designated positive control for 
screening against FI, CD46, CD35, CD55 and CD59 (Kavanagh et al., 2012; Watson et al., 
2015). A minimum threshold for positive autoantibodies was determined by the 97.5th 
percentile of values from screening of at least 100 blood donor controls for the same protein. 
In a small number of patients, a value above the cut-off was noted. A specific antibody 
response to these proteins was not demonstrated in Western blot analysis by Dr. Kevin 
Marchbank (data not shown). Therefore, no autoantibodies were identified against other 
complement regulatory components (FI, CD46, CD35, CD55 and CD59) (Figure 47). 
 
Figure 47 Screening for auto-antibodies to complement regulatory proteins 
Data and figure generated by Dr. Marchbank. Autoantibodies to FH were identified, but not to FI, CD46, CD35, CD55 or 
CD59. BDC = blood donor control, line indicates 97.5th percentile, the minimum threshold for identifying an autoantibody. 
Positive findings were not confirmed in western blot testing. 
 
Screening for autoantibodies was performed against the FHR proteins. FHR proteins were 
expressed in mammalian cell lines by Dr. Kevin Marchbank. Data is shown as optimal 
density readings and not converted to response units due to the lack of a positive control. A 
minimum threshold for positive autoantibodies was determined by the 97.5th percentile of 
values from screening of at least 100 blood donor controls for the same protein (Figure 48). 
Screening for autoantibodies was also performed against the complement components C3b 
and FB. Data is shown as optimal density readings and not converted to response units due to 
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the lack of a positive control. A minimum threshold for positive autoantibodies was 
determined by the 97.5th percentile of values from screening of at least 100 blood donor 
controls for the same protein (Figure 49). 
 
Figure 48 Screening for autoantibodies to FHR proteins 
Data and figure generated by Dr. Marchbank. BDC = blood donor control, line indicates 97.5th percentile, the minimum 
threshold for identifying an autoantibody. Autoantibodies were identified in patients against FHR1-4, but not FHR5. Further 
confirmation of the specificity of the antibody response is required. 
 
 
Figure 49 Screening for autoantibodies to C3b and FB. 
Data and figure generated by Dr. Marchbank. BDC = blood donor control, line indicates 97.5th percentile, the minimum 
threshold for identifying an autoantibody. Autoantibodies were identified in patients against C3b and FB. Further 
confirmation of the specificity of the antibody response is required. 
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Most of the autoantibody data was generated and presented in raw form by Dr. Kevin 
Marchbank. I have undertaken the analysis of this data. The minimum threshold to define 
positivity for an autoantibody to a protein was the 97.5th percentile of values measured in 
blood donor controls. I have identified all patients that fulfil this minimal criterion as patients 
who may have autoantibodies to either the FHR proteins, C3b or FB. 
Patients with autoantibodies to the FHR proteins are summarised in Figure 50. There were 22 
patients that positive for autoantibodies to FHR1, FHR2, FHR3 or FHR4 during the initial 
screening protocol. No patients had autoantibodies to FHR5. There were 16 patients who had 
cross-reactivity to different FHR proteins and FH, of which 6 were to FHR1, FHR3 and 
FHR4 and a further 6 patients were to at least two of FHR3, FHR4 or FH. One patient had 
cross-reactivity to FHR1 and FHR2 and none of the patients had cross-reactivity to FH and 
FHR1. 
Patients with autoantibodies to C3b and FB are compared to those with C3 nephritic factor 
identified at diagnosis (Figure 51). Three patients had an autoantibody to C3b. Eight patients 
had an autoantibody to FB. Of patients identified with a C3 nephritic factor, 2 also have an 
autoantibody to FB. 
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Figure 50 Patients with autoantibodies to FHR proteins 
Patients with autoantibodies to FHR1, FHR2, FHR3 and FHR4 identified in the initial screening are shown. Numbering is 
taken from RaDaR cohort. Underlined and in box are patients with autoantibodies to FH. Cross-reactivity to different FHR 
proteins and FH is observed in 16 of the 22 patients. 
 
 
Figure 51 Patients with autoantibodies to C3b and FB 
Patients with autoantibodies to C3b and FB in the initial screening are shown. Numbering is taken from RaDaR cohort. 
Patients that had a detectable C3 nephritic factor at diagnosis are also shown. Underlined and in box are patients with 
autoantibodies to FH. Confirmation of specificity of these autoantibodies using western blot is an important next step. *C3 
nephritic factor was negative for patient 485 and 755 but not available in all other patients with autoantibodies to C3b or 
FB.  
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3.2.6 Genetic Studies in RaDaR cohort 
3.2.6.1 Rare Genetic Variants 
Patients were screened for genetic variants in C3, CFB, CFH, CFI and CD46 in the Northern 
Molecular Genetics Service in Newcastle. I undertook the analysis of the genetic sequencing 
data. Rare genetic variants were defined as a minor allele frequency of <1% in the exome 
variant server database (evs.gs.washington.edu/). 
In total, 71 patients in the RaDaR cohort were screened for genetic variants. Rare genetic 
variants were identified in 6 patients. Four patients had 1 variant and 2 patients had 2 variants 
(Figure 52). The overall prevalence of patients with rare genetic variants was 8.5%. Three 
variants were in CFH, 3 in C3, 1 in CFB and 1 in CFI (Figure 52). A further 9 patients had 
genetic variants in CFH with a minor allele frequency of 1-5% in the exome variant server 
database (Appendix 6, Table 60). 
 
Figure 52 Proportion of RaDaR cohort with a rare genetic variant 
Rare genetic variant defined as <1% in evs.gs.washington.edu/. 
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Patient Disease Gene 
Base pair 
change 
Amino acid 
change 
Frequency in 
control cohort1 
C3 
(0.68-1.38 g/L) 
C4 
(0.18-0.60 g/L) 
FH 
(0.35-0.59 g/L) 
FI 
(38-58 mg/L) 
C3 nephritic 
factor 
Autoantibody 
to FH 
491 C3GN CFI 1657C>T P553S 0.14% 1.22 0.2 0.74 73 Not done Negative 
527 
IC-
MPGN 
CFH 1949G>T G650V 0.023% 1.03 0.16 0.54 63 Not done Negative 
501 
IC-
MPGN 
CFH 1001G>C G334A N/A 
1.092 
0.92 
0.042 
0.11 
0.44 47 Not done Negative 
827 
IC-
MPGN 
CFB 621A>C E207D N/A 
0.713 
0.81 
0.123 
0.07 
0.46 58 Not done Positive 
686 
IC-
MPGN 
C3 
CFH 
1855G>A 
2675C>T 
K155Q 
A892V 
0.22% 
0.023% 
0.233 
0.1 
0.123 
0.11 
0.67 55 Not known Negative 
771 DDD 
C3 
CFI 
4594C>T 
355G>A 
R1532W 
G119R 
0.0077% 
0.085% 
0.113 
0.58 
0.263 
0.22 
0.52 36 Positive Negative 
Table 23 Rare genetic variants identified in RaDaR cohort 
1 Control population taken from evs.gs.washington.edu/ C3 and C4 levels at diagnosis at >26 months or 3<6 months prior follow up. All other complement levels are at follow up, N/A = C3 
levels were normal, C3 nephritic factor testing not done in the clinic, Not known = C3 levels were low, no C3 nephritic factor data available, Normal ranges of complement levels in brackets. 
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Of the 6 patients with rare genetic variants, 4 had IC-MPGN, 1 had DDD and 1 had C3GN 
(Table 23). C3 and C4 levels at diagnosis were available for 4 of these patients. The three 
patients with IC-MPGN all had low C4 levels, and only 1 had low C3 levels at diagnosis. 
One patient with DDD had low C3 and normal C4 levels at diagnosis. One patient had a rare 
genetic variant and an autoantibody to FH. One patient had a rare genetic variant and C3 
nephritic factor. 
 
3.2.6.2 Copy Number Variation 
Patients were screened for copy number variation in the CFH and CFHR genes in the 
Northern Molecular Genetics Service in Newcastle. I undertook the analysis of the data. The 
allele frequency of the CFHR3/1 deletion in each sub-group and in patients with 
autoantibodies to FH are summarised in Table 24 and Table 25 respectively. The CFHR3/1 
gene was deleted in a total 9.0% of alleles and was protective against cases in the RaDaR 
cohort (P=0.01). The protective effect was observed only in the IC-MPGN group (P=0.02) 
and not in patients with IC-GN and DDD. 
The allele frequency of the CFHR3/1 gene deletion was 4.5% in patients who developed an 
autoantibody to FH and lower than in controls but this difference was not statistically 
significant. There was no evidence of copy number variation in the remainder of the CFHR 
genes (Data reported by the Northern Molecular Genetics Service in Newcastle and not 
shown). 
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CFHR3/1 
deletion 
del/del del/+ +/+ Frequency of 
risk allele 
Odds Ratio 
(95% CI) 
P (vs 
control) 
All 0 13 59 0.090 0.47 (0.26-0.85) 0.01 
Ig-GN 0 2 6 0.125 0.67 (0.15-2.99) 0.60 
Ig-MPGN 0 3 26 0.052 0.26 (0.08-0.83) 0.02 
DDD 0 4 9 0.143 0.85 (0.29-2.52) 0.78 
C3GN 0 4 18 0.091 0.47 (0.17-1.33 0.16 
Control    0.175 
  
Table 24 Allele frequency of CFHR3/1 copy number in disease sub-group 
CFHR3/1 gene is deleted (del) or present (+). Control cohort was taken from (Moore et al., 2010). The allele frequency of 
the CFHR3/1 deletion was 175 out of 1000. 
 
CFHR3/1 
deletion 
del/del del/+ +/+ Frequency of 
risk allele 
Anti-FH POS 0 1 10 0.045 
Anti-FH NEG 0 12 48 0.10 
Fisher’s Exact test, P=0.37 
Table 25 Allele frequency of CFHR3/1 copy number and autoantibodies to FH 
CFHR3/1 gene is deleted (del) or present (+). Autoantibodies to FH (anti-FH) were either positive (POS) or negative 
(NEG). 
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3.2.6.3 Risk Polymorphisms 
Patients were genotyped for common risk polymorphisms in C3, CFB, CFH and CD46 in the 
Northern Molecular Genetics Service in Newcastle. I undertook the analysis of genetic 
sequencing data. The genotypes and allele frequency of disease associated SNPs are 
summarised (Appendix 5, Table 59). Due to testing of 10 SNPs, a value of P<0.005 was 
regarded as significant. Only one SNP had a P<0.005, C3 R102G that has previously been 
associated with DDD. 
In patients who had C3 nephritic factor testing, the allele frequency of the SNP, C3 102G was 
higher in patients who were C3 nephritic factor positive, but this did not reach statistical 
significance (P=0.18) (Table 26). 
 
 G/G G/C C/C Frequency of risk allele 
C3 NEF Neg 2 10 21 0.212 
C3 NEF Pos 2 9 10 0.310 
Fisher’s Exact test, 1 tail, p=0.18 
Table 26 Allele frequency C3 R102G in patients with C3 nephritic factor 
The allele frequency of C3 102G was 1.46 times higher in patients with C3 nephritic factor compared to those without C3 
nephritic factor (P=0.18). 
 
 
3.2.7 Associations of Low Complement Levels in RaDaR cohort 
C3 levels were significantly lower in patients with C3 nephritic factor as described in section 
3.2.3. There were no differences in C3 levels in patients who had an autoantibody to FH or 
those who had a rare genetic variant compared to those who had neither, either at diagnosis or 
at follow-up (Figure 53). 
The pattern of C4 levels in the presence of an autoantibody to FH or those who had a rare 
genetic variant was similar to the pattern of C3 levels. One difference was that patients who 
had an autoantibody to FH had lower C4 levels at follow-up compared to those who did not 
(P=0.02) (Figure 54). 
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Figure 53 C3 levels in patients with autoantibody to FH or rare genetic variant 
Dotted line indicates lower limit of normal C3 (0.68g/L). n = number of patients in sub-group with data available. C3 levels 
between patients who were either positive (POS) or negative (NEG) for an autoantibody to FH (anti-FH) or a rare genetic 
variant, were not statistically significant at either diagnosis (Dx) or at follow-up (FU). 
 
 
Figure 54 C4 levels in patients with autoantibody to FH or rare genetic variant 
Dotted line indicates lower limit of normal C4 (0.18g/L). n = number of patients in sub-group with data available. C4 levels 
between patients who were either positive (POS) or negative (NEG) for an autoantibody to FH (anti-FH) or a rare genetic 
variant, were not statistically significant, except at FU for those with autoantibodies to FH. *P<0.05. 
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Complotypes have been defined by the SNPs C3 R102G, CFB R32Q and CFH I62V. Patients 
with the alleles comprising the most active complotype (C3 102GG, CFB 32RR and CFH 
62VV) were compared to those with the least active complotype (C3 102RR, CFB 32QQ and 
CFH 62II). In-vitro assays demonstrated a 6-fold difference in AP activity between these 
complotypes (Heurich et al., 2011). Comparisons were made based upon the number alleles 
carried pertaining to the most active complotype (Table 27 and Table 28). There were no 
differences in complement levels between patients with the most active and less active 
complotypes in this cohort. 
 
 At Diagnosis At Follow up P (Follow-up 
vs Diagnosis) 
Risk 
alleles 
n Median C3 (g/L) IQR n Median C3 (g/L) IQR 
5 or 6 15 0.42 0.11-0.66 21 0.740 0.30-0.97 0.02 
4  20 0.250 0.09-0.49 23 0.760 0.18-0.99 0.011 
2 or 3 15 0.380 0.20-0.80 20 0.970 0.55-1.09 0.008 
Table 27 C3 levels according to number of risk alleles of an active complotype 
n=number of patients with data available. A complotype defined by C3 R102G, CFB R32Q and CFH I62V associates with 
alternative pathway activity. C3 levels between patients with the most active complotype (5 or 6 risk alleles) did not differ 
from those with the least active complotypes (4 risk alleles and 2 or 3 risk alleles). No patients had the least active 
complotypes of 0 or 1 risk alleles. 
 
 At Diagnosis At Follow up 
P (Follow-up 
vs Diagnosis) Risk 
alleles 
n Median C4 (g/L) IQR n Median C4 (g/L) IQR 
5 or 6 15 0.140 0.07-0.26 21 0.150 0.11-0.21 0.91 
4 20 0.110 0.06-0.20 23 0.170 0.12-0.23 0.06 
2 or 3 14 0.185 0.12-0.26 20 0.200 0.15-0.26 0.273 
Table 28 C4 levels according to number of risk alleles of an active complotype 
n=number of patients with data available. A complotype defined by C3 R102G, CFB R32Q and CFH I62V associates with 
alternative pathway activity. C4 levels between patients with the most active complotype (5 or 6 risk alleles) did not differ 
from those with the least active complotypes (4 risk alleles and 2 or 3 risk alleles). No patients had the least active 
complotypes of 0 or 1 risk alleles.  
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3.3 Study of a Retrospective Cohort Study of MPGN and C3G 
3.3.1 Recruitment and Study Protocol 
Patients were referred to Prof Tim Goodship or Dr. David Kavanagh and screening for 
abnormalities in AP was performed on a case by case basis. The diagnosis was recorded on 
the Newcastle Complement Genetics Service Patient Registry. 243 patients were entered onto 
the clinical database with a diagnosis of MPGN, DDD or C3GN (Figure 55). Biopsies were 
not reviewed and the diagnosis was based upon the clinical information provided. Based upon 
the clinical discussion between a clinician and an expert in complement and renal disease, a 
decision was made to undertake either screening for rare genetic variants in C3 CFB, CFH, 
CFI and CD46 and/or screening for autoantibodies to FH. Sequencing of each gene became 
available incrementally over several years. Complement levels were measured in the 
laboratory at Newcastle Hospitals NHS Foundation trust at time of referral. The diagnoses 
included MPGN type 1 and type 3, DDD, C3GN and unspecified MPGN. I performed a 
retrospective analysis of the available data. 
 
3.3.2 Characteristics of Cohort 
In total, 222 patients went on to have screening for rare variants in at least one gene or 
autoantibodies to FH. 52.3% were male. This was a cohort of childhood and early adulthood 
(Figure 56). Many patients had low C3 levels at time of referral, and the median C3 level was 
lowest at time of referral in cases of DDD (Figure 57). Median C4 levels were within the 
normal range (Figure 58). 
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Figure 55 Patients referred to Newcastle with a diagnosis of MPGN or C3G 
Patients were screened for autoantibodies to FH (antiFH) or a rare genetic variant in up to 5 genes – C3, CFB, CFH, CFI 
and CD46. Tx = transplant. 
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Figure 56 Age at referral of Newcastle cohort 
n = number of patients in sub-group with data available. 
 
Figure 57 C3 levels at referral of Newcastle cohort 
Dotted line indicates lower limit of normal C3 (0.68g/L). n = number of patients in sub-group with data available. C3 levels 
were lower in patients with DDD and C3GN compared to MPGN. *P<0.05. 
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Figure 58 C4 levels at referral of Newcastle cohort 
Dotted line indicates lower limit of normal C4 (0.18g/L). n = number of patients in sub-group with data available. There 
were no statistically significant differences between groups. 
 
3.3.3 Screening for Autoantibodies to FH 
Serum from patients was screened for the presence of autoantibodies to FH by Dr. Kevin 
Marchbank. Screening was performed in 145 patients. An autoantibody to FH was identified 
in 21 cases (14.5%). There were no differences in C3 or C4 levels at the time of referral 
between patients who had an autoantibody to FH and those who did not (Table 29), though 
median C3 levels were below normal in patients with an autoantibody to FH. C3 nephritic 
factor data was not available. An association of low C3 levels with C3 nephritic factor cannot 
be excluded. 
 
 Anti-FH POS Anti-FH NEG  
C3 levels 0.55 (0.30-0.99) 0.81 (0.28-1.05) P=0.375 
C4 Levels 0.30 (0.19-0.34) 0.22 (0.19-0.30) P=0.095 
Table 29 Complement levels in patients screened for autoantibodies to FH in Newcastle cohort 
Complement levels were not statistically different if patients had autoantibodies to FH or not. 
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3.3.4 Screening for Rare Genetic Variants 
Screening for rare genetic variants in C3, CFB, CFH, CFI and CD46 was performed in the 
Newcastle cohort of patients in the Northern Molecular Genetics Service. A total of 208 
patients had screening of at least 1 gene. 161 patients had all 5 genes screened. C3 was 
screened in a total of 165 patients, CFI in 192, CD46 in 188, and CFH was screened in a total 
of 199 patients. The differences in testing reflect the availability of testing for each gene 
during the history of the genetics service. There were a total of 29 different variants were 
identified in 28 individuals and two families in this cohort. 
The prevalence of rare genetic variants was highest in C3 and CFH. A rare variant was 
identified in 6.7% and 6.0% of patients screened in C3 and CFH respectively (Table 30). 
Rare variants in CFB and CFI were less frequently identified (3.7 and 1.6%) and one variant 
was identified in CD46. An estimate of the overall prevalence of patients with rare genetic 
variants in C3, CFB, CFH, CFI and CD46 in this cohort was 17.9%. 
 
 C3 CFB CFH CFI CD46 Anti-
FH 
Number of patients with rare 
genetic variants or autoantibody 
to FH (anti-FH) 
11 51 122 33 1 21 
Number of patients screened 165 161 199 192 188 145 
Prevalence of abnormality 6.7% 3.1% 6.0% 1.6% 0.5% 14.5% 
Table 30 Prevalence of rare genetic variants and autoantibodies to FH in Newcastle cohort 
A total of 29 different rare genetic variants were identified in 28 patients and 2 families following screening in the 5 genes, 
C3, CFB, CFH, CFI and CD46. 14 patients had two variants in CFB, 2one patient had two variants in CFH, 32 patients had 
2 variants in 2 genes (C3/CFI and CFH/CFI). 
 
3.3.5 Clinical Significance of Autoantibodies to FH and Rare Genetic Variants 
In 111 patients, screening was undertaken for autoantibodies to FH and rare genetic variants 
in C3, CFB, CFH, CFI and CD46. C3 levels were lower in patients who had a rare genetic 
variant or an autoantibody to FH compared to those who had neither abnormality but this 
difference was not statistically significant (Figure 59). The proportion of patients with low C3 
in each group was similar. C3 nephritic factor data was not available in this cohort, so their 
importance in explaining many of the cases of low C3 cannot be excluded. 
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C3 and C4 levels are shown in Figure 60 for the patients who were screened for a rare genetic 
variant in C3, CFB, CFH, CFI and CD46, and for an autoantibody to FH. Approximately half 
of patients had low C3 levels, regardless of the presence or not of a rare genetic variant or an 
autoantibody to FH. In total, 28 patients had a low C3 level despite having neither 
abnormality. In 8 patients, this was associated with low C4 levels. Again, the association of 
low C3 levels with a C3 nephritic factor cannot be excluded. 
 
 
Figure 59 C3 levels in patients with rare variant or autoantibodies to FH in Newcastle cohort 
Dotted line indicates lower limit of normal C3 (0.68g/L). n = number of patients in sub-group with data available. The 
differences between groups were not statistically significant. 
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Figure 60 Complement levels in patients screened for a rare variant or autoantibodies to FH 
Dotted lines indicates lower limit of normal C3 (0.68g/L) or C4 (0.18g/L). Patients’ C3 levels were spread evenly within and 
below normal range, regardless of a rare genetic variant or autoantibody to FH. 
 
In this group of 111 patients, 27 patients could be positively identified as CKD stage 5 (pre-
dialysis, on dialysis or transplanted). The proportion of patients with a rare genetic variant or 
autoantibodies to FH was compared to the remaining patients in whom CKD stage 5 had not 
been positively identified. Furthermore, 17 patients could be positively identified as having 
disease recurrence in renal transplant. Again, the proportion of patients with a rare genetic 
variant or autoantibodies to FH was compared to the remaining patients in whom disease 
recurrence in renal transplant had not been positively identified. The likelihood of a rare 
genetic variant or autoantibody to FH was not significantly higher in a group of patients with 
either confirmed CKD stage 5 (Table 31) or disease recurrence in a renal transplant (Table 
32). 
Complement levels at time of referral in patients with disease recurrence in renal transplant 
can be seen in 14 individuals (Figure 61). Three patients had either an autoantibody to FH, a 
rare genetic variant or both. One patient with low C3 did not have an autoantibody to FH or a 
rare genetic variant. Data for C3 nephritic factor was not available. In total, 10 patients have 
normal C3 (and are unlikely to have a functionally significant C3 nephritic factor), no rare 
genetic variant in C3, CFB, CFH, CFI and CD46 and no autoantibody to FH. 
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CKD 5 
Confirmed? 
Yes No 
CKD 5 
Confirmed? 
Yes No 
Rare Variant 6 12 anti-FH Ab 3 12 
No Rare Variant 21 72 No anti-FH Ab 24 72 
% with Variant 22.2% 14.3% % with anti-FH Ab 11.1% 14.3% 
OR (95% CI) 1.71 (0.57-5.12) 
 
0.75 (0.20-2.88) 
P value 0.33  0.68 
Table 31 Rare genetic variants or autoantibodies to FH in patients with CKD5 
Patients with confirmed chronic kidney stage 5 (CKD5) did not have a significantly higher percentage (%) of patients with a 
rare genetic variants or autoantibody to FH (anti-FH Ab) compared to the remainder of patients. 
 
 
Recurrence in Tx 
Confirmed? 
Yes No 
Recurrence in Tx 
Confirmed? 
Yes No 
Rare Variant 3 15 anti-FH Ab 3 12 
No Rare Variant 14       79 No anti-FH Ab 14 82 
% with Variant 17.6% 16.0% % with anti-FH Ab 17.6% 12.7% 
OR (95% CI) 1.13 (0.29-4.41) 
 
1.46 (0.37-5.86) 
P value 0.86  0.59 
Table 32 Rare genetic variants or autoantibodies to FH in patients with disease recurrence in renal transplant 
Patients with confirmed disease recurrence in a renal transplant (Tx) did not have a significantly higher percentage (%) of 
patients with a rare genetic variants or autoantibody to FH (anti-FH Ab) compared to the remainder of patients. 
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Figure 61 Complement abnormalities in patients with disease recurrence in transplant 
Dotted lines indicates lower limit of normal C3 (0.68g/L) or C4 (0.18g/L). In total, 10 patients had disease recurrence in 
transplant, and at time of referral, had normal C3 and no evidence of autoantibodies to FH or a rare genetic variant. 
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3.4 Discussion 
C3 nephritic factor is the prototypal abnormality of AP leading to overactivation of AP 
activity by stabilising C3bBb and consumption of C3. It is consistently the most prevalent 
finding in cohorts of MPGN/C3G. In this chapter, I have analysed the data following 
screening of a prospective and a retrospective cohort of MPGN/C3G for autoantibodies to FH 
and rare genetic variants in C3, CFB, CFH, CFI and CD46. I have also analysed data 
following screening of a prospective cohort of MPGN/C3G for autoantibodies to other 
complement components and SNPs that have been associated with MPGN/C3G in previous 
studies. 
 
3.4.1 C3 Nephritic Factor in MPGN/C3G 
C3 nephritic factor data from this study was available only from the clinical data provided, 
though screening in the prospective cohort is now underway. The available data from 
referring centres in the prospective study confirms the prevalence of C3 nephritic factor in 
this cohort of patients, ranging from 28.6% in cases of IC-MPGN to 66.7% in cases of DDD, 
although no patients with IC-GN had a C3 nephritic factor. The prevalence of C3 nephritic 
factor in the prospective cohort is only slightly lower than in recent relatively large cohorts of 
MPGN/C3G identifying 44.4-54% in cases of MPGN type 1 and C3GN and up to 86.4% in 
DDD (Servais et al., 2012; Iatropoulos et al., 2016). The clinical importance of a C3 nephritic 
factor remains unclear given that neither of these studies demonstrates it as a predictor of 
poor outcomes. 
C3 nephritic factor and low C3 are strongly associated at diagnosis. Given that C3 levels tend 
to be higher during follow-up, an explanation might be that C3 nephritic factor does not 
constantly remain detectable in patients with MPGN/C3G (Servais et al., 2012). This may be 
due to treatments that generally include immunosuppressive agents. One important factor is 
that testing for C3 nephritic factor is neither simple nor consistent as described in a number of 
larger studies that describe heterogeneity in C3 nephritic factor testing (Paixao-Cavalcante et 
al., 2012; Zhang et al., 2012). The relationship of clinical course and treatments in 
conjunction with systematic screening and study of different C3 nephritic factors in a 
prospective study may be helpful. 
In patients who had undergone C3 nephritic factor testing, patients who were positive for C3 
nephritic factor had a higher prevalence of the SNP, C3 R102G compared to those who were 
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negative for C3 nephritic factor (31% vs 21.1%) though this association was not statistically 
significant. These data are comparable with the statistically significant association of C3 
nephritic factor with the SNP C3 R102G that was observed in an earlier study in which the 
prevalence of C3 R102G was 32.7% in patients positive for C3 nephritic factor compared to 
an expected prevalence of 20% in the population (Finn and Mathieson, 1993). Confirmation 
of this association may be possible in a larger sample. 
 
3.4.2 Autoantibodies to Complement Proteins in MPGN/C3G 
Screening for autoantibodies to FH was performed in both cohorts of this study. In my 
prospective cohort, autoantibodies to FH were identified in 16.7% of patients. Epitope 
binding studies were performed demonstrating a predominance of binding to a FH fragment 
(FH SCR1-7) that comprises the N-terminal regulatory domain of FH. Screening for 
autoantibodies to FH is now well established as part of the investigation of aHUS and 
protocols followed by Dr. Kevin Marchbank are part of the standardised protocols followed 
by research laboratories globally (Watson et al., 2014). The prevalence of autoantibodies in 
this cohort is a little higher than that of previous cohorts of both MPGN/C3G (11%) (Blanc et 
al., 2015) and aHUS (6.3-9.2%) (Dragon-Durey et al., 2005; Moore et al., 2010) and similar 
to my retrospective cohort of MPGN/C3G (14.5%). 
The predominant binding to the N-terminal domain of FH in this study is consistent with 
previous reports in cohorts of MPGN/C3G (Goodship et al., 2012; Blanc et al., 2015) though 
studies demonstrating the ability of these autoantibodies to impair regulation have not yet 
been performed for the autoantibodies identified in my study. This predominant binding to 
the N-terminal domain of FH contrasts with those autoantibodies to FH in patients with 
aHUS that bind predominantly to the C-terminal domain of FH (Jozsi et al., 2007). This is in 
keeping with impairment of FH regulatory function in the fluid-phase and cell-surface 
respectively and consistent with the paradigm of loss of fluid phase complement regulation in 
MPGN/C3G. 
A further difference between autoantibodies in MPGN/C3G, and in patients with aHUS is the 
difference in association of autoantibodies to FH with the CFHR3/1 deletion. No patients 
with autoantibodies to FH in this cohort had the CFHR3/1 deletion in homozygosity, an 
observation that is consistent with previous studies (Blanc et al., 2015) and is contrary to that 
observed for cohorts of aHUS. Autoantibodies to FH from patients with aHUS cross-react 
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with the C-terminal domain in FHR1 that is structurally very similar. This FHR1 C-terminal 
domain would be absent in patients that have the CFHR3/1 deletion in homozygosity and also 
in a small number of patients that have the CFHR3/1 deletion and CFHR4/1 deletion on 
different alleles (Moore et al., 2010) and may be important in pathogenesis. Patients with 
MPGN/C3G generally do not have CFHR1 deletion, and the autoantibodies in these patients 
are not directed against the C-terminal domain of FH, suggesting that autoantibodies to FH in 
MPGN/C3G and aHUS have a different aetiology. 
In a childhood cohort of MPGN/C3G, 41% of patients with autoantibodies to FH also had C3 
nephritic factor (Blanc et al., 2015). From the data available, this association was observed in 
15.4% of patients in my prospective childhood of MPGN/C3G cohort. C3 levels were low in 
a further 6 patients in whom C3 nephritic factor may have been positive. The role of these 
autoantibodies in disease remains to be determined, though purification of IgG for functional 
studies as previously performed (Goodship et al., 2012; Blanc et al., 2015) and serial analysis 
in a prospective study may be of benefit. 
The presence of autoantibodies to other complement proteins is less well established. 
Autoantibodies to C3b and FB were identified in 11 patients in this cohort. Given the 
prevalence of C3 nephritic factor, an autoantibody that binds to and stabilises C3bBb, it 
might be expected that there would be cross-reactivity of autoantibodies to either C3b or FB. 
This association was observed in 2 cases in which autoantibodies to FB associate with C3 
nephritic factor, though C3 nephritic factor data was not available for all patients so this 
association might be greater. Patients with autoantibodies to C3b and FB (Chen et al., 2011), 
C3b (Jozsi et al., 2014) and FB have been previously described (Strobel et al., 2010; Zhang et 
al., 2012). Autoantibodies in two of these studies were able to stabilise C3bBb and further 
analysis did not identify C3 nephritic factor (Strobel et al., 2010; Chen et al., 2011). In these 
studies, there was evidence of complement overactivation that would support the association 
of these autoantibodies with disease. Further studies of the autoantibodies to C3b and FB 
identified in my cohort are required. 
Autoantibodies to at least one of 4 FHR proteins (FHR1-4) were found in 22 patients. No 
patients had an autoantibody to FHR5. A role for autoantibodies to FHR proteins in 
MPGN/C3G has not yet been described. The dominant feature of these autoantibodies is the 
cross-reactivity to several FHR proteins that were expressed in mammalian cell lines. Cross 
reactivity of a monoclonal antibody response might have occurred between SCRs of high 
sequence homology such as that observed between SCR1 and 2 of FHR1, FHR2 and FHR5 
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(Goicoechea de Jorge et al., 2013) and also of SCR5 or FHR1 and SCR20 of FH (Moore et 
al., 2010). Cross reactivity to these proteins was observed in only one patient, between FHR1 
and 2. 
Sequence homology between SCRs 3 and 4 of FHR3 and corresponding SCRs of FHR4 are 
also high (Jozsi et al., 2005). This might explain the high degree of cross-reactivity between 
autoantibodies in 8 patients to these proteins. However, of these 8 patients, 6 also 
demonstrated cross-reactivity with FHR1 where sequence homology is not as high. A further 
4 patients with autoantibodies to FHR3 or FHR4 had cross-reactivity to FH. The possibility 
of a non-specific polyclonal response cannot be ruled out and further experiments to confirm 
the specificity of these autoantibodies to individual FHR proteins are required. 
 
3.4.3 Rare Variants in CFH in 2 Cohorts of MPGN/C3G 
There were a total of 13 different rare genetic variants in CFH identified in this chapter. 
Complement levels are summarised for these variants in 16 patients (Table 33). 2 variants 
(R232X and W1096R) resulted in low FH levels and should be considered significant. The 
variant W1096R, identified in a case of familial DDD was the only variant inherited in 
homozygosity in this cohort, resulting in complete FH deficiency. The R232X variant was 
inherited in heterozygosity and resulted in partial FH deficiency. Both variants associated 
with low C3 levels. The variant, C431S identified in my cohort had normal FH levels, but has 
previously been described in association with low FH levels and is likely to be significant 
(Dragon-Durey et al., 2004). The introduction of a stop codon in the variant E1172X is 
highly likely to be functionally significant and may not be secreted. Assuming it is secreted, 
it would be as a truncated protein that lacks most of an important C-terminal recognition 
domain. FH levels were not available in this patient. 
Of the remaining 9 variants, functional studies have only been performed in one, T956M that 
was found in 3 patients. No functional effect was observed in haemolytic assays (Szarvas et 
al., 2016). All others are variants of uncertain significance (VUS) (Kavanagh and Anderson, 
2012). Three of these VUS lead to amino acid substitutions within the regulatory domain, 
including the familial variant R83S that associates with low C3 (Figure 62). The variant 
R83S (and S199G) is at interface of FH and C3b and a mutant protein may have impaired 
binding to C3b resulting in loss of regulatory function, consistent with the paradigm of 
complement dysregulation in MPGN/C3G. 
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Figure 62 Rare genetic variants in CFH in the N-terminal functional domain identified in chapter 3 
P26S, R83S and S199G (red spheres) are modelled on the co-crystal structure of FH SCR1-4 (blue ribbon) and C3b (grey) 
using Pymol. The variants R83S and S199G are at interface of FH and C3b and a mutant protein may have impaired 
binding to C3b resulting in loss of regulatory function, consistent with the paradigm of complement dysregulation in 
MPGN/C3G. 
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Disease SCR Amino Acid Change CKD5 NEF ANTI-FH C3 C4 FH FI 
C3GN 1 P26S NK NK N ↔ ↓ ↔ ↔ 
MPGN1 1 R83S1 Y Y N ↓ ↔ ↔ ↔ 
MPGN 4 S199G2 T NK NK NK NK NK NK 
C3GN 4 R232X NK NK N ↓ ↔ ↓ ↔ 
IC-MPGN 6 G334A NK N N ↔ ↓ ↔ ↔ 
C3GN 7 C431S Y NK N ↔ ↔ ↔ ↔ 
MPGN1 10 V609I T NK Y NK NK NK NK 
MPGN3 10 V609I NK NK NK NK NK NK NK 
IC-MPGN 11 G650V NK N N ↔ ↓ ↔ ↔ 
MPGN1 15 H878Y NK NK NK ↔ ↔ ↔ ↔ 
IC-MPGN 15 A892V3 NK N N ↓ ↓ ↔ ↔ 
C3GN 16 T956M NK NK N ↔ ↓ ↔ ↔ 
MPGN1 16 T956M4 NK NK N ↓ ↓ ↔ ↔ 
MPGN1 16 T956M NK NK NK NK NK NK NK 
DDD 18 W1096R1,5 NK NK Y ↓ ↔ ↓ ↔ 
MPGN1 20 E1172X2 T NK NK NK NK NK NK 
Table 33 Patients with rare genetic variants in CFH identified in chapter 3 
MPGN1 = MPGN Type 1, MPGN3 = MPGN Type 3, SCR = short consensus repeat, CKD5 = chronic kidney disease stage 
5, NEF = C3 nephritic factor, anti-FH = autoantibodies to FH, NK = not known, ↔ within normal range, ↓ below 
normal range, T = transplanted, 1familial, 22 variants in same patient, 3also has K155Q in C3, 4also has P553S in CFI, 
5homozygous. 
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3.4.4 Rare Variants in C3 in 2 Cohorts of MPGN/C3G 
Genetic screening revealed 11 different rare genetic variants in C3 in this chapter (Table 34). 
All were inherited in heterozygosity. Most of the previous studies of rare genetic variants in 
C3 were identified in cases of aHUS (Fremeaux-Bacchi et al., 2008; Martinez-Barricarte et 
al., 2015; Schramm et al., 2015). Familial variants in DDD (Martinez-Barricarte et al., 2010) 
and C3GN (Chauvet et al., 2015) have also been shown to be functionally significant. 
Functionally significant variants in C3 that have been studied are usually due to impaired 
binding to FH, CD46 or CR1. As a result, there is impairment of FI-mediated inactivation of 
C3b. In one study of 23 variants, 4 of the variants that did not affect show a clear functional 
defect were not in the FH binding surface (Schramm et al., 2015). Rarely, a mutant C3 
protein has enhanced binding to FB and C3bBb formation (Lhotta et al., 2009) or the 
formation of C3bBb that is resistant to decay (Martinez-Barricarte et al., 2010). 
Nine variants in C3 identified in this chapter are shown in a co-crystal structure of C3b with 
FH SCR1-4 (Figure 63). One of these, T1383N (reported as T1361N without the signal 
sequence) (Schramm et al., 2015) has been previously studied and was shown to have no 
effect on binding to any of FH, CD46 or CR1. Loss of binding to FH, an important regulator 
of C3b in the fluid phase would be in keeping with the paradigm of loss complement 
regulation in the fluid phase. However, none of the 9 variants, including T1383N were at the 
interface directly opposing FH SCR1-4. One other variant, R1532W however is near the 
interface with FB and may lead to enhanced FB binding and C3bBb formation. This patient 
also had a C3 nephritic factor. Functional studies of these variants should be performed to 
determine whether any of these variants in C3 have a functional defect. 
Two variants previously studied, Y832X and C1136W were shown to result in impaired 
secretion. Two variants in this study, a splice site change (689-3C>G) and the introduction of 
a stop codon (F1246X) both associate with very low levels of C3. How these variants 
associate with would fit with a complement overactivation model of disease is unclear. It is 
possible that these variants, although functionally significant are not associated with the 
pathogenesis of disease. 
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Figure 63 Rare genetic variants in C3 identified in chapter 3 
Rare variants in C3 found in <1% (green sphere) and <0.1% (red sphere) of exome variant server cohort are shown on the 
co-crystal structure of FH SCR1-4 (grey) and C3b (blue ribbon) using Pymol. None of the variants are in the binding 
domain with FH. Centre inset shows C3b on the co-crystal structure with FB (grey). The variant, R1532W is near the 
binding domain near to FB and may lead to enhanced FB binding and C3bBb formation. 
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Disease Amino Acid Change CKD5 NEF Anti-FH C3 C4 FH FI 
IC-MPGN K155Q1 NK N N ↓ ↓ ↔ ↔ 
C3GN K155Q NK NK NK NK NK NK NK 
MPGN1 689-3C>G  NK N N ↓ ↔ ↔ ↔ 
MPGN3 I348V NK NK N ↔ ↔ ↔ ↔ 
MPGN V619M NK NK NK NK NK NK NK 
MPGN1 T788M R NK N ↔ ↔ ↔ ↔ 
DDD P890L  NK NK N ↔ ↔ ↔ ↔ 
DDD R1072R 5 NK N ↓ ↔ ↔ ↔ 
C3GN F1246X     NK NK N ↓ ↔ ↔ ↔ 
C3GN T1383N  T N N ↔ ↔ ↔ ↔ 
DDD D1440A T N P ↓ ↓ ↔ ↔ 
DDD R1532W2 NK P N ↓ ↔ ↔ ↔ 
Table 34 Patients with rare genetic variants in C3 identified in chapter 3 
MPGN1 = MPGN type 1, MPGN3 = MPGN type 3, CKD5 = chronic kidney disease stage 5, NEF = C3 nephritic factor, 
anti-FH = autoantibodies to FH, 1Also has A892V in CFH, NK = not known, ↓ below normal range, ↔ within normal 
range, R=recurrence in transplant, T = transplanted, 2also has G119R in CFI. 
 
3.4.5 Rare Variants in CFB in 2 Cohorts of MPGN/C3G 
Genetic screening revealed 7 different rare genetic variants in CFB in this chapter (Table 35). 
All variants were inherited in heterozygosity. Functional studies of rare genetic variants in 
CFB have been performed in variants reported in aHUS (Goicoechea de Jorge et al., 2007; 
Marinozzi et al., 2014). Six of the rare variants identified in this study are shown in Figure 64 
alongside several gain-of-function mutations previously described but they do not share a 
similar position on FB. Nonetheless, two variants, E207B and V669L are in close proximity 
to C3b and may have enhanced binding to C3b. Functional studies of these variants should be 
performed. A 7th variant results in the introduction of a stop codon. Assuming that this leads 
to a secreted protein, it would be truncated. Analysis of patient serum for evidence of a 
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truncated protein would be an initial step before determining whether such a protein could be 
result in complement activation and be associated with MPGN/C3G. 
 
Figure 64 Rare genetic variants in CFB identified in chapter 3 
Rare variants in CFB found <1% (green sphere) and <0.1% (red sphere) of exome variant server cohort are shown on the 
co-crystal structure of CFB (blue ribbon) and C3b (grey) using Pymol. Previously studied gain-of-function mutants are also 
shown (yellow sphere). Variants in this study do not cluster with the previously studied variants, though E207D and V669L 
are at an interface with C3b that might lead to enhanced C3b binding and C3bBb formation that would be consistent with a 
model of complement overactivation in MPGN/C3G. If expressed, the R203X protein would be truncated and is also 
modelled. 
 
Disease Amino Acid Change CKD5 NEF ANTI-FH C3 C4 FH FI 
C3GN R203X  Y Y N ↓ ↔ ↔ ↔ 
IC-MPGN E207D NK NK Y ↔ ↓ ↔  ↔  
MPGN1 R379R and E566A Y NK NK NK NK NK NK 
C3GN R379R and E566A NK NK NK NK NK NK NK 
DDD K533R and E566A NK Y NK ↓ ↔  ↔  ↔  
C3GN V577I and V669L NK NK N ↔  ↔  ↔  ↔  
Table 35 Rare genetic variants in CFB identified in chapter 3 
CKD5 = chronic kidney disease stage 5, NEF = C3 nephritic factor, anti-FH = autoantibodies to FH, ↓ below normal 
range, ↔ within normal range, NK = not known, 1 2 3 denote 2 rare variants in same patient. 
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3.4.6 Rare Variants in CFI and CD46 in 2 Cohorts of MPGN/C3G 
None of the 3 variants identified in CFI in this chapter were novel and have all been 
described in aHUS cohorts (Table 36). The G119R variant is functionally significant and has 
been associated with low FI levels in AMD cohorts (Kavanagh et al., 2015) though normal 
levels have been reported in cases of aHUS (Fremeaux-Bacchi et al., 2013) as observed in 
this case. R317W has been shown to have impaired co-factor activity and associated with 
normal FI levels (Kavanagh et al., 2007) though this was not observed in a subsequent study 
(Nilsson et al., 2010). P553S is associated with normal FI levels (Bienaime et al., 2010). No 
functional data is available. 
There was 1 rare genetic variant in CD46 in this chapter (Table 36). The D185G variant 
identified in this chapter has not previously studied, but the D185N variant has been 
previously studied. Functional studies showed impairment of C4b binding and inactivation of 
C4b; C3b binding however, and C3b inactivation by FI was not affected (Fremeaux-Bacchi et 
al., 2006). 
 
Disease Gene 
Amino Acid 
Change 
CKD5 NEF ANTI-FH C3 C4 FH FI 
DDD CFI G119R1 NK P N ↓ ↔ ↔ ↔ 
C3GN CFI P553S NK NK N ↔ ↔ ↔ ↔ 
MPGN1 CFI P553S2 NK NK N ↓ ↓ ↔ ↔  
MPGN CFI R117W NK NK NK NK NK NK NK 
MPGN CD46 D185G NK NK NK NK NK NK NK 
Table 36 Rare genetic variants in CFI and CD46 identified in chapter 3 
MPGN1 = MPGN type 1, CKD5 = chronic kidney disease stage 5, NEF = C3 nephritic factor, anti-FH = autoantibodies to 
FH, NK = not known, ↓ below normal range, ↔ within normal range, 1 also has R1532W in C3, 2 also has T956M in CFH. 
 
3.4.7 Rare Variants in 2 Cohorts of MPGN/C3G 
Rare genetic variants were identified in both cohorts of MPGN/C3G in this chapter. The 
prevalence of rare genetic variants patients in the prospective cohort (8.2%) is low, and After 
allowing for the possibility that some of the variants identified might not be causative in 
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disease (discussed further in next section), it makes it difficult to justify routine screening for 
rare genetic variants in C3, CFB, CFH, CFI and CD46 in a prospective paediatric cohort. The 
prevalence of patients with a rare genetic variant in the retrospective cohort was 17.9%, 
higher than in the prospective cohort and may be due to selection bias of patients with 
particular clinical characteristics that may include persistent complement activation as 
evidenced by low C3 or adverse outcomes including recurrence in renal transplantation. 
Additional clinical data is required to address these important issues. 
Nonetheless, the prevalence of rare genetic variants in my retrospective cohort is comparable 
to the prevalence recently reported in an Italian cohort in whom 18% of patients had a rare 
genetic variant in one or more of the genes, C3, CFB, CFH, CFI and CD46 (Iatropoulos et 
al., 2016). The prevalence of rare genetic variants would probably be higher in the French 
cohort if screening for C3 and CFB was included (17.9% in the genes CFH, CFI and CD46) 
(Servais et al., 2012) and is higher in an American cohort (43.3% in C3, CFB, CFH, CFI and 
CD46) (Bu et al., 2015). These differences may reflect cohort selection and importantly, 
these prevalence data precede any functional analysis. The true prevalence of functionally 
rare genetic variants in cohorts of MPGN/C3G is likely amongst the lower prevalence rates 
and low compared to prevalence rates of the acquired abnormalities. Future studies to 
determine clinical significance of rare genetic variants are required. 
 
3.4.8 Limitations of Study 
Several important limitations need to be addressed. The functional importance of many 
abnormalities identified in these cohorts, both acquired and genetic is yet to be established. 
Furthermore, this data will need be correlated with clinical outcomes and the characteristics 
of complement abnormalities during follow up, especially C3 nephritic factor and 
autoantibodies to FH. The prospective study of a RaDaR cohort and the inclusion of central 
pathology review is a rich resource for ongoing study that may address these important 
questions. Further clinical information from the retrospective study of the Newcastle cohort 
including a more comprehensive assessment of pathology and disease classification will 
contribute to this analysis.  
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3.5 Summary 
In this chapter, I have described a prospective and a retrospective cohort of patients with 
MPGN/C3G. Screening for rare genetic variants in C3, CFB, CFH, CFI and CD46 in these 
cohorts reveals a low prevalence of abnormalities. Compared to the prevalence rate of C3 
nephritic factor identified in this prospective cohort, and the prevalence rate of other 
autoantibodies identified in both the prospective and retrospective cohorts, it is clear that the 
predominant abnormalities in these cohorts are acquired, suggesting that MPGN/C3G is 
largely an autoimmune phenomenon. 
The rate of detection for rare genetic variants in the prospective paediatric cohort is 
particularly low at 8.2% of the cohort, and pending functional testing, the prevalence of 
functionally significant variants in this cohort maybe even lower. The prevalence of rare 
genetic variants was higher, at 17.9% in a retrospective cohort. These higher rates of rare 
genetic variants in this retrospective cohort and other published studies may be reflective of 
selection bias in a clinically referred cohort, and not representative of a prospective cohort. 
Further longitudinal follow up of these cohorts and the characterisation of abnormalities, both 
acquired and genetic are required to improve our understanding of MPGN/C3G. Data from 
this study does not change the current paradigm of complement overactivation in the fluid 
phase as a hallmark of MPGN/C3G. 
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Chapter 4 – Structural and Functional Study of a Rare Genetic Variant in 
CFH in Familial MPGN 
4.1 Introduction 
A case of familial MPGN was first described in 1990 (Power et al., 1990). Two family 
members had biopsy-proven MPGN (1:2 and 2:1) and progressed to ESRD. These two 
affected members and a third (2:4) also had APL. C3 nephritic factor was positive in all three 
patients with APL. At that time, no genetic studies had been undertaken. These clinical 
findings are summarised in Figure 65. 
 
 
Figure 65 A case of familial MPGN, acquired partial lipodystrophy and C3 nephritic factor 
Taken from (Power et al., 1990). Patient 1:2 and 2:1 had biopsy-proven MPGN, patient 1:2, 2:1 and 2:4 all had acquired 
partial lipodystrophy (abbreviated to PLD in this figure) and C3 nephritic factor (C3 NeF). 
 
A number of novel rare genetic variants were identified in two cohorts of MPGN/C3G in 
chapter 3 of this thesis. The retrospective cohort study included members of the family 
described above. In an updated pedigree, patient 2.2 also developed ESRD. Screening for rare 
genetic variants in C3, CFB, CFH, CFI and CD46 revealed a rare genetic variant in CFH that 
segregated with members of this family with the renal phenotype. 
Of all of the novel rare genetic variants identified in chapter 3, this rare genetic variant 
identified in a familial case of MPGN was prioritised for functional study. It had a high 
likelihood of being pathogenic and it was in a functional domain of FH for which assays have 
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been previously described to study the structural (Hocking et al., 2008) and functional (Pechtl 
et al., 2011) consequences.  
 
4.1.1 Chapter Aims 
In this chapter I will therefore revisited this family to solve a long standing conundrum in the 
field complement mediated renal disease. 
1. I will update clinical details and complement abnormalities of this family with 
MPGN in which a rare genetic variant in CFH was identified; 
2. I will study the structural consequences of the genetic variant and 
3. I will study the functional consequences of the genetic variant. 
Overall, my aim is to solve the genetic basis of the disease in this family. 
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4.2 Clinical Description of a Case of Familial MPGN 
4.2.1 Clinical Details 
4.2.1.1 Patient 1:2 
MPGN type 1 was diagnosed on renal biopsy (Figure 66) in 1975 following presentation with 
nephrotic syndrome and renal failure. She was aged 42. APL of the face was noted although 
the onset was not clear. C3 levels were low and sometimes undetectable with normal C4. She 
progressed to ESRD in 1984 and commenced haemodialysis. She died four months later due 
to complications of her renal failure. 
 
4.2.1.2 Patient 2:1 
MPGN type 1 was diagnosed on renal biopsy (Figure 66) in 1981 following presentation with 
dipstick albuminuria, haematuria, normal renal function and low C3 levels. He was aged 18. 
APL was noted although the time of onset was not clear. In 1985 he developed nephrotic 
syndrome and renal failure. He progressed to ESRD in 1988. He received a cadaveric renal 
transplant that failed after 7 years. 
 
4.2.1.3 Patient 2:2 
Initial presentation was with insulin-dependent diabetes mellitus aged 11. He had a spinal 
injury resulting in a complete T10 paraplegia aged 39. Renal failure and proteinuria 
developed and he progressed to ESRD aged 41. He did not have a renal biopsy and did not 
have APL. He died of sepsis aged 43. 
 
4.2.1.4 Patient 2:3 
Born in 1967, she remains healthy with no proteinuria, no haematuria and normal renal 
function. She does not have APL. 
 
4.2.1.5 Patient 2:4 
Born in 1969, he developed APL aged 8. He also has evidence of auto-immune diseases and 
developed arthritis of both knees aged 25 and multisystem symptoms with anti-nuclear 
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antibodies and double-stranded DNA antibodies aged 33. He does not however have evidence 
of renal disease. At latest follow up, his creatinine was 61μmol/L and he had normal 
urinalysis. 
 
4.2.2 Biopsy Findings 
Patients 1.2 and 2.1 had renal biopsies confirming MPGN type 1 (Figure 66). Both patients 
had light microscopy appearances of glomerular mesangial expansion, cellular proliferation 
and double contouring of glomerular basement membrane consistent with an MPGN pattern 
of injury. Electron microscopy revealed prominent sub-endothelial dense deposits. 
In patient 1.2, reports from immunofluorescence studies describe localization of C3 and IgM 
in a coarsely granular pattern along capillary walls and in the mesangium. IgG, IgA and fibrin 
were present to a lesser extent. The immunofluorescence studies for patient 2.1 contained no 
glomeruli, but C3 was present in the arteriolar walls. 
Patient 2.2 developed progressive renal failure. He was suspected of having MPGN type 1 
due to the family history and low C3 levels. He did not have confirmatory renal biopsy. 
 
Figure 66 Biopsies of patients 1.2 and 2.1 
Adapted from (Wong et al., 2014)(A-C) Light microscopy of renal biopsy from patient 1.2. (A) demonstrates layering of the 
glomerular basement membrane at initial diagnosis of MPGN (methenamine silver stain). (B) demonstrates diffuse global 
endocapillary proliferation and double layering of glomerular basement membrane (hematoxylin and eosin) in a post-
mortem sample. (C) is a high power view and demonstrates part of the glomerular tuft on the right and Bowman’s capsule 
and the beginning of proximal tubule on the left showing double layering of the glomerular basement membrane 
(methenamine silver stain) in a post-mortem sample. (D) Electron microscopy of renal biopsy from patient 2:1 
demonstrating subendothelial and mesangial deposits. 
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4.3 Screening for Complement Abnormalities 
Complement abnormalities are described below and summarised in Table 37. 
 
4.3.1 Complement Levels 
Patient 1:1 and 2:3 who were both healthy had no evidence of low C3 or C4. Patient 1:2, 2:1 
and 2:4 all have had very low C3 levels. Patient 2:4 has persistently low C3 levels, whilst 
patient 2.1 subsequently had normal C3 levels. Patient 2:2 subsequently had slightly low C3 
levels. There was no evidence of deficiency of FH, FI or CD46. 
 
Patient 1:1 1:2 2:1 2:2 2:3 2:4 
C3 (0.68-1.38 g/l) N1 ↓1 ↓1 / 0.73 N1 / 0.61 N1 / 1.87 ↓1 / 0.24 
C4 (0.18-0.60 g/l) N1 N1 N1 / 0.19 N1 / 0.18 N1 N1 / 0.13 
FH (0.35-0.59 g/l) N/A N/A 0.76 0.71 N/A 0.52 
FI (38-58 mg/L) N/A N/A 58 62 N/A 59 
C3 Nephritic Factor -1 +1 +1 / - -1 / - -1 +1 / + 
Autoantibody to FH N/A N/A -
2
 - - + 
CFH genetic analysis N/P R83S R83S R83S WT WT 
CFH haplotype N/P N/P H3/H5 H3/H5 N/P H3/H3 
CD46gaggt haplotype N/P N/P 1 copy 1 copy N/P 2 copies 
CD46aaggt haplotype N/P N/P 0 copies 0 copies N/P 0 copies 
C3 R102G N/P N/P R/V V/V R/R R/V 
C3 P314L N/P N/P R/V V/V N/P R/V 
Table 37 Complement abnormalities in a family with MPGN 
Adapted from (Wong et al., 2014). Complement levels, autoantibodies to complement components and genetic variants were 
measured and have been summarised. All measurements performed in 2009 unless stated. N – normal; 1 Historical 
measurements quoted in (Power et al., 1990); ↓ - reduced; N/A- not available. 2 Although a positive result was seen on 
ELISA, confirmatory western blot was negative. N/P- genetic analysis not performed; WT CFH genetic screening normal; 
R83S- variant present in heterozygosity; R- Reference sequence; V– Variant sequence.  
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4.3.2 Autoantibodies 
C3 nephritic factor was present in patient 1:2, 2:1 and 2:4 when initially measured. Patient 
2:2 was negative for C3 nephritic factor. Patient 2.1 subsequently was negative for C3 
nephritic factor. Patient 2.4 remains positive for C3 nephritic factor. 
Screening for autoantibodies to FH and subsequent characterisation was performed by Dr. 
Kevin Marchbank for patients 2:1, 2:2, 2:3 and 2:4. They were detected by ELISA. 
Confirmation of specificity for FH was confirmed on Western blot in patient 2:4 only. The 
autoantibodies were polyclonal in nature (Figure 67). 
 
 
Figure 67 Autoantibodies to FH in familial case of MPGN 
Figure generated by Dr. Marchbank and taken from supplementary data (Wong et al., 2014) RU=response units, –+ve = 
positive, –ve = negative. (a) The positive cut-off was derived from the 97.5th percentile of the autoantibody titre in controls 
(Goodship et al., 2012). (b) Purified FH was run on 10% SDS-PAGE and transferred to nitrocellulose. Strips were 
incubated with patient and control sera. Intervening irrelevant strips of the screening blot have been excised as indicated by 
T bar. Only individual 2:4, was positive. (c) Epitope mapping was undertaken using short fragments of FH and FHR1 using 
the same ELISA protocol as for purified FH. The autoantibody response for patient 2:4 was polyclonal in nature. 
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4.3.3 Genetic Screening 
4.3.3.1 Identification of Rare Genetic Variants 
All patients with the renal phenotype (1:2, 2:1 and 2:2) carried a rare genetic variant in CFH 
in heterozygosity. The rare variant c.249G>T that results in a non-synonymous substitution in 
the regulatory domain of FH, p.R83S was identified. The variant was not identified in 
patients 2:3 and 2:4. 
No rare genetic variants were identified in C3, CFB, CFI or CD46. 
R83S was predicted to be ‘deleterious’ and ‘possibly damaging’ in in-silico analysis, using 
Provean and Polyphen respectively. 
 
4.3.2.2 Identification of Common Polymorphisms 
Patients 2:1, 2:2, 2:3 and 2:4 were genotyped for SNPs in C3, CFH and CD46. The affected 
patients 2:1 and 2:2 carried the CFH haplotypes H3 and H5 that contain the DDD-associated 
SNP I62V. They also carried the DDD-associated SNPs in C3, R102G and P314L. No patient 
carried the CD46aaggt haplotype associated with C3GN and MPGN type 1. Patients 2:1 and 
2:2 both carried one copy of the CD46gaggt associated with aHUS. 
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4.4 Structural Effects of the R83S Variant 
4.4.1 Expression and Purification of WT and R83S SCR1-2 fragment of FH 
The genetic variant described in this family of MPGN was a point mutation that resulted in an 
amino acid substitution within SCR1-2 of FH. In order to study the structural consequences 
of this, recombinant WT and R83S sequence variants in the pPICZαB vector were generated 
in Pichia pastoris in the setting of SCR1-2 FH using 15N-ammonium sulphate as the sole 
nitrogen source in culture media. Figure 68 confirms successful introduction of R83S into the 
pPICZαB vector containing cDNA encoding SCR1-2 of FH (residues 19-142) (Hocking et 
al., 2008). 
 
Figure 68 Sanger sequencing of maxiprep DNA to confirm introduction of point mutations – R83S 
Site-directed mutagenesis was used to introduce the R83S variant into pPICZαB containing cDNA encoding SCR1-2 of FH 
(residues 19-142). The mutation was confirmed by Sanger sequencing. 
 
Expressed protein was purified from supernatant using cation exchange. The protein was free 
of aggregates and degradation products following size exclusion and reverse phase 
chromatography (Figure 69). 
 
 
Figure 69 Purified FH SCR1-2 protein on SDS-PAGE – R83S 
WT and R83S SCR1-2 fragments of FH expressed in Pichia pastoris using 15N-ammonium sulphate has the sole nitrogen 
source in culture media were free of aggregates or degradation products following cation exchange, size exclusion and 
reverse phase chromatography. Following 4-15% SDS-PAGE and under non-reducing conditions, bands are visualised at 
~15kDa the expected size of the protein. 
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4.4.2 NMR Spectroscopy 
NMR spectroscopy was used to determine the functional consequences of the R83S mutant 
protein. The data was acquired at 37°C and two dimensional 1H15N-HSQC spectra were 
generated and overlaid for analysis by Dr. Andy Herbert and summarised in Figure 70, 
generated by Dr. Andy Herbert. Data was compared with a previously assigned WT spectrum 
(Hocking et al., 2008). 
Spectra from both WT and R83S proteins demonstrated good chemical shift dispersion 
consistent with a well-structured protein. Furthermore, the differences between the two 
spectra were few, and localised to the intermodular interface between FH SCR1 and 2. 
 
 
Figure 70 Analysis of HSQC spectra obtained from NMR spectroscopy of WT and R83S FH SCR 1-2 
Taken from (Wong et al., 2014).  1H-15N-heteronuclear single quantum coherence spectra of WT and R83S FH SCR1-2 were 
acquired at 37°C, and resonances were assigned where possible by comparison with previously assigned WT FH SCR1-2 
spectra (Hocking et al., 2008). (A) Overlay of 1H-15N-heteronuclear single quantum coherence spectra of FH SCR1–2 WT 
(blue) and R83S (red) show good chemical shift dispersion consistent with a well-structured protein, implying that R83S 
does not result in local unfolding of the protein. (B) The combined 1H and 15N chemical shift differences of R83S with 
respect to WT chemical shifts are represented graphically. Residues for which no chemical shift difference could be ascribed 
have been given a value of -0.01. Most residues exhibits only minor chemical shift differences (only 18 amino acids with 
combined chemical shift difference greater than 0.05 ppm), indicating that the overall fold of the protein should remain 
largely unchanged as a result of this mutation. (C) Chemical shift differences are represented on a cartoon: line thickness and 
colour (blue to red with increasing chemical shift difference) indicate the degree of chemical shift difference. The positions 
of proline residues (for which it is not possible to assign chemical shifts) are displayed in black, and residues with chemical 
shift that could not be confidently assigned are displayed in white. It is clear from this representation that the mutation R83 
results in only localized changes in the structure of the protein; however, these changes are located at the intermodular 
interface between SCRs 1 and 2. 
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4.4.3 Structural Modelling of R83S Mutant Protein 
The R83S variant was then modelled on the co-crystal structure of FH1-4:C3b and displayed 
using Pymol (Figure 71). It was found to be in direct opposition to C3b. NMR spectroscopy 
revealed only small localised changes in structure consistent with a secreted protein and 
normal FH levels. However, the amino acid change (R to S) results in the loss of electrical 
change, which I predicted would weaken the interaction of FH with C3b and impair the 
regulatory activity of FH in keeping with in-silico analysis. I therefore studied the functional 
consequences of the R83S variant. 
 
 
Figure 71 Structural modelling of R83S variant on co-crystal structure of FH SCR1-4 and C3b 
Taken from (Wong et al., 2014). The mutated amino acid R83S is modelled on the co-crystal structure of FH:C3b using 
Pymol. R83S is on the surface of FH and is at the interface of FH SCR1-4 (light grey) and C3b (dark grey). 
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4.5 Functional Consequences of the R83S Mutant Protein 
4.5.1 Expression and Purification of WT and R83S FH SCR1-4 
In order to study the functional consequences of the R83S variant, recombinant wildtype 
(WT) and R83S sequence variants were generated in Pichia pastoris in the setting of SCR1-4 
FH. Site-directed mutagenesis was used to introduce the R83S variant into pPICZαB 
containing cDNA encoding SCR1-4 of FH (residues 19-263). The mutation was confirmed 
by Sanger sequencing. 
Expressed protein was purified by nickel-affinity chromatography and size exclusion and 
were free of aggregates and degradation products as shown in Figure 72. 
 
Figure 72 Purified FH SCR1-4 protein on SDS-PAGE – R83S 
WT and R83S SCR1-4 fragments of FH expressed in Pichia pastoris are free of aggregates or degradation products 
following Nickel-affinity chromatography and size exclusion. Following 4-15% SDS-PAGE and under reducing conditions, 
bands are visualised at ~30kDa. 
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4.5.2 Determination of Affinity of FH SCR1-4 to C3b 
The affinity of FH SCR1-4 to C3b was determined using SPR. The steady-state binding 
response of FH SCR1-4 fragments at different concentrations were plotted to generate an 
affinity curve. The affinity constant (KD) was then determined using Biacore T200 
Evaluation software in a steady state affinity model. The KD was 10.7µM for the WT FH 
SCR1-4 interaction with C3b. There was minimal interaction of R83S FH SCR1-4 to C3b 
observed using the concentrations of protein available (up to 40µM). An estimated KD for the 
R83S interaction with C3b was 75µM in the same conditions (Figure 73). 
 
Figure 73 Binding of FH SCR1-4 to C3b using SPR – R83S 
Taken from (Wong et al., 2014). C3b was immobilized to a CM5 chip using standard amine coupling. Injections of WT and 
R83S FH SCR1-4 were performed in duplicate in 10mM HEPES-buffered saline with 3mM EDTA and 0.05% surfactant P20. 
Overlaid sensograms show steady-state binding response (resonance units) of (a) WT (0.04–20 µM) and (b) R83S (0.04–40 
µM) to C3b. An affinity curve was plotted from steady-state response (resonance units) versus concentration and used to 
estimate KD and shown for (c) WT and (d) R83S. 
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4.5.3 Determining Decay Activity in Real Time using SPR 
The functional consequences of impaired binding to C3b were then assessed. Decay 
acceleration was studied in an SPR-based decay acceleration assay. Figure 74 shows that 
R83S FH SCR1-4 exhibits minimal decay activity compared to WT FH SCR1-4. 
 
Figure 74 Decay activity in real time using SPR – R83S. 
Adapted from (Wong et al., 2014). The flow of FB and FD on the surface of C3b immobilised on a CM5 biosensor chip 
forms an on-chip C3bBb as shown on overlyaing sensograms. C3bBb is allowed to naturally decay before the injection of 
0.5µM FH SCR1-4 over the chip surface. WT FH SCR1-4 accelerates the natural decay of the on-chip C3bBb. R83S FH 
SCR1-4 has minimal effect on the natural decay of the on-chip C3bBb. 
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4.5.4 Determining Decay Activity in Sheep Erythrocyte Haemolysis Assays 
Decay acceleration was also studied on the surface of sheep erythrocytes in a haemolytic 
assay. WT FH SCR1-4 was 9.1-times more effective than R83S FH SCR1-4 at protecting 
cells from lysis (IC50 for WT was 97.5 nM compared to IC50 for R83S 870 nM) (Figure 75). 
 
Figure 75 Decay activity on sheep erythrocytes – R83S 
Adapted from (Wong et al., 2014). FH SCR1-4 was incubated with C3bBb formed on the surface of sheep erythrocytes. FH 
decays C3bBb and prevents lysis instigated by the addition of serum depleted of FB and FH. WT FH SCR1-4 is 9.1-times 
more effective than R83S FH SCR1-4 at protecting cells from lysis (IC50 WT95.5nM vs R83S 870 nM). Error bars represent 
1 standard deviation from experiments performed in triplicate. 
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4.5.5 Determining Co-factor Activity in a fluid-phase assay 
The effect of the R83S variant on co-factor activity was then studied in a fluid phase co-
factor assay. WT FH SCR1-4 cleaved the α’ chain of C3b to generate α chain fragments in a 
time course assay. R83S FH SCR1-4 had minimal activity compared to WT (Figure 76). 
 
Figure 76 Co-factor activity in fluid-phase – R83S 
Taken from (Wong et al., 2014). Limiting concentrations of WT and R83S FH SCR1-4 were incubated with FI and C3b for 
increasing time points. (A) The C3b-cleavage products were separated on 10% SDS-PAGE/Western blot under reducing 
conditions and scanned using densitometry and analysed by VisionWorks®LS Analysis Software. (B) The time-course 
analysis shows the loss of C3b cleavage activity (ratio of α’-chain to β-chain normalized to percentage of negative control) 
of R83S compared with WT.  
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4.5.6 Determining Co-factor Activity in Sheep Erythrocyte Haemolysis Assays 
The loss of co-factor activity due to the R83S variant compared to the WT FH SCR1-4 was 
also confirmed on sheep erythrocyte cell surface assays (Figure 77). The IC50 for WT was 
4.3μM. At this same concentration, the mutant R83S protein exhibited no co-factor activity. 
 
Figure 77 Co-factor activity on sheep erythrocytes – R83S 
Adapted from (Wong et al., 2014). FH SCR1-4 was incubated with sheep erythrocytes coated with C3b and factor I for 8 
minutes. C3bBb was formed on intact C3b and lysis instigated by the addition of serum depleted of FB and FH. C3b is 
inactivated in the presence of FI and its cofactor, FH. This prevents subsequent C3bBb formation and protects cells from 
lysis. WT FH SCR1-4 is more effective than than R83S FH SCR1-4 at protecting cells from lysis. Error bars represent 1 
standard deviation from experiments performed in triplicate. 
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4.6 Discussion 
4.6.1 Abnormalities of the Alternative Pathway in a Case of Familial MPGN 
In this chapter I have described a rare genetic variant that was identified through screening 
for rare genetic variants in a case of familial MPGN. The variant, c.249G>T results in the 
amino acid substitution R83S and segregates completely with affected members. Structural 
studies suggested that the mutant protein results in only minor perturbations in structure 
localised to the intermodular interface of SCR1 and SCR2 of FH. This finding ruled out the 
possibility that R83S causes significant disruption to structure that might otherwise have led 
to unfolding and non-secretion of protein. FH levels in affected patients were not low and in 
keeping with a secreted mutant protein. 
Structural modelling demonstrated that the affected amino was on the surface of FH directly 
interacting with C3b. In-silico analysis predicted the variant would have an effect on 
function, and functional studies confirmed that the affinity of the mutant R83S FH is 
markedly reduced compared to wildtype resulting in loss of decay and co-factor activity. 
These findings are similar to those of the R78G variant that was previously studied (Pechtl et 
al., 2011). 
The rare variant R83S was not the only complement abnormality identified in this family. 
Affected members also inherited the functionally significant risk polymorphisms in C3 (Finn 
and Mathieson, 1993; Abrera-Abeleda et al., 2011) and risk haplotype in CFH (Abrera-
Abeleda et al., 2006; Pickering et al., 2007) that associate with increase in AP activity and 
DDD. These common polymorphisms are likely to contribute to disease but cannot 
individually cause disease. 
In addition to the genetic abnormalities, two acquired abnormalities were described in this 
family, C3 nephritic factor and autoantibodies to FH. C3 nephritic factor has been described 
in ~50-80% of cases of MPGN/C3G (Servais et al., 2012). It is possible that the C3 nephritic 
factor is partly responsible in this family for the development of renal disease, in concert with 
the R83S variant leading to complement overactivation. The possibility that patient 2:2 had a 
C3 nephritic factor earlier in the clinical course cannot be excluded. C3 nephritic factor is 
observed in patient 2:4 who does not have renal disease. This suggests that in this family, the 
finding of C3 nephritic factor alone was insufficient for the onset of MPGN. 
Patient 2:4 had an autoantibody to FH. The prevalence of autoantibody to FH in two cohorts 
of MPGN and C3G described in chapter 3 was 14.5 and 16.7%, a little higher than the 11% 
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reported in a French cohort (Blanc et al., 2015). In most cases, autoantibodies to FH in these 
cohorts bound predominantly to an N-terminal fragment of FH. In this patient, the 
autoantibody bound well to SCR1-4, SCR6-8 and SCR15-18 suggesting polyclonal 
reactivity. Autoantibodies to FH have previously also been described in 11.5% of a cohort of 
rheumatoid arthritis (RA) and 6.7% of a cohort of systemic lupus erythematosus (SLE) 
(Foltyn Zadura et al., 2012). Unlike in MPGN and C3G, where predominant binding to the 
N-terminal domain of FH is observed, autoantibodies to FH in RA and SLE were polyclonal 
with respect to epitope binding. Given the clinical features of patient 2.4 in addition to 
autoantibodies against dsDNA and anti-nuclear antibodies and C3 nephritic factor, the 
autoantibodies to FH in this patient are more consistent with underlying predisposition to 
autoimmunity rather than MPGN. 
The familial nature of APL as first highlighted in this chapter was also a conundrum (Power 
et al., 1990). The R83S variant in CFH did not segregate with APL. Whole exome 
sequencing was used by Dr. Rachel Challis to identify a rare genetic variant in lipodystrophy-
associated genes (Appendix 7, Table 61). No variants were found in this analysis. All 
individuals with APL did however, have C3 nephritic factor and carried the C3 R102G 
polymorphism previously associated with C3 nephritic factor (Finn and Mathieson, 1993). 
The segregation of C3 nephritic factor with APL is consistent with previous studies (Finn and 
Mathieson, 1993; Misra et al., 2004). A role for C3 nephritic factor in the pathogenesis of 
APL has been previously described (Mathieson et al., 1993; Williams, 1997) and would be in 
keeping in this family in which C3 nephritic factor segregates with APL. 
 
4.6.2 A Familial Case of MPGN and C3 Glomerulopathy? 
The term C3G was developed to alert the clinician to the possibility of an underlying 
complement abnormality (Pickering et al., 2013). The earliest classifications of C3G 
precluded the presence of any Ig staining within the glomerulus (Fakhouri et al., 2010a). A 
diagnosis of C3G is currently considered if there is dominant C3 deposition, where dominant 
is defined as C3 intensity ≥2 orders of magnitude more than any other immune reactant on a 
scale of 0 to 3 (including 0, trace, 1+, 2+, 3+) (Pickering et al., 2013). The presence of Ig 
staining on biopsy as observed in patient 1.2 does not exclude C3G and a diagnosis of C3G 
based upon the current consensus guidelines cannot be ruled out. Whilst this familial case has 
features in keeping with C3G a diagnosis of MPGN is certain. This case is a reminder that 
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abnormalities in AP can be found in cases of MPGN. The inability to positively identify a 
case of C3G on renal biopsy should not dissuade the clinician or researcher from similarly 
investigating the AP. 
 
4.6.3 Limitations of study 
Within the complexities of this familial case of MPGN, the finding and study of the R83S 
variant in CFH appears to elucidate a role of rare genetic variants in CFH in the pathogenesis 
of MPGN. Correlation of functional studies in this case and others in a cohort of patients is 
still required to understand their importance in defining disease phenotype and outcomes. 
Interpretation of the functional loss due to R83S variant assumes that these studies in the 
setting of FH SCR1-4 can be extrapolated to the full length protein. 
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4.7 Summary 
Figure 78 summarises the genetic and acquired complement abnormalities described in this 
pedigree. Patients 1:2, 2:1 and 2:2 all have the renal phenotype and carry the rare genetic 
variant, R83S in heterozygosity. These also carry risk SNPs in C3 and CFH that associate 
with increased AP activity. Acquired abnormalities in AP were also found in this family, 
these were also found in cases without the renal phenotype. 
 
Figure 78 Updated pedigree and complement abnormalities in a case of familial MPGN 
The results of CFH screening, CFH haplotype, C3 SNPs and C3 nephritic factor found in this pedigree are shown where 
available. 
 
In summary, I have demonstrated that the rare genetic variant, R83S, in the N-terminal region 
of CFH in a case of familial MPGN was functionally significant and resulted in loss of 
regulatory function and solved a long standing conundrum in the field of complement-
mediated renal disease. Further studies of other rare genetic variant in the N-terminal region 
of CFH are warranted. 
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Chapter 5 - Functional Study of rare N-terminal genetic variants in 
Complement Factor H 
5.1 Introduction 
Acquired and genetic abnormalities of the AP result in excess complement activation and 
associate with MPGN and C3G. Screening for such abnormalities in cohorts of MPGN/C3G 
has identified rare genetic variants in CFH in 4-16.2% (Servais et al., 2012; Bu et al., 2015; 
Iatropoulos et al., 2016) of cases. 
FH is the major fluid phase regulator of AP. Pathogenic variants may lead to quantitative FH 
deficiency (type 1 mutations) or normal levels of functionally impaired FH (type 2 mutation). 
The gold standard for confirming the pathogenic significance of type 2 mutations requires 
functional studies. If data from functional tests is not available, then the pathogenicity of a 
variant should be interpreted with caution and should be called variants of uncertain 
significance (VUS) (Kavanagh and Anderson, 2012). 
Functional studies of rare genetic variants in CFH have generally been limited to those found 
within domains of known function. In aHUS, rare genetic variants in CFH cluster in the C-
terminal recognition domain and have been extensively studied (Sanchez-Corral et al., 2002; 
Ferreira et al., 2009). Functional studies generally show that mutant FH proteins fail to 
regulate complement on host surfaces. 
A smaller number of studies have described the functional consequences of variants in the N-
terminal regulatory domain of CFH using either recombinant short fragments of FH or FH 
from serum, both purified and non-purified (Table 38). 
Studies using non-purified FH from serum include a recent study in which the variant, 
W198R described in aHUS was tested in haemolytic assays in which patient serum was used 
to lyse sensitised sheep erythrocytes (Szarvas et al., 2016). These assays do not differentiate 
between decay and co-factor activity and are dependent upon the lytic properties in the 
patient serum (Sanchez-Corral et al., 2002). 
A different approach to investigate the effects of variants within the N-terminal domain of 
CFH is to use purified FH from serum. Purified mutant FH protein from patient serum can be 
studied to determine the effects of a rare genetic variant on C3b binding, decay and co-factor 
activity (Licht et al., 2006; Tortajada et al., 2009). C-terminal function can also be tested in 
heparin and endothelial cell binding assays (Licht et al., 2006). 
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A final approach has been to recombinantly express mutant proteins in a fragment of FH 
comprising the N-terminal regulatory domain (FH SCR1-4). Effects on individual regulatory 
functions can be determined and study of these mutants is not reliant upon patient sampling 
to obtain serum for functional tests (Pechtl et al., 2011; Wong et al., 2014). 
 
Functional test Recombinant protein1 Serum Purified FH 
C3b binding SPR (Pechtl et al., 2011)  
SPR and peptide spot assay 
(Licht et al., 2006) 
Decay  
SPR and haemolytic assay 
(Pechtl et al., 2011) 
Haemolytic assay2 (Licht 
et al., 2006) 
 
Co-factor fluid 
phase 
Fluid phase and haemolytic 
assay (Pechtl et al., 2011) 
 
Fluid phase assay (Licht et al., 
2006) 
Regulatory 
activity 
 
Haemolytic assay3 
(Szarvas et al., 2016) 
 
C-terminal 
function 
  
C3d, heparin and endothelial cell 
binding assays (Licht et al., 
2006) 
Table 38 Functional studies of rare disease-associated N-terminal mutations 
1Recombinant protein was in the setting of SCR1-4 only. Assays used in the studies above (Pechtl et al., 2011) have also 
been described in full length FH protein purified from patients for the study of the common polymorphism, I62V (Tortajada 
et al., 2009), 2Patient serum containing mutant FH is used to initiate lysis after C3bBb has formed on the surface of sheep 
erythrocytes in a decay assay, 3Patient serum containing mutant FH is used to initiate lysis of sensitised sheep erythrocytes. 
 
5.1.1 Chapter Aims 
In this chapter I will 
1. Review the rare genetic variants in CFH that have been described in cases 
MPGN/C3G. 
2. Determine the functional significance of rare genetic variants in the N-terminal 
domain of CFH found in MPGN/C3G using recombinant FH SCR1-4 proteins in 
assays to test C3b binding, decay and co-factor activity. 
3. Compare the functional effects of variants N-terminal domain of CFH in MPGN/C3G 
to those found in other diseases including aHUS and AMD.  
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5.2 Selection of Rare Genetic Variants in MPGN and C3G for Functional Study 
5.2.1 Identification of Rare Genetic Variants in MPGN/C3G from the Literature 
Rare genetic variants in CFH were identified from the literature in cases of MPGN or C3G. 
The published rare genetic variants and those identified in the cohort studies described in 
chapter 3 are summarised (Figure 79 and Appendix 8, Table 62). In total, 43 different rare 
variants in CFH were identified in 51 patients or pedigrees with MPGN or C3G. Two patients 
had 2 different rare variants. Seventeen variants (39.5%) were type 1 mutations that result in 
either complete or partial FH deficiency depending on whether they were inherited in 
homozygosity or heterozygosity respectively (Table 39). Functional studies have been 
performed for an additional 6 variants. Three of these, R78G (Pechtl et al., 2011), delK224 
(Licht et al., 2006) and R83S (Wong et al., 2014), (a variant identified in familial MPGN 
studied in chapter 4) are variants within the N-terminal domain of CFH and were shown to 
result in a mutant protein with complete loss of regulatory function. A fourth functionally 
significant variant was R1210C in the C-terminal domain (Recalde et al., 2015). Functional 
studies have also been performed to determine the effect of the variants, Q950H and T956M. 
In these studies, a small loss of regulatory function was reported in the Q950H variant only 
(Szarvas et al., 2016). Further data including FH levels and/or functional studies are required 
in the remaining variants to determine functional significance. 
Five variants (P26S, R53C, DelE122-G128, D130N, A161S) identified in the functional N-
terminal regulatory domain of CFH associate with normal FH levels and are the logical first 
choice variants for functional studies (Figure 79, Table 40). 
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Figure 79 Rare genetic variants identified in CFH in MPGN and C3G 
43 rare variants identified in 51 patients or pedigrees have been annotated on a representation of the 20 short consensus 
repeats of FH and the functional domains. Disease types have been labelled in colour - C3GN (red), MPGN (green) and 
DDD (blue). * homozygous L low FH levels / Type 1 mutations F = familial members affected. Two patients carried 2 rare 
variants each, S199G/E1172X1 and V837L/E1145D2. IVS11+5 not shown. Original sources are referenced in Appendix 8.8, 
Table 62. 
 
 Type 1 mutations – low FH levels Functionally significant type 2 mutations 
Homozygous  
P88T1 
R127L1 
C431S 
C597R (2) 
P621Y 
C673S 
Y899X 
Y1008X 
W1096R1 
 
R78G 
DelK2241 
 
 
 
Heterozygous 
P76X 
L77X 
V143I 
I216T 
R232X (2) 
C673R 
K768X 
C1043X 
R83S1 
R1210C (2) 
 
 
Table 39 Rare genetic variants in CFH in MPGN and C3G leading to FH deficiency 
1indicates familial disease () = number of patients with variant. 
 
 144 
 
Normal FH levels FH levels not known 
P26S 
R53C (3) 
DelG122-E128 
D130N 
A161S 
G334A 
C431S 
IVS11+5 
G650V (2) 
F717L (2) 
H878Y 
A892V 
R1210V 
R127C 
S199G/E1172X 
N516K 
V609I (2) 
M725X 
V837I/E1145D 
Q950H1 
T956M (3)1 
 
 
 
 
 
Table 40 Rare genetic variants in CFH in MPGN and C3G of uncertain significance 
() = Indicates number of patients with a particular rare variant.1Q950H and T956M had normal levels in published cases of 
aHUS in which functional studies were performed. Their levels in MPGN/C3G patients are not known. 
 
5.2.2 N-terminal Rare Variants in CFH in other Renal Diseases 
A total of 26 rare genetic variants in the N-terminal domain of CFH were identified in 28 
patients with aHUS from the literature and includes 3 unpublished variants from the 
Newcastle aHUS registry (Table 41 and Appendix 9, Table 63). All were inherited in 
heterozygosity. Of these, 11 were type 1 mutations and 2 were functionally significant type 2 
mutations. Of the remaining 13 variants, 6 associated with normal FH levels. FH levels in the 
remaining 7 cases could not be determined from the available literature. Two variants, R53C 
and A161S, have also been described in cases of MPGN/C3G. 
Three rare genetic variants, also in the N-terminal domain of CFH, were identified in other 
renal phenotypes (Table 42). These all associated with low levels of FH. 
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Type 1 mutations Functionally Significant VUS (Normal FH levels) 
VUS (Unknown FH 
levels) 
R28Ifs5X 
T30Nfs10X 
I32X 
Y118Ifs4X 
I124Mfs12X 
R127L 
P139S1 
S159N2 
G218E 
R232X 
P258L 
R53H 
R78G 
 
 
 
 
 
 
 
 
 
R53C 
W71R 
Q81P 
A161S (3) 
M162V 
W198R 
 
 
 
 
 
R53S 
S58A 
V111E 
W134R 
R166L 
Y235C 
C247G 
 
 
 
 
Table 41 N-terminal rare genetic variants in CFH in aHUS 
() = indicates number of patients with a particular rare variant. All were inherited in heterozygosity.1P139S associated with 
low FH levels in (Schejbel et al., 2011), 2S159N was initially identified in AMD in Newcastle Complement Genetics Service 
with associated normal FH levels and selected for study. 
 
 Variant Disease Reference 
Complete FH 
deficiency1 
P139S 
E189X2 
Endocapillary GN 
Lupus Nephritis 
(Schejbel et al., 2011) 
(Brai et al., 1988) (Sanchez-Corral et al., 2000) 
Partial FH 
deficiency3 
A48S IgA Nephropathy (Schmitt et al., 2011) 
Table 42 N-terminal rare genetic variants in CFH in other renal phenotypes 
1inherited in homozygosity, 2familial disease, 3inherited in heterozygosity. 
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5.2.3 N-terminal Rare Variants in CFH in AMD 
N-terminal variants in CFH have also been described in AMD, a disease associated with 
DDD. Two variants, G69E (Raychaudhuri et al., 2011) and D90G (Yu et al., 2014) had been 
described during the research period and were studied alongside those identified in renal 
disease. A third variant, S159N was identified in a case of AMD in the Newcastle 
Complement Genetics Service with normal FH levels. This was also selected for study. It was 
subsequently identified in a case of aHUS in the Newcastle Complement Genetics Service 
and associated with low FH levels (Table 40). A larger number of variants in AMD that were 
recently identified will be discussed later in this chapter. 
 
5.2.4 Structural Modelling of N-terminal Variants Selected for Functional Study 
The variants of uncertain significance in the N-terminal domain of CFH in MPGN, DDD, 
C3GN, aHUS and AMD were considered for functional studies. The variants P26S, W71R, 
W198R and S199G were not known to me at the time of study. The variants selected for 
study in this chapter were R53C, G69E, Q81P, D90G, delG122-E128, D130N, S159N, 
A161S and M162V. 
The variants in the N-terminal domain of CFH described in renal diseases result in an amino 
acid substitution in SCR 1 (R53C, Q81P), in SCR 2 (D130N) and SCR 3 (S159N, A161S and 
M162V). One large deletion results in the loss of 7 amino acids in exon 2 (delG122-E128). 
The secreted variants in the N-terminal domain of CFH described in AMD only, result in an 
amino acid substitution in SCR 1 (G69E) and SCR2 (D90G) (Figure 80). Five variants 
(Q81P, D90G, S159N, A161S and M162V) affect amino acids that are on the surface of FH 
and interface with C3b. Two variants (R53C and D130N) are on the surface of FH and face 
away from C3b and on a putative surface that interacts with FI. The deletion G122-E128 
results in the loss of 7 amino acids that are mostly on a surface that faces away from C3b. 
G69E faces away from both C3b and FI binding sites. 
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Figure 80 Co-crystal structure of FH SCR1-4:C3b showing rare genetic variants selected for functional study 
Genetic variants in the N-terminal domain of CFH that had normal serum FH levels are modelled on a co-crystal structure 
of FH SCR1-4 (blue) and C3b (grey). The variants are all found on the surface of FH SCR1-4. Variants are coloured red if 
been described in MPGN/DDD/C3GN. The remaining variants are coloured green if described in aHUS (green) and lastly 
blue, if only described in AMD. The residues involved in the deletion G122-E128 (described in DDD) are shown in black to 
distinguish from other variants. 
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5.3 Functional Study of Rare Genetic Variants in the N-terminal Domain of CFH 
5.3.1 Small Scale Expression of Mutant Protein 
In order to study the functional consequences of the variants described in 5.2.4, recombinant 
WT and mutant sequence variants in the pPICZαB vector were generated in Pichia pastoris 
in the setting of FH SCR1-4. Figure 81 confirms successful introduction of each mutation by 
site-directed mutagenesis into the FH SCR1-4 clone in pPICZαB. A clone of the S159N 
variant was a gift from Professor Alan Wright, University of Edinburgh. Confirmation of 
introduction of this mutation is also shown. The 21bp deletion in the delG122-E128 variant 
was also successfully introduced and shown in Figure 82. 
Following transformation of KM71H clones with the mutated FH SCR1-4 clones in 
pPICZαB, small scale expression of protein was performed. Figure 83 shows the successful 
expression of several mutant proteins in one experiment as demonstrated by the detection of 
bands on Western blotting. Bands migrating at the expected 25kDa under non-reducing 
conditions, consistent in size with a FH SCR1-4 protein were visualised. A band at this size 
was not present in the empty vector control and not in the delG122-E128 clone, suggestive of 
impaired secretion of FH of the delG122-E128 clone. 
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Figure 81 Chromatograms following Sanger sequencing of maxiprep DNA to confirm introduction of point mutations 
Point mutations were introduced in order to express the mutant proteins R53C, G69E, Q81P, D90G, D130N, S159N, A161S 
and M162V in the setting of the FH SCR1-4 clone in pPICZαB. Amino acids and the positions flanking the mutated amino 
acid are shown above chromatograms for mutant and wildtype sequence. 
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Figure 82 Chromatograms following Sanger sequencing of maxiprep DNA to confirm a 21bp deletion 
The sequence of 21bp encoding the amino acids from G122-E128 were deleted from the FH SCR1-4 clone in pPICZαB. The 
6bp flanking either side of the deleted sequences are shown encoding L120-L121 and C129-D130 (shaded boxes). These 
four amino acid are adjacent and in-frame in the mutated sequence. 
 
 
Figure 83 Expression of FH SCR1-4 variants on Western blot 
Small scale cultures were centrifuged and the remaining supernatant was collected. Samples were separated on 4-15% 
gradient SDS-PAGE under reducing conditions and then transferred onto nitrocellulose membrane for Western blotting 
using a goat anti-FH antibody (1:14000) and rabbit anti-goat-HRP secondary antibody (1:3000). The Western blots show 
the presence of a band migrating to ~30kDa consistent in size with FH SCR1-4 in R53C, D130N, S159N and A161S. these 
bands were not visible in the empty vector control (that does not contain cDNA for FH SCR1-4) or DelG122-E128. 
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5.3.2 Confirmation of Purity of Purified Protein 
Expressed protein was purified by nickel-affinity chromatography and size exclusion and was 
free of aggregates and degradation products. Figure 84 shows purified wildtype and mutant 
proteins. 
 
 
Figure 84 Purified FH SCR1-4 protein on SDS-PAGE 
Samples of pooled purified protein (20μL, 1.5μM) were separated by 4-15% gradient SDS-PAGE under non-reducing 
conditions. Bands at ~25kDa are consistent with FH SCR1-4 and free from aggregates or degradation products. A) and B) 
show proteins expressed in different batches. 
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5.3.3 Reporting of Functional Effects of Rare Genetic Variant 
Functional testing of the variants R53C and D90G was performed in comparison with 
wildtype in one batch of testing. Functional testing of the variants G69E, Q81P, D130N, 
S159N, A161S and M162V was performed during another batch of testing. Small changes to 
the testing protocol were made as part of ongoing optimisation of assays and are described in 
each individual section. For each variant, experiments were always performed in direct 
comparison with wildtype protein. The effect of a variant on KD or IC50 was reported relative 
to the value determined for wildtype for each experiment. Representative data for 
experiments testing R53C and D90G are shown in separate figures to experiments testing the 
other variants. 
 
5.3.4 Determination of Affinity of FH SCR1-4 to C3b 
The affinity of FH SCR1-4 to C3b was determined using SPR. The steady-state binding 
response of FH SCR1-4 fragments at different concentrations were plotted to generate an 
affinity curve. The affinity constant (KD) was then determined using Biacore T200 
Evaluation software in a steady state affinity model. 
The interaction between Q81P and C3b was the weakest of all of the variants tested. A KD for 
this interaction could not be calculated using the concentration of protein available. The 
remaining variants bound well, with small differences ranging between 0.92-fold to 1.47-fold 
the KD calculated for the interaction of WT FH SCR1-4:C3b (Figure 85 and Figure 86), 
suggestive that there was slight impairment of affinity for some variants. 
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Figure 85 Binding of FH SCR1-4 to C3b using SPR - R53C and D90G 
860 Resonance units (RU) of C3b was immobilised on the surface of a CM5 chip. FH SCR1-4 (WT, R53C and D90G) was 
flowed over the surface at a range of concentrations (0.4-40µM). Overlaying sensograms demonstrate binding of FH SCR1-
4 to C3b for WT, R53C and D90G (A, C, E). The steady state response was plotted against the concentration of FH SCR1-4 
to generate an affinity curve. A KD was calculated for the interaction between mutant FH SCR1-4 and C3b. The ratio of KD 
for the mutant FH SCR1-4 interaction compared to the WT FH SCR1-4 interaction with C3b was 1.47-fold for R53C and 
0.92-fold for D90G. 
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Figure 86 Binding of FH SCR1-4 to C3b using SPR - G69E, Q81P, D130N, S159N, A161S and M162V 
480 RU C3b was immobilised on the surface of a CM5 chip. FH SCR1-4 (WT, G69E, Q81P, D130N, S159N, A161S and 
M162V) was flowed over the surface at a range of concentrations (0.4-40µM). Representative overlaying sensograms for 
WT (top right) shows that steady state binding was achieved over a range of concentrations. The steady state response was 
plotted against the concentration of FH SCR1-4 to generate an affinity curve and a KD was calculated for the interaction 
between the mutant FH SCR1-4 and C3b. The difference in KD compared to the WT FH SCR1-4 interaction with C3b was 
1.22-fold for G69E, 1.44-fold for D130N, 1.20-fold for S159N, 0.97-fold for A161S and 1.23-fold M162V. A KD could not be 
determined for the interaction between Q81P and C3b. 
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5.3.5 Determining Decay Activity in Real-time Using SPR 
The functional consequences of impaired binding to C3b were then assessed. Decay 
acceleration was studied in an SPR-based decay acceleration assay. C3bBb was generated on 
immobilised C3b captured on the surface of a CM5 biosensor chip. In the experiments testing 
R53C and D90G, C3bBb was generated using 500nM FB and 60nM FD. The subsequent 
batch of experiments testing G69E, Q81P, D130N, S159N, A161S and M162V were 
performed using 250nM FB and 30nM FD during the formation of C3bBb as described in the 
methods. All convertases were allowed 210 seconds of natural dissociation before the 
injection of wildtype and mutant FH SCR1-4 protein to determine its effect on decay of the 
remaining convertase visualised in real-time. Sensograms (Figure 87 and Figure 88) are 
overlaying showing C3bBb formation and decay using wildtype and mutant FH SCR1-4 at 
equimolar concentrations. Sensograms have been normalised from the baseline prior to the 
injection of FB and FD (0%) to the maximal binding at the end of the injection (100%). 
At 500nM, R53C had minimal convertase decay activity compared to wildtype whereas 
D90G had comparable decay activity to wildtype (Figure 87). 
 
Figure 87 Decay activity in real time using SPR - R53C and D90G 
Adapted from (Yu et al., 2014) The flow of FB and FD on the surface of C3b immobilised on a CM5 biosensor chip forms an 
on-chip C3bBb and is shown in overlaying sensograms. C3bBb is allowed to naturally decay before the injection of 0.5µM 
FH SCR1-4 over the chip surface. WT FH SCR1-4 and D90G FH SCR1-4 accelerate the natural decay of the on-chip 
C3bBb. R53C FH SCR1-4 has minimal effect on the natural decay of the on-chip C3bBb. 
 
In the second batch of experiments, 166nM of WT achieved complete C3bBb decay. At this 
concentration, Q81P had only a minimal effect on C3bBb decay. All other mutants 
demonstrated ability to decay C3bBb though small losses in decay activity compared to WT 
were observed and were greatest for G69E and D130N (Figure 88). 
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Figure 88 Decay activity in real time using SPR - G69E, Q81P, D130N, S159N, A161S and M162V 
The flow of FB and FD on the surface of C3b immobilised on a CM5 biosensor chip forms an on-chip C3bBb and is shown 
in overlaying sensograms. C3bBb is allowed to naturally decay before the injection of 0.17µM FH SCR1-4 over the chip 
surface. WT FH SCR1-4 and mutant FH SCR1-4 (except Q81P) accelerate the natural decay of the on-chip C3bBb though 
G69E and D130N appear silghtly less active. Q81P FH SCR1-4 has minimal effect on the natural decay of the on-chip 
C3bBb. 
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5.3.6 Determining Decay Activity in Sheep Erythrocyte Haemolysis Assays 
The effect of each rare variant on decay acceleration activity was then tested on C3bBb 
formed on the surface of sheep erythrocytes. R53C had a loss of decay activity on C3bBb 
formed on the surface of sheep erythrocytes. At the equivalent concentration of IC50 for WT, 
R53C had no decay activity (Figure 89). Q81P also had a loss of decay activity on C3bBb 
formed on the surface of sheep erythrocytes. As in the case for R53C, at the equivalent 
concentration of IC50 for WT, Q81P had no decay activity (Figure 90). In these experiments, 
R53C and Q81P required 22.4-fold and 25.1-fold higher concentration of FH than wildtype 
respectively to achieve 50% protection from lysis. D130N, G69E and A161S had slight 
impairment of decay activity requiring 2-fold, 1.3-fold and 1.3-fold more FH respectively to 
achieve 50% protection from lysis. There was no change in decay acceleration regulatory 
activity for the remaining variants. 
  
Figure 89 Decay activity on sheep erythrocytes - R53C 
FH SCR1-4 was incubated with C3bBb formed on the surface of sheep erythrocytes. FH decays C3bBb and prevents lysis 
instigated by the addition of serum depleted of FB and FH. WT FH SCR1-4 is 22.4-times more effective than R53C FH 
SCR1-4 at protecting cells from lysis (IC50 WT 95.5nM vs R53C 2138 nM). Error bars represent 1 standard deviation from 
experiments performed in triplicate. 
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Figure 90 Decay activity on sheep erythrocytes - G69E, Q81P, D130N, S159N, A161S and M162V 
FH SCR1-4 was incubated with C3bBb formed on the surface of sheep erythrocytes. FH decays the C3bBb and prevents 
lysis instigated by the addition of serum depleted of FB and FH. Q81P FH SCR1-4 is 25.1-times less effective than WT FH 
SCR1-4 at protecting cells from lysis. The difference in IC50 for mutants compared to WT FH SCR1-4 was 1.3-fold for G69E, 
2.0-fold for D130N, 0.9-fold for S159N, 1.3-fold for A161S and 1.0-fold M162V. Error bars represent 1 standard deviation 
from experiments performed in triplicate. 
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5.3.7 Determining Co-factor Activity in a Fluid-phase Assay 
The ability of FH SCR1-4 to act as a co-factor in the FI-mediated proteolytic cleavage of C3b 
into iC3b was assessed in the fluid phase. In Figure 91, co-factor activity as determined by 
the loss of the C3b α’ chain and appearance of the α1 chain appears to be slightly impaired. 
These assays were repeated independently using WT, R53C and D90G FH SCR1-4 expressed 
in mammalian cell lines by Dr. Elizabeth Schramm, Washington University School of 
Medicine, St. Louis. In these experiments, the loss of the α’-chain was quantified using 
densitometry and normalised to the intensity of the β-chain and plotted over a time-course. A 
small difference in activity could be detected for both R53C and D90G compared to WT 
(Figure 92). 
 
Figure 91 Co-factor activity in fluid phase - R53C and D90G 
WT and mutant FH SCR1-4 were incubated with FI and C3b for 30 minutes. The C3b-cleavage products were separated on 
10% SDS-PAGE under reducing conditions Co-factor activity is observed by the loss of α’-chain and the appearance of the 
β-chain for all mutants. 
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Figure 92 Co-factor activity in fluid phase – time course - R53C and D90G 
Adapted from (Yu et al., 2014). Experiments performed by Dr. Elizabeth Schramm using FH SCR1-4 expressed in HEK293 
cells as described in (Yu et al., 2014). Percentage (%) of C3b remaining was determined by quantitation of the a′ produced 
over time relative to the amount of a′ present originally are the average of four independent experiments; error bars 
represent one standard deviation. Quantification was done by densitometrically scanning the a′ bands and normalizing to 
the amount of C3b in that lane (β- chain). R53C has lower CA in the fluid phase assay (P<0.05 at all time points, two-tailed 
t-test.) D90G has a significant defect in co-factor activity (CA) (P<0.01 at all time points, two-tailed t-test. 
 
In a second batch of fluid phase co-factor assays, the Q81P variant clearly had very little co-
factor activity, as seen by the clear intact α’ band and virtually no formation of the α1 
cleavage products (Figure 93). All other variants exhibited co-factor activity. 
 
Figure 93 Co-factor activity in fluid phase - G69E, Q81P, D130N, S159N, A161S and M162V 
WT and mutant FH SCR1-4 were incubated with FI and C3b for 30 minutes. The C3b-cleavage products were separated on 
10% SDS-PAGE/Western blot under reducing conditions Co-factor activity is observed by the loss of α’-chain and the 
appearance of the β-chain. Co-factor activity was evident for all mutants except Q81P. 
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5.3.8 Determining Co-factor Activity in Sheep Erythrocyte Haemolysis Assays 
The effect of each rare variant to act as a co-factor in the FI-mediated proteolytic cleavage of 
C3b into iC3b was then assessed on the surface of sheep erythrocytes. R53C had evidence of 
co-factor activity when compared to wildtype. Approximately 1.3-fold higher concentration 
of R53C was required to achieve 50% protection from lysis compared to wildtype (Figure 
94). 
 
Figure 94 Co-factor activity on sheep erythrocytes - R53C 
Adapted from (Yu et al., 2014). FH SCR1-4 was incubated with sheep erythrocytes coated with C3b and factor I for 8 
minutes. C3bBb was formed on intact C3b and lysis instigated by the addition of serum depleted of FB and FH. FH acts as a 
co-factor and C3b is inactivated in the presence of factor I, This prevents subsequent C3bBb formation and protects cells 
from lysis. WT FH SCR1-4 is slightly more effective than R53C FH SCR1-4 at protecting cells from lysis (IC50 WT 4266nM 
vs R53C 5888 nM). Error bars represent 1 standard deviation from experiments performed in triplicate. 
 
Q81P had a loss of co-factor activity on the surface of sheep erythrocytes. At the equivalent 
concentration of IC50 for WT, Q81P had no co-factor activity. Q81P required 11- fold and 
higher concentration of FH than wildtype respectively to achieve 50% protection from lysis 
(Figure 95). The other variants had differences in co-factor activity requiring 1.1-1.66-fold 
more FH to give sheep erythrocytes 50% protection from lysis. 
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Figure 95 Co-factor activity on sheep erythrocytes - G69E, Q81P, D130N, S159N, A161S and M162V 
FH SCR1-4 was incubated with sheep erythrocytes coated with C3b and factor I for 15 minutes. C3bBb was formed on intact 
C3b and lysis instigated by the addition of serum depleted of FB and FH. FH acts as a co-factor and C3b is inactivated in 
the presence of factor I, This prevents subsequent C3bBb formation and protects cells from lysis. WT FH SCR1-4 is 11-fold 
more effective than Q81P (IC50 WT 603nM vs Q81P 6607nM). The difference in IC50 for the other mutants compared to WT 
FH SCR1-4 was 1.1-fold for G69E, 1.66-fold for D130N, 1.54-fold for S159N, 1.26-fold for A161S and 1.48-fold forM162V. 
Error bars represent 1 standard deviation from experiments performed in triplicate. 
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5.4 Discussion 
In this chapter, I have characterised 8 rare disease-associated genetic variants in the setting of 
a recombinant FH SCR1-4 protein. The functional characteristics of these, and those 
published previously in the setting of FH SCR1-4 are summarised in Table 43. The functional 
characteristics of the common DDD-associated risk polymorphism V62 compared to I62 are 
also shown. A 9th variant (delG122-E128) was transformed into Pichia pastoris but there was 
no evidence of any protein expression. 
Table 43 Functional effects of variants studied in the setting of FH SCR1-4 
Disease-associated variants described in this chapter are summarised alongside R83S described in Chapter 4 and the 
published variants R53H and R78G. The common polymorphism associated with risk of aHUS and DDD, I62V is also 
shown. SPR = surface plasmon resonance, E= erythrocytes, N/P = not performed. Numbers are ratio of KD or IC50 of 
mutant:WT. Numbers >1 suggest less C3b binding or regulatory function. Where KD or IC50 has not been determined, 
arrows indicate a decrease (↓) or no effect (↔) on affinity to C3b or regulatory activity 1small differences in co-factor 
activity were confirmed using densitometry (Yu et al., 2014), 2are data from previous studies (Pechtl et al., 2011). 
 Effect of Variant on  
Variant Affinity to C3b Decay on SPR 
Assay 
Decay on Sheep 
E 
Co-factor Fluid 
Phase 
Co-factor on 
Sheep E 
R53C 1.47 ↓ 22.4 ↓1 1.38 
R53H2 1.20 ↓ 40.0 ↓ 2.6 
I62V2 1.4 ↔ 1.1 ↓ 2 
G69E 1.2 ↓ 1.3 ↔ 1.1 
R78G2 3.40 ↓ 25.1 ↓ 2.6 
Q81P ↓ ↓ 25.1 ↓ 11.0 
R83S 7.01 ↓ 9.1 ↓ ↓ 
D90G 0.92 ↔ N/P ↓1 N/P 
D130N 1.44 ↓ 2.0 ↔ 1.66 
S159N 1.20 ↔ 0.9 ↔ 1.54 
A161S 0.97 ↔ 1.3 ↔ 1.26 
M162V 1.23 ↔ 1.02 ↔ 1.48 
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I have determined the affinity of each variant to C3b using SPR, and tested decay and co-
factor regulatory activity using SPR, fluid phase and sheep erythrocyte haemolytic assays. 
The variant Q81P studied in this chapter exhibited a clear loss of decay and co-factor activity 
in functional assays, a pattern consistent with two previously studied variants in the setting of 
FH SCR1-4, R78G (Pechtl et al., 2011) and R83S (Wong et al., 2014). The variant R53C also 
exhibited a clear loss of decay activity with some loss of co-factor activity, a pattern 
consistent with the previously studied variant R53H (Pechtl et al., 2011). The functional 
consequences of these 5 rare variants are of complete loss in at least one of the regulatory 
functions of FH. The magnitude of this loss of regulatory function is different to that 
demonstrated for the other 6 disease-associated rare variants studied in this chapter and that 
of the previously studied disease-associated common polymorphism I62V (Pechtl et al., 
2011). The differences in magnitude of effect on complement regulatory function suggests 
these variants may not have the same pathogenicity in disease. 
 
5.4.1 Rare genetic variants in CFH resulting in complete loss of regulatory function 
Rare genetic variants in CFH leading to FH deficiency, or type 1 mutations can be found in a 
number of renal phenotypes, including MPGN/C3G and aHUS (Dragon-Durey et al., 2004). 
The regulatory function of FH is contained within the N-terminal domain. A variant in the N-
terminal domain of CFH may result in a defective protein that fails to regulate complement 
by decay or co-factor activity. If the mutant protein is completely defective, then levels of 
functional FH could be expected to be similar to those with a type 1 mutation. 
The Q81P variant studied in this chapter is in close proximity to two other disease-associated 
variants, R78G and R83S. All three of these variants are at the binding interface with C3b 
(Figure 96). In the case of R78G and R83S, the amino acid substitution results in the loss of a 
positive charge. In the case of Q81P, there is a loss of a polar side chain (Table 44). Taking 
into account in-silico prediction software tools, all three variants were predicted to be 
functionally significant. In studies of these three variants in a mutant FH SCR 1-4 protein, a 
clear loss of C3b binding was demonstrated resulting in loss of both decay and co-factor 
activity. 
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Figure 96 Structural modelling of R78G, Q81P and R83S associated with complete loss of regulatory function 
The mutated amino acids R78G (yellow), Q81P (green) and R83S (red) are modelled on the co-crystal structure of FH/C3b 
using Pymol. All three are on the surface of FH and are at the interface of FH SCR1-4 (blue ribbon) and C3b (dark 
spheres). 
 
Variant Electrostatic property change Polyphen Prediction Provean Prediction 
R78G 
Electrically 
charged (+ve) 
Non-polar side 
chains 
Deleterious Possibly damaging 
Q81P 
Polar side 
chains 
Non-polar side 
chains 
Deleterious Probably damaging 
R83S 
Electrically 
charged (+ve) 
Polar uncharged 
side chain 
Deleterious Possibly Damaging 
Table 44 Electrostatic effects and in-silico prediction for effect of R78G, Q81P and R83S 
 
The amino acid R53 is on the surface of FH and faces a putative binding site with FI (Figure 
97). The current and previous functional study of two mutant proteins (R53C and R53H) in 
the setting of FH SCR1-4 demonstrated only a small reduction of C3b binding and co-factor 
 166 
 
activity. However, there was a profound loss of decay acceleration activity. One amino acid 
change (R to C) results in the loss of positive charge but the other change (R to H) does not. 
Both arginine and histidine have basic side chains at neutral pH resulting in a positive charge. 
However, one distinction between these amino acids is that arginine holds onto the proton 
more strongly than histidine due to its higher pKa. When also taking into account in-silico 
prediction models, both variants were predicted to be functionally significant (Table 45). A 
large effect on C3b binding would not be expected based upon the structural modelling as 
shown. A larger effect on co-factor activity might have been expected based upon the 
putative binding site with FI. Instead, a large effect on decay activity was observed and 
suggests that the affected amino acid might play a more important role in decay rather than 
co-factor activity. 
 
 
Figure 97 Structural modelling of R53C associated with complete loss of decay activity 
The mutated amino acid R53 (red) representative of both the R53C and R53H mutant proteins, is modelled on the co-crystal 
structure of FH1-4:C3b using Pymol. It is on the on the surface of FH and at a putative interface of FH SCR1-4 (blue 
ribbon) and FI (not shown). C3b is also shown (dark spheres). 
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Variant Electrostatic property change Polyphen Prediction Provean Prediction 
R53C 
Electrically charged 
(+ve) 
Polar uncharged 
side chain 
Deleterious Probably Damaging 
R53H 
Electrically charged 
(+ve) 
Electrically charged 
(+ve) 
Deleterious Possibly Damaging 
R53S 
Electrically charged 
(+ve) 
Polar uncharged 
side chain 
 Deleterious Probably Damaging 
Table 45 Electrostatic effects and in-silico prediction for effect of R53C, R53H and R53S 
 
Complement levels of patients with these rare variants resulting in loss of regulatory function 
and of patients with type 1 mutations are shown in Table 46. All C3 levels are low even in the 
absence of a C3 nephritic factor and regardless of the differences in FH levels between those 
with type 1 and type 2 mutations. They are lowest in patients who have a rare variant 
inherited in homozygosity. 
Rare genetic variants in CFH that lead to complete loss of function should be considered 
functionally significant and pathogenic. 
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Variant 
He 
Ho 
Type 
1 or 2 
Disease C3 C4 FH FI 
C3 
NEF 
Reference 
C431S Ho 1 DDD 215 112 <20 49 N (Servais et al., 2012) 
C597R Ho 1 C3GN 179 218 <20 75 N (Servais et al., 2012) 
C597R Ho 1 MPGN1 <40 133 <10 75 N (Servais et al., 2012) 
R53C Ho 2 MPGN1 144 234 643 65 N (Servais et al., 2012) 
R53C Ho 2 MPGN1 ↓ ↔ ↔ ↔ P/N1 (Janssen van Doorn et al., 2013) 
L77X He 1 C3GN 616 271 260 74 N (Servais et al., 2012) 
V132I He 1 DDD 530 199 270 58 P (Servais et al., 2012) 
R232X He 1 DDD 538 160 275 52 P (Servais et al., 2012) 
C673R He 1 DDD 377 147 204 56 P (Servais et al., 2012) 
C1043S He 1 MPGN1 85 69 286 52 P (Servais et al., 2012) 
R53C He 2 C3GN 572 195 658 74 N (Servais et al., 2012) 
R53C He 2 aHUS2 509 160 689 65 ND (Fakhouri et al., 2010b) 
Q81P He 2 aHUS2 497 326 418 57 ND (Fakhouri et al., 2010b) 
R83S
3
 He 2 MPGN1 ↓ ↔ ↔ ↔ P (Wong et al., 2014) 
R83S
3
 He 2 MPGN1 ↓ ↔ ↔ ↔ P/N1 (Wong et al., 2014) 
R83S
3
 He 2 MPGN1 ↓ ↔ ↔ ↔ N (Wong et al., 2014) 
Table 46 Complement levels associated with rare genetic variants in CFH leading to complete loss of function 
Normal range of C3 (660-1250mg/L), and C4 (90-380mg/L), FH (338-682mg/L) and FI (42-78mg/L) (Fakhouri et al., 
2010b; Servais et al., 2012), Complement levels in other studies adopt a different normal range and arrows denote low or 
normal levels. MPGN1= MPGN type 1, He = heterozygous, Ho = homozygous, C3 NEF = C3 nephritic factor, ↓ = below 
normal range, ↔ = within normal range, ND = not done, 1Results from serial measurements of C3 nephritic factor were not 
the same at all time points, 2pregnancy-related, 3familial. 
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5.4.2 N-terminal Rare Genetic Variants in CFH that do not lead to Complete Loss of 
Regulation 
Functional assays of 6 other rare genetic variants in the N-terminal domain of CFH (G69E, 
D90G, D130N, S159N, A161S and M162V) do not cause a complete loss of complement 
regulatory activity. In all assays, the mutant FH SCR1-4 proteins exhibited evidence of C3b 
binding, decay and co-factor activity at concentrations where the wildtype protein was 
functional. 
The functional effects of these 6 rare variants should be considered in the context of the 
common polymorphism I62V. This polymorphism is associated with an increased risk of 
developing aHUS and DDD (Abrera-Abeleda et al., 2006; Pickering et al., 2007). The risk 
allele is carried by 80% of healthy individuals (evs.gs.washington.edu/). In functional studies, 
there was no effect on decay activity but it did have a small but significant effect on C3b 
binding and cofactor activity (Tortajada et al., 2009; Pechtl et al., 2011). In my studies of this 
group of variants, mutant FH was up to 1.66-fold less active than wildtype for co-factor 
activity and up to 2-fold less active than wildtype for decay activity. This compares with 
previous studies of the I62V variant that was 2-fold less active in co-factor activity (Pechtl et 
al., 2011). 
Of these 6 variants and including the common disease-associated polymorphism, I62V, five 
were found at the interface of FH and C3b (Figure 98). The amino acid substitutions did not 
affect electrical charge or polarity of side chains in the case of 4 of these, I62V, S159N, 
A161S or M162V. Furthermore, in-silico prediction did not predict a functional effect for 
these 4 variants (Table 47). The small effects on co-factor and decay activity in my studies 
for S159N, A161S and M162V are thus consistent with each other, and with the magnitude of 
the small but statistically significant effect of the common polymorphism I62V. 
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Figure 98 Structural modelling of I62V, D90G, S159N, A161S and M162V 
The mutated amino acids (red spheres) are modelled on the co-crystal structure of FH1-4:C3b using Pymol. All are near or 
at the surface of FH and at a putative interface of FH SCR1-4 (blue ribbon) and C3b (dark spheres). 
 
Of those variants at the interface of FH with C3b, the amino acid change and in-silico 
prediction for a 5th variant, D90G are comparable (Table 47) to those reported for the 
functionally significant variants R78G, Q81P and R83S. This suggests that D90G should 
result in a functional effect. Given the position of D90G at the C3b binding site (Figure 98), a 
functional effect resulting in complete loss of function would have been predicted. However, 
although statistically significant, the actual magnitude of effect on function was small and 
limited to co-factor activity. 
Two variants studied were found at a putative FI binding site (Figure 99). Of all of the 
variants described in this sub-section, D130N consistently had the largest effect on decay and 
co-factor activity, being 2-fold and 1.66-fold less active than wildtype respectively. 
Nonetheless, the D130N mutant protein did demonstrate both decay and co-factor activity 
and did not result in complete loss of regulatory activity. From this perspective, the D130N 
mutant is consistent with the in-silico prediction that there would be no effect on function 
(Table 47). 
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Figure 99 Structural modelling of G69E and D130N 
The mutated amino acids are modelled on the co-crystal structure of FH/C3b using Pymol. They are on the on the surface of 
FH SCR1-4 (blue ribbon). C3b is also shown (dark spheres). 
 
The final variant studied was G69E. In-silico analysis predicted a ‘deleterious’ and a 
‘probably damaging’ effect. Both C3b binding and co-factor activity were only minimally 
affected and is consistent with structural modelling shows that this variant affects an amino 
acid that is not in proximity with C3b or a putative FI binding site. The effect of this variant 
on decay activity was also minor. It is possible that despite the predicted effects, that the 
position of the affected amino acid is not directly involved in the regulatory activity of FH. 
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Variant Electrostatic property change Polyphen Prediction Provean Prediction 
V62I 
Non-polar side 
chains 
Non-polar side 
chains 
Neutral Benign 
D90G Acidic side chain 
Non-Polar 
uncharged side 
chain 
Deleterious Probably Damaging 
S159N 
Polar uncharged 
side chain - 
Polar uncharged 
side chain - 
Neutral Probably Damaging 
A161S 
Non-Polar 
uncharged side 
chain 
Non-Polar 
uncharged side 
chain 
Neutral Benign 
M162V 
Non-Polar 
uncharged side 
chain 
Non-Polar 
uncharged side 
chain 
Neutral Benign 
D130N Acidic side chain 
Polar uncharged 
side chain 
Neutral Benign 
G69E 
Non-Polar 
uncharged side 
chain 
Acidic side chain Deleterious Probably Damaging 
Table 47 Electrostatic effects and in-silico prediction for effect of variants with small changes in function 
 
The variants discussed in this section did not exhibit a complete loss of function. The 
functional effects were small and comparable to the effects of the common polymorphism, 
I62V. The largest functional effect observed on decay and co-factor activity was a 2-fold and 
1.66-fold reduction in activity respectively, compared to wildtype. The levels of functional 
FH in an individual who inherits such a variant in heterozygosity are unlikely to be as low as 
those with a type 1 mutation that associate with low C3 levels. 
C3 levels in patients with these variants that do not cause complete loss of regulatory 
function are shown in Table 48. Functional studies of one variant, S159N identified in aHUS 
and AMD were performed on the basis that this protein was normally secreted, suggested by 
normal FH levels in a case of AMD. In functional studies it demonstrated only a small loss of 
co-factor activity. However, in a case of aHUS, low C3 levels were present and in association 
with low FH levels. It is possible that S159N is in fact a type 1 mutation. 
C3 levels (where available) were within normal range for the remainder of the variants 
studied. This includes the variant, delG122-E128 that I had intended to study. This protein 
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did not express in small scale test expressions yet FH levels in a patient were within normal 
range. An explanation could be that normal FH levels are due to the wildtype allele alone. 
Study of FH directly from patient serum may be helpful to determine if a secreted truncated 
protein is present. If the patient was heterozygous for the common polymorphism, Y402H, 
relative levels of each variant could be measured (Hakobyan et al., 2010). 
In this section, functional testing distinguished these variants from those that led to complete 
loss. Based on the functional testing alone, these variants should not be regarded as 
functionally significant and pathogenic. Instead, as exemplified by the common 
polymorphism, I62V, they should be regarded as disease-associating and not individually 
pathogenic. 
 
Variant Disease C3 C4 FH FI C3 NEF Reference 
DelE122-G128 DDD 883 254 449 73 P (Servais et al., 2012) 
D130N DDD 1240 328 663 55 N (Servais et al., 2012) 
S159N1 aHUS ↓ ↓ ↓ ↔ ND Newcastle cohort, unpublished 
A161S aHUS2 733 248 530 76 ND (Fakhouri et al., 2010b) 
A161S aHUS ↔ ↔  ↔ ↔ ND Newcastle cohort, unpublished 
A161S DDD 802 345 602 68 P (Servais et al., 2012) 
M162V aHUS NK NK ↔ NK ND (Fremeaux-Bacchi et al., 2013) 
Table 48 Complement profile of patients with N-terminal rare variants in CFH that do not lead to complete loss of 
function 
Normal range of C3 (660-1250mg/L), and C4 (90-380mg/L), FH (338-682mg/L) and FI (42-78mg/L) (Fakhouri et al., 
2010b; Servais et al., 2012), Complement levels in Newcastle adopt a different normal range and arrows denote low or 
normal levels. All variants were heterozygous. C3 NEF = C3 nephritic factor, ↓ = below normal range, ↔ = within normal 
range, ND = not done in aHUS patients, NK = not known, 1 = initially selected for study in association with normal levels of 
FH in case of AMD in Newcastle Complement Genetics Service, 2 Pregnancy-associated. 
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5.4.3 Pleotropic Effects of Rare Genetic Variants in CFH 
A recently studied example of a rare genetic variant that highlights the pleotropic effects of 
FH is R1210C (Recalde et al., 2015). C-terminal variants were generally considered a cause 
of loss of complement regulation at the host cell surface leading to aHUS. In order to explain 
the association of the R1210C variant with MPGN/C3G, aHUS and AMD, studies using 
monoclonal antibodies confirmed that the covalently linked albumin on the free cysteine 
residue affects the functional domains in SCR1-4, SCR6-8 and SCR19-20. Thus, this was a 
variant of global FH dysfunction and not an isolated loss of C-terminal function. Patients 
with this variant in heterozygosity effectively have partial FH deficiency, like those with 
variants described in section 5.4.1. 
In this chapter, rare genetic variants in the N-terminal domain of CFH have been described in 
MPGN/C3G, aHUS and AMD. Other rare genetic variants in the N-terminal domain of CFH 
have been identified in AMD cohorts and are summarised (Appendix 10, Table 64) (Duvvari 
et al., 2015; Triebwasser et al., 2015). A review of these variants identifies a total of 7 
variants that associate with renal disease and AMD (Table 49). Most notably, the R53C and 
A161S variants have been described in MPGN/C3G, aHUS and AMD and is further evidence 
of the pleotropic effects of FH. 
 
Protein SCR MPGN/C3G aHUS 
p.P26S 1 Y  
p.R53C 1 Y Y 
p.R53H 1  Y 
p.S58A 1  Y 
p.D130N 2 Y  
p.S159N 3  Y 
p.A161S 3 Y Y 
p.I216T 4 Y  
Table 49 Pleotropic effects of Rare genetic variants in N-terminal domain of CFH found in AMD 
Rare genetic variants identified in AMD have also been described in cases of MPGN/C3G and aHUS. R53C and A161S have 
been identified in all of these phenotypes. 
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5.4.4 Limitations of Study 
The functional tests described in this chapter were performed in the setting of the short 
fragment, FH SCR1-4 only. None, except for the previously studied common polymorphism 
I62V (Tortajada et al., 2009; Pechtl et al., 2011) have been studied in both the setting of FH 
SCR1-4 and full length protein in which only small difference in co-factor activity was 
demonstrated. Therefore, extrapolation of the effects of the functionally significantly mutant 
proteins from studies in short fragments to full length protein is based on studies of this 
polymorphism alone. Confirmatory studies of functionally significant rare genetic variants in 
the N-terminal domain in the setting of full length protein should be considered. 
In this study, functional studies of the S159N mutant protein that were initially based on the 
normal FH levels identified in a case of AMD, did not demonstrate a complete loss of 
function. However, analysis of FH levels from another case identified low FH levels 
suggestive of a type 1 mutation. Functional studies alone may have been misleading. 
Sampling of patient serum could allow additional evaluation of FH, to look for the possibility 
of degradation of protein by Western blot or the relative amounts of each variant, though this 
is reliant upon access to individual patients and in the latter, heterozygosity for the Y402H 
polymorphism and (Hakobyan et al., 2010; Szarvas et al., 2016). 
Finally, the clinical need to understand the pathogenicity of individual variants in the 
MPGN/C3G cohort is an important factor driving this research. In aHUS, confirmation of the 
pathogenicity of variants in CFH allows stratification of patient prognosis and management 
(Wong et al., 2015). Whilst functional studies have confirmed pathogenicity for a small 
number of variants, correlation with longitudinal data in these patient cohorts is yet to be 
done.  
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5.5 Summary 
Rare genetic variants in the regulatory domain of CFH have been reported in several diseases 
that associate with excess complement activation. Many are type 1 mutations and are 
significant. The study of N-terminal variants in CFH in this chapter in the setting of FH 
SCR1-4 has contributed to previous functional studies of type 2 mutations that have been 
described in MPGN/C3G and aHUS. Combined with my studies, it is clear from functional 
studies of mutant proteins in the setting of FH SCR1-4 that complete loss function due to 
several type 2 mutations, R53C, R53H, R78G, Q81P and R83S can be demonstrated and like 
type 1 mutations should be considered significant in disease. 
It is also clear from functional studies of mutant proteins in the setting of FH SCR1-4 that 
complete loss function is not evident for all rare genetic variants identified in this functional 
domain. These variants, that include the common polymorphism I62V, may be associated 
with disease but not causative. This highlights the need for such functional studies. 
Furthermore, rare genetic variants in CFH can be found in a range of different disease 
phenotypes and include those that are functionally significant and those that are associated 
with disease. This suggests that abnormalities alone in FH, even in those with a functionally 
significant variant may not be sufficient to cause aHUS, AMD or MPGN/C3G and further 
studies are required to address this. 
Finally, further studies to understand the role of rare genetic variants in CFH are required. 
These include correlation of functionally significant variants in longitudinal studies in patient 
cohorts and verification of the significance of these studies in the setting of FH SCR1-4 in 
full length protein. The next chapter describes my study of functionally significant CFH 
variants in the setting of a full length FH protein. 
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Chapter 6 Functional Study of Disease-Associated Variants in FH 
6.1 Introduction 
FH is the major fluid phase regulator of AP. Rare genetic variants in CFH have been 
identified in 4-16.2% (Servais et al., 2012; Bu et al., 2015; Iatropoulos et al., 2016) of 
patients in cohorts of MPGN/C3G and in a quarter of patients with aHUS (Noris et al., 2010; 
Fremeaux-Bacchi et al., 2013). Approximately half of variants reported in CFH in patients 
with aHUS (Fremeaux-Bacchi et al., 2013) and in patients with MPGN/C3G (as shown in 
chapter 5) lead to FH deficiency. These are type 1 mutations and are considered pathogenic. 
In the remainder of cases, functional studies are required to confirm pathogenicity. 
Functional studies have been performed on disease-associated rare genetic variants identified 
throughout CFH. Studies of rare variants in the N- and C-terminal functional domains of 
CFH are summarised (Table 50). These studies of rare variants include the use of 
recombinantly expressed mutant proteins that comprise the functional domains, SCR1-4 or 
SCR19-20 domains of FH. Other studies use patient serum containing mutant FH in FH-
dependent haemolysis assays in which wildtype FH protects sensitised sheep erythrocytes 
from lysis (Sanchez-Corral et al., 2002). 
Recombinant mutant proteins that contain the SCR19-20 recognition domain have been 
studied to determine the effects on C3b, C3d, heparin and endothelial cell binding due to rare 
genetic variants in the C-terminal domain of CFH (Jozsi et al., 2006; Ferreira et al., 2009). 
Furthermore, these mutant proteins also been tested in competition assays with full length 
wildtype FH on the surface of erythrocytes in FH-dependent haemolysis assays. 
Recombinant mutant proteins in the setting of SCR1-4 have been used to determine 
differences in effect on individual regulatory functions in C3b binding, decay and co-factor 
assays (Pechtl et al., 2011; Wong et al., 2014). An important advantage in studies using 
recombinant proteins is that they are not reliant upon patient sampling. Studies using 
recombinant fragments account for a high proportion of studies of different rare genetic 
variants in the N- and C-terminal domains of CFH. However, the consequences of these 
mutant proteins must be extrapolated to understand their significance in a full length protein 
that may lead to incorrect interpretation of the significance of a rare variant. 
False negative results are an important consideration of haemolytic assays used to test FH 
from patient serum. These assays are dependent upon an active complement system to enable 
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lysis. Samples that are not properly manipulated or samples from individuals with low 
complement levels may fail to lyse cells resulting in false negatives (Sanchez-Corral 2002). 
Use of purified full length mutant proteins account for a minority of studies of rare genetic 
variants reported in the N- or C–terminal domain of CFH. However, they enable a diverse 
range of functional testing that includes the detection of small functional differences of the 
polymorphic variant, I62V (Tortajada et al., 2009) and the novel molecular insights resulting 
from bound albumin on the R1210C mutant protein (Recalde et al., 2015). 
In the study of R1210C, a variant associated with risk of aHUS, MPGN/C3G and AMD, it 
was shown that the free cysteine in the R1210C mutant protein bound to human serum 
albumin. This additional albumin resulted in impaired binding of 3 different monoclonal 
antibodies that each had specificity to a different functional domain of FH. This rendered the 
mutant FH protein functionally inert (Recalde et al., 2015). 
Collaborators in the Barlow laboratory, Edinburgh have optimised a protocol using Pichia 
pastoris to express and purify human full length FH (Schmidt et al., 2011). Disease-
associated variants can be introduced using site-directed mutagenesis and expressed for 
functional studies (Herbert et al., 2015). Mutant FH can then be purified to homogeneity. 
 
6.1.1. Chapter Aims 
In this chapter I will contribute to the studies of rare genetic variants in the N- and C-terminal 
domain of CFH using full length FH proteins. Using mutant FH proteins recombinantly 
expressed in the Barlow laboratory, I will describe the use of sheep erythrocyte haemolytic 
assays to test the effect of 
 One N-terminal disease-associated variant in full length FH and 
 Two C-terminal disease-associated variants in full length FH. 
Studies of these purified full length mutant proteins will allow me to validate the numerous 
studies that have been performed in fragments of FH, including SCR1-4 and SCR19-20. 
I will then demonstrate the utility of the sheep erythrocyte haemolytic assays in a study of a 
novel hybrid FH/FHR3 protein identified in a patient with aHUS. 
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Variant SCR 
Recombinant 
FH (SCRs)t 
Patient FH 
C3b/d 
binding 
Heparin 
Binding 
Co-
factor 
Decay 
Endothelial 
Cell 
Binding 
Lysis 
Assay 
Reference 
R53C 1 1-4 N/A ↓ N/A ↓ ↓ N/A ↓1 (Yu et al., 2014) 
R53H 1 1-4 N/A ↔ N/A ↓ ↓ N/A ↓1 (Pechtl et al., 2011) 
I62V 1 1-4 Purified ↔ ND ↓ ↔ ND ↓1 (Tortajada et al., 2009; Pechtl et al., 2011) 
R78G 1 1-4 N/A ↓ N/A ↓ ↓ N/A ↓1 (Pechtl et al., 2011) 
R83S 1 1-4 N/A ↓ N/A ↓ ↓ N/A ↓1 (Wong et al., 2014) 
D90G 2 1-4 N/A ↔ N/A ↓ ↔ N/A ND (Yu et al., 2014) 
W198R 3 N/A Serum ND N/A ND ND ND ↓2 (Szarvas et al., 2016) 
ΔK224 4 N/A Purified ↓3, 4 ↔ ↓ ↓5 ↔ ND (Licht et al., 2006) 
D1119G 19 19-20 ND ↔ / ↓ ↔ N/A N/A ↔6 ↓7 (Ferreira et al., 2009; Lehtinen et al., 2009) 
Y1142C 19 ND Serum ND ND N/A N/A ND ↓2 (Abarrategui-Garrido et al., 2008) 
W1157R 19 8-20 ND ↓ ↓ N/A N/A ND ND (Jozsi et al., 2006)  
P1161T 19 ND Serum ND ND N/A N/A ND ↓2 (Szarvas et al., 2016) 
E1172X 20 ND Purified ↓ ↓ N/A N/A ↓8 ND (Manuelian et al., 2003; Jokiranta et al., 2005) 
R1182S 20 19-20 ND ↓9 ↓ N/A N/A ND ↓7 (Ferreira et al., 2009; Kopp et al., 2012) 
W1183R 20 
1-2010 
19-20 
Purified / 
Serum 
↑9 ↑ ↔ N/A ND ↓2, 7 
(Sanchez-Corral et al., 2002; Sanchez-Corral et al., 2004; Ferreira et al., 
2009; Kopp et al., 2012) 
W1183L 20 
8-20 
19-20 
ND ↓ ↓ N/A N/A ↓ 6/8 ↓2,7 (Jozsi et al., 2006; Ferreira et al., 2009; Lehtinen et al., 2009) 
  
 
1
8
0
 
T1184R 20 19-20 ND ↔ / ↑ ↑ N/A N/A ↑ 6 ↓7 (Ferreira et al., 2009; Lehtinen et al., 2009) 
L1189R 20 19-20 ND ↔ / ↑ ↔ / ↑ N/A N/A ↑ 6 ↓7 (Ferreira et al., 2009; Lehtinen et al., 2009) 
L1189F 20 19-20 ND ↑ ↑ N/A N/A ND ↓7 (Ferreira et al., 2009) 
S1191L 20 19-20 Serum ↑ ↔ N/A N/A ND ↓2, 7 (Heinen et al., 2006; Ferreira et al., 2009) 
SV 20 
18-20 
19-20 
Serum ↓ / ↑ ↔ N/A N/A ND ↓2 (Heinen et al., 2006; Ferreira et al., 2009) 
V1197A 20 8-20 
Purified / 
Serum 
↓ ↓ ↔ N/A ND ↓2, 7 
(Jozsi et al., 2006) (Sanchez-Corral et al., 2002; Sanchez-Corral et al., 
2004; Heinen et al., 2006) 
E1198A 20 19-20 ND ↔ ↔ N/A N/A ↔6 ND (Lehtinen et al., 2009) 
E1198K 20 ND Serum ND ND N/A N/A ↓8 ↓2 (Vaziri-Sani et al., 2006) 
R1203W 20 ND Serum ND ND N/A N/A ND ↓2 (Szarvas et al., 2016) 
R1210C 20 
8-20 
19-20 
Purified / 
Serum11 
↓ ↓ ↔ N/A ↓8 ↓2, 7 
(Sanchez-Corral et al., 2002; Manuelian et al., 2003; Sanchez-Corral et 
al., 2004; Jozsi et al., 2006; Ferreira et al., 2009; Recalde et al., 2015) 
R1215G 20 
8-20 
19-20 
ND ↓ ↓ N/A N/A ↓8 ↓7 (Manuelian et al., 2003; Jozsi et al., 2006; Ferreira et al., 2009) 
R1215Q 20 19-20 ND ↔ ↓ N/A N/A ↔6 ND (Lehtinen et al., 2009) 
T1216del 20 ND Serum ND ND N/A N/A ND ↔2 (Szarvas et al., 2016) 
P1226S 20 8-20 ND ↓ ↓ N/A N/A ND ND (Jozsi et al., 2006) 
Table 50 Functional studies of rare genetic variants identified in N- and C-terminal of CFH 
Recombinant proteins were made in the setting of the short consensus repeats (SCR) stated, patient FH was tested either in serum or purified, some patients had contradicting results from 
different studies indicated by multiple arrows. The variant ‘SV’ = S1191L/V1197A. 1Decay and co-factor activity of FH is tested on the surface of sheep erythrocytes before cells are lysed with 
serum depleted of FH, 2Patient serum is used on sheep erythrocytes, 3includes peptid spot assay, 4includes C3d binding, 5Patient serum is used on C3bBb formed on sheep erythrocytes, 
6Endothelial cell binding using mouse glomerular endothelial cell, 7Recombinant FH proteins compete with wildtype in sheep haemolysis assay, 8Endothelial cell binding using human umbilical 
vein endothelial cells, 9Impaired pentraxin binding, 10Expressed in COS cell line, 11FH-bound to serum albumin. 
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6.2 Functional Study of Genetic Variants Using Recombinant Full Length FH 
6.2.1 Selection of Genetic Variants 
The three rare genetic variants selected for study have all been described in aHUS and 
previously studied in the setting of FH fragments (Figure 100). R53H is a rare variant in the 
N-terminal regulatory domain of CFH and has been previously described in the setting of FH 
SCR1-4. This study demonstrated a small reduction of C3b binding and co-factor activity. 
However, there was a profound loss of decay acceleration activity (Pechtl et al., 2011). These 
differences are consistent with the effects of the disease-associated variant R53C that affects 
the same amino acid described in chapter 5 (Yu et al., 2014). 
D1119G is a rare genetic variant in the C-terminal recognition domain of CFH and has been 
previously studied in the setting of FH SCR19-20 (Ferreira et al., 2009). A final variant is the 
result of a gene conversion event between exon 23 of CFH and exon 5 of CFHR1 resulting in 
a C-terminal domain that differs by two amino acids, S1191L and V1197A 
(S1191L/V1197A). This variant has also been studied in the setting of FH SCR 19-20 
(Heinen et al., 2006; Ferreira et al., 2009). In studies of both C-terminal variants, the mutant 
protein fails to regulate complement on host surfaces as shown in haemolytic assays. D1119G 
had the greatest impairment on cell surface assays in functional studies of a series of 16 
aHUS-associated variants in the C-terminal domain of CFH (Ferreira et al., 2009). 
A clone expressing full length FH in Pichia pastoris has been optimised in the Barlow group 
in Edinburgh (Schmidt et al., 2011; Herbert et al., 2015). The wildtype clone carried the 
polymorphisms I62/Y402/D936 (IYD) commonly found in CFH. Wildtype and mutant 
sequence variants were expressed in Pichia pastoris in the setting of full length FH and 
purified in a protocol optimised by Dr. Herbert and Dr. Kerr from the University of 
Edinburgh. I then used the purified protein in sheep erythrocyte haemolytic assays. 
A fourth ‘mutant’ protein was also expressed in a clone expressing full length FH. Two 
common polymorphic variants were introduced resulting in a mutant protein carrying the 
polymorphisms V62/Y402/E936 (VYE) also found in CFH. Previous studies have 
demonstrated a small but significant difference in co-factor activity between the I62 and V62 
FH protein in studies of full length FH (Tortajada et al., 2009) and FH SCR1-4 (Pechtl et al., 
2011). 
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Figure 100 Co-crystal structures of FH SCR1-4:C3b and FH SCR19-20:C3b 
The R53H variant (pink sphere) in the N-terminal domain of FH (blue) and 3 affected amino acids (green) in the C-terminal 
domain of FH (red) are modelled on a co-crystal structure of FH SCR1-4 and C3b (grey spheres) and FH SCR19-20 (grey 
ribbon) that have been aligned using Pymol. The common polymorphism I62V is also shown (pink sphere). 
 
6.2.2 Determining Decay and Co-factor Activity in Sheep Erythrocyte Haemolysis Assays 
Firstly, the function of recombinantly expressed full length FH was compared against plasma 
purified FH (obtained from Dr. Herbert). In a decay acceleration assay on the surface of 
sheep erythrocytes, the recombinantly expressed full length FH was only slightly less 
effective than plasma purified FH (Figure 101). 
 
Figure 101 Decay activity on sheep erythrocytes – full length recombinant FH and plasma purified FH 
FH was incubated with C3bBb formed on the surface of sheep erythrocytes. FH decays C3bBb and prevents lysis instigated 
by the addition of serum depleted of FB and FH. Recombinant full length FH (IC50 = 1.49nM)is 1.3-times less effective than 
plasma purified FH (IC50 = 1.21nM). Error bars represent 1 standard deviation from experiments performed in triplicate.  
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The ability of each of the disease-associated mutations to regulate complement on the surface 
of sheep erythrocytes was then tested in the haemolytic assay. ‘Mutant’ FH was tested 
alongside WT FH (IYD) in each case. 
The VYE variant had no effect on decay activity on the surface of sheep erythrocytes (IC50 
IYD 1.23nM vs IC50 VYE 1.20nM). All three aHUS associated genetic variants had an effect 
on decay activity on the surface of sheep erythrocytes. Compared to the wildtype FH, IYD, 
R53H required 4.7-fold higher concentration to achieve 50% protection from lysis, 
S1191L/V1197A required 1.7-fold and D1119G required 8.9-fold higher (Figure 102). 
 
Figure 102 Decay activity on sheep erythrocytes – full length recombinant FH mutant proteins 
FH and mutants were incubated with C3bBb formed on the surface of sheep erythrocytes. FH decays the C3bBb and 
prevents lysis instigated by the addition of serum depleted of FB and FH. The reference FH, IYD, is more effective than all 
three mutant proteins at protecting cells from lysis. The polymorphic variant VYE however showed no difference in decay 
activity compared to IYD. Error bars represent 1 standard deviation from experiments performed in triplicate. 
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There was only a small difference in co-factor activity on the surface of sheep erythrocytes 
between the VYE variant and IYD (IC50 IYD 8.13nM vs IC50 VYE 9.55nM – 1.17-fold 
difference). The three disease associated rare genetic variants had a large effect on co-factor 
activity on the surface of sheep erythrocytes. Compared to the IYD control FH, R53H 
required 2.5-fold higher concentration to achieve 50% protection from lysis, 
S1191L/V1197A required 2.6-fold and D1119G required >17-fold higher (Figure 103). 
 
Figure 103 Co-factor activity on sheep erythrocytes – full length mutant recombinant FH mutant proteins 
FH (and mutants) were incubated with sheep erythrocytes coated with C3b and factor I for 15 minutes. C3bBb was formed 
on intact C3b and lysis instigated by the addition of serum depleted of FB and FH. FH acts as a co-factor and inactivates 
C3b in the presence of factor I and prevents subsequent C3bBb formation and protects cells from lysis. The reference FH, 
IYD, is more effective than all three mutant proteins at protecting cells from lysis. The polymorphic variant VYE 
demonstrated a mild impairment in co-factor activity compared to IYD. Error bars represent 1 standard deviation from 
experiments performed in triplicate. 
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6.3 Functional Study of a Hybrid FH/FHR3 Protein Purified from Patient Serum 
6.3.1 Clinical Case 
A patient with aHUS was studied initially by Dr. Rachel Challis (Challis et al., 2015). She 
used MLPA and Sanger sequencing to demonstrate that this patient with aHUS had a genetic 
deletion of exons 21 to 23 of CFH. This was predicted to result in an mRNA transcript that 
read from exon 20 of CFH to the next available splice acceptor site, predicted to be in exon 2 
of CFHR3. The presence of this mRNA transcript, a hybrid between exons 1 to 20 of CFH 
and exons 2 to 6 of CFHR3 was confirmed using cross gene polymerase chain reaction. 
Western blotting was used initially to confirm that this transcript led to a translated protein in 
the serum. 
A wildtype FH protein from the normal allele and hybrid FH/FHR3 protein from the 
abnormal allele was initially co-purified using a FH SCR5 specific (OX24) immunoaffinity 
column. The identity of the 22 SCR hybrid protein, containing SCR1-17 of FH and SCR1-5 
of FHR3 was confirmed on mass spectrometry. Figure 104 shows that the hybrid FH/FHR3 
protein is larger than FH and that the hybrid FH/FHR3 protein lacks the critical C-terminal 
recognition domain of FH. This patient was also heterozygous for the Y402H polymorphism 
and in Dr. Challis’ previous work, this was confirmed using specific antibodies, MBI6 and 
MBI7 to both the 402Y and 402H polymorphism respectively on Western blot. This showed 
that the wildtype FH was carried on the 402H allele and that the hybrid FH/FHR3 protein was 
carried on the 402Y allele (Figure 104). I undertook functional analysis of this hybrid 
FH/FHR3 protein to confirm its functional significance. 
The work below describes the steps taken by me to purify the hybrid FH/FHR3 protein to 
homogeneity before characterisation of the hybrid protein in decay and co-factor assays on 
the surface of sheep erythrocytes and assays to test heparin binding and fluid-phase co-factor 
activity. 
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Figure 104 SCRs of FH and the hybrid FH/FHR3 protein 
Adapted from Challis et al. The 20 SCRs of WT FH protein is represented by 20 numbered (unfilled) circles (1-20). Due to a 
gene deletion of exons 21-23 of CFH in one allele of CFH in the patient, an mRNA transcript is generated that leads to the 
expression of a 22 SCR hybrid protein. This hybrid FH/FHR3 protein contains 22 SCRs. The first 17 SCRs are identical to 
FH. SCRs 18-20 are missing and replaced by SCRs 1-5 of FHR3 shown by blue circles. OX24 is a monoclonal antibody to 
SCR5, common to both proteins. The patient has one copy of the normal CFH gene that is carried on the 402H allele. The 
WT FH protein is recognised by a FH 402H specific monoclonal antibody, MBI7. The patient has one copy of the hybrid 
CFH/CFHR3 gene that is carried on the 402Y allele. The FH/FHR3 hybrid protein is recognised by a FH 402Y specific 
antibody, MBI6. 
 
6.3.2 Purification of Y-402 Specific FH from Serum 
An antibody specific to the 402Y variant of SCR7 was obtained from the Harris/Morgan 
laboratories at the University of Cardiff. Specificity of this antibody (MBI6) was confirmed 
using Western blotting against genotyped controls (Figure 105). This antibody recognised the 
FH/FHR3 hybrid protein (and a putative degradation product) in patient sera and FH in 
control sera. Therefore the MBI6 antibody was used to produce a purification column that 
was specific to FH 402Y (MBI6 column) and used to purify the hybrid FH/FHR3 protein for 
functional studies. 
Serum from a donor control homozygous for FH 402Y was used to optimised the purification 
of FH from the MBI6 column. Standard elution using 0.1M glycine pH 2.7 and subsequently 
pH 2.3 and 2.2 failed to elute any FH (Figure 106). 
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Figure 105 Western blot confirming specificity of MBI6 antibody to the hybrid FH/FHR3 protein 
Serum (1:100) from patient and a genotyped control (CFH 402YY) was separated by 6% SDS-PAGE under non-reducing 
conditions and transferred onto nitrocellulose membrane. Following incubation with the mouse monoclonal antibodies 
MBI6 (1:2000) or MBI7 (1:2000) on separate blots followed by the secondary antibody sheep-anti mouse HRP (1:4000), FH 
402Y in control serum was detected when using MBI6 as the primary antibody. Also detected was a larger protein consistent 
with the hybrid FH/FHR3 protein and a smaller protein consistent with a degradation product. When using the 402H 
specific (MBI7) antibody as a primary antibody, only the wildtype FH protein from patient serum carried on the 402H allele 
can be detected. 
 
 
Figure 106 FH is not eluted from MBI6 column using 0.1M glycine 
1ml of serum was loaded onto an OX24 (FH SCR5 specific) and also an MBI6 (FH SCR7 402Y specific) immunoaffinity 
column. FH is eluted using 0.1M glycine at pH 2.7 and is shown following 4-15% gradient SDS-PAGE migrating to its usual 
position between the 150kDa and 100kDa markers under non-reducing conditions. Attempts to elute FH using 0.1M glycine 
at pH 2.7, 2.3 and 2.2 were unsuccessful. A faint band suggestive of FH was visible when 0.1M glycine pH 2.2 was used as 
an elution buffer and only when extensively concentrated as shown. 
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Elution was then attempted successfully using PBS containing 0.05% diethylamine, pH 11.5. 
In these conditions, a large elution peak was observed and a pure protein was identified at the 
same size as FH from an OX24 column (Figure 107). 
 
Figure 107 FH eluted from MBI6 and OX24 columns 
FH is eluted from affinity column with specificity to FH 402Y (MBI6) using PBS containing 0.05% diethylamine, pH 11.5 
and is shown following 4-15% gradient SDS-PAGE migrating to its expected size between the 150kDa and 100kDa markers 
under non-reducing conditions. FH eluted from an affinity column with specificity to FH SCR5 (OX24) using 0.1M glycine 
at pH 2.7 migrates to the same position. 
 
Using the optimised elution conditions, hybrid FH/FHR3 protein was purified from patient 
serum and a control FH protein was purified from genotyped control serum using the MBI6 
column. Purified protein free of aggregates or degradation products were obtained following 
size-exclusion and shown on SDS-PAGE gel in Figure 108. FH migrates to ~130kDa under 
non-reducing conditions. The purified FH/FHR3 hybrid is larger than the WT FH.  
 
 
Figure 108 Purified WT FH and hybrid FH/FHR3 protein 
Taken from Challis et al. WT FH from donor control serum and hybrid FH/FHR3 protein from patient serum was purified in 
two-steps using a SCR7 402Y specific immunoaffinity column followed by size exclusion. Following 4-15% gradient SDS-
PAGE under non-reducing conditions,  WT FH migrates at the expected size in between the 150kDa and 100kDa markers. 
FH/FHR3 as predicted is larger in size.  
 189 
 
6.3.3 Determining Regulatory Activity in Sheep Erythrocyte Haemolysis Assays 
The ability of the hybrid FH/FHR3 protein to regulate complement was tested on the surface 
of sheep erythrocytes in a series of haemolytic assays.  
The hybrid FH/FHR3 protein was less effective than FH control in decay activity on the 
surface of sheep erythrocytes in a haemolytic assay. The IC50 for FH was 3.9nM vs 6.6nM for 
a hybrid FH/FHR3, a 1.7-fold difference (Figure 109). 
 
Figure 109 Decay activity on sheep erythrocytes - hybrid FH/FHR3 protein 
Adapted from Challis et al. The hybrid FH/FHR3 and FH were incubated with C3bBb formed on the surface of sheep 
erythrocytes. FH decays the C3bBb and prevents lysis instigated by the addition of serum depleted of FB and FH. FH is 1.7-
times more effective than FH/FHR3 hybrid at protecting cells from lysis (IC50 FH 3.9 nM vs FH/FHR3 hybrid 6.6 nM). 
Error bars represent 1 standard deviation from experiments performed in triplicate. 
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The hybrid FH/FHR3 protein was also less effective than the FH control in co-factor activity 
on the surface of sheep erythrocytes in a haemolytic assay. The IC50 for FH was 38.5nM. An 
exact IC50 could not be determined for the hybrid protein (Figure 110). 
 
 
Figure 110 Co-factor activity on sheep erythrocytes - hybrid FH/FHR3 protein 
Adapted from Challis et al. The hybrid FH/FHR3 or FH were incubated with sheep erythrocytes coated with C3b and factor 
I for 8 minutes. C3bBb was formed on intact C3b and lysis instigated by the addition of serum depleted of FB and FH. FH 
acts as a co-factor and inactivates C3b in the presence of factor I and prevents subsequent C3bBb formation and protects 
cells from lysis. FH is more effective than than FH/FHR3 hybrid at protecting cells from lysis. Error bars represent 1 
standard deviation from experiments performed in triplicate. 
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6.3.4 Heparin Binding and Co-factor Activity 
The hybrid FH/FHR3 protein lacks the C-terminal domain of FH that can bind heparin. 
Impaired binding to heparin compared to wildtype FH is demonstrated in (Figure 111). The 
other heparin domain in SCR6-8 of FH is unaffected. Fluid-phase co-factor activity, a 
function of the N-terminal domain was not impaired (Figure 112). 
 
 
Figure 111 Heparin binding - hybrid FH/FHR3 protein 
Taken from Challis et al. Purified proteins from patient (FH/FHR3) and control FH (402Y) were bound to a HiTrap heparin 
column and eluted with NaCl. The hybrid FH/FHR3 protein (black) eluted at 325mM and FH (grey) at 357mM, indicating 
reduced binding. Dashed line indicates gradient of NaCl. 
 
 
Figure 112 Co-factor activity in fluid-phase – hybrid FH/FHR3 protein 
Adapted from Challis et al. Equimolar concentrations of wildtype FH and FH/FHR3 were used in a fluid phase co-factor 
assay. In the fluid phase the hybrid FH/FHR protein has comparable levels of co-factor activity compared to wildtype FH, 
as FI cleaves C3b to iC3b as seen by the loss of the α’chain and generation of the α1 chain. 
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6.4 Discussion 
6.4.1 Comparison of Studies in the Setting of Full Length and Fragments of FH 
In this chapter, I have studied 3 disease-associated rare genetic variants and 1 disease-
associated common polymorphism in the setting of recombinant full length FH. Clear 
differences in decay and co-factor activity were observed in the study of all three-disease 
associated mutant proteins when compared with the control, IYD. A small difference was 
observed in cofactor activity when comparing VYE and IYD. These differences are 
summarised in Table 51 and compared to the previously published studies of these mutant 
proteins. 
R53H was selected for study as loss of regulatory activity had been previously demonstrated 
in the setting of the short fragment, FH SCR1-4. The effects on regulatory activity are 
confirmed in my studies of R53H in full length FH. In both fragment and full length studies, 
there was marked loss of decay activity and some loss of co-factor activity. 
I62V has been studied previously in the setting of FH SCR1-4 and purified full length FH 
from serum. The finding of small functional effects on co-factor activity and not decay 
activity in my study is comparable to previous studies. 
Studies of other variants on the interface of the N-terminal domain of FH and C3b will be 
useful to further validate the observations in full length FH. These should include variants 
such as R83S that resulted in complete loss of both decay and co-factor activity, or A161S 
where the effect on function was markedly less. 
Previous studies of the two C-terminal variants, S1191L/V1197A and D1119G in FH 
SCR19-20 did not allow direct testing of decay or co-factor activity as the proteins used 
lacked the N-terminal domains. These two mutants were chosen for study because loss of 
function was demonstrated in assays testing cell surface binding. Impaired cell surface 
binding would result in a failure of FH to regulate complement on surface-bound C3b by 
decay and co-factor activity as was demonstrated in my studies using full length protein. The 
magnitude of the effect was greatest in both assays for D1119G and is consistent with the 
observations that D1119G had the greatest impairment on cell surface assays in previous 
studies (Ferreira et al., 2009). In studies of both C-terminal variants in full length FH, 
impairment of co-factor activity appeared to be greater than decay as measured by differences 
in IC50. This is an observation that could be tested in a larger sample of C-terminal variants. 
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Overall, the functional effects demonstrated in full length protein are consistent with those 
observed in previous studies using fragments of FH, such as SCR1-4 and SCR19-20. My 
studies confirm the functional effects observed in the original studies performed in short 
fragments. 
Variant Protein used 
Difference in IC50 of mutant protein 
Decay activity Co-factor activity 
R53H Full Length 4.7-fold 2.46-fold 
R53H FH SCR1-4 40-fold 2.6-fold 
VYE Full Length No difference 1.2-fold 
I62V Full Length No difference 1.6-1.8-fold 
I62V FH SCR1-4 No difference 2-fold 
S1191L/V1197A Full Length 1.87-fold 3.8-fold 
S1191L/V1197A FH SCR19-20 N/A N/A 
D1119G Full Length 8.9-fold >17.5-fold 
D1119G FH SCR19-20 N/A N/A 
Table 51 Comparison of functional assays using full length and fragments of FH 
Differences in IC50 of mutant proteins compared to WT or V62 to I62 are shown. The functional effects of R53H are greater 
in decay than co-factor activity in both full length and fragment studies. The functional effects of D1119G and 
S1191L/V1197A are greater in co-factor activity than decay both full length and fragment studies. The small effects on co-
factor activity and not decay are observed in all studies of the I62V polymorphism. It should be noted that the full length 
protein containing the V62 variant also differed from I62 at the amino acid 936. 
 
My studies of mutant full length FH proteins expressed in Pichia pastoris contribute to the 
small number of studies of mutant full length FH proteins previously described in the 
literature. Sanchez-Corral et al expressed the W1183L mutant in COS7 cells. They were able 
to demonstrate a loss of surface-bound C3b binding but no differences in fluid phase co-
factor assays, consistent with the effects of a C-terminal variant. These findings were 
comparable to those using W1183L purified from serum (Sanchez-Corral et al., 2002). 
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More recently, Mohlin et al expressed the Q950H mutant in HEK293 cells and reconstituted 
serum depleted of FH with mutant or wildtype protein in haemolytic assays. Using 
recombinant protein, they confirmed their earlier findings that the mutant protein had 
impaired regulation of complement in a sheep erythrocyte haemolytic assay. They then 
showed that the Q950H mutant recombinant protein had no impairment of co-factor activity 
in the fluid-phase, suggesting that the differences shown in haemolysis assays were due to 
loss of binding (Mohlin et al., 2015). 
In both of these studies, there was a comparison of recombinant and plasma purified FH. In 
my study, there was a small difference in decay activity between a recombinant and plasma 
purified wildtype FH protein. These differences were small, when compared to the 
differences in function that were observed due to the disease-associated rare variants (R53H, 
D1119G and S1191L/V1197A). However, it is possible that smaller differences of other 
variants may be masked. Further comparison of wildtype and mutant studies using both 
recombinant and plasma purified protein may be helpful, especially for the study of mutant 
proteins where the functional effects are smaller. 
 
6.4.2 Methods of Purification of Full Length FH 
I then went on to fully characterise a novel hybrid FH/FHR3 protein identified in Dr. Challis’ 
studies of aHUS. In my experiments, the hybrid protein was purified from serum. FH was 
captured on a FH 402Y (MBI6) specific immunoaffinity column and eluted. The purified 
protein from serum was then used to determine the effect of the loss of the C-terminal 
recognition domain on decay and co-factor activity on the surface of sheep erythrocytes. 
A number of different methods have been described for the purification of FH from serum 
(Table 52). The earliest methods involved polyethylene glycol 8000 precipitation, dissolution 
in PBS followed by multiple purification steps including heparin affinity, ion exchange 
followed by a final gel-filtration step. 
More recently, immunoaffinity chromatography using a number of different monoclonal 
antibodies has been described. Antibodies specific to FH can be used to bind FH from serum 
and then eluted. The eluted FH would be a mixture of wildtype and mutant forms unless a 
variant was inherited in homozygosity or in the case of Sanchez-Corral et al, the V1197A 
variant was inherited with a type 1 mutation (Sanchez-Corral et al., 2002). Given that most 
rare variants in CFH are inherited in heterozygosity, a method to separate wildtype from 
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mutant is required. The technique chosen by me in this chapter and that of others is to use an 
antibody specific to either form of the common polymorphism Y402H. One novel 
purification strategy that has been described involved the use of a purification column that 
binds albumin, exploiting the binding of the R1210C to albumin. 
Variant He/Ho Purification technique Reference 
I62V Ho Multi-step (Tortajada et al., 2009) 
DelK224 Ho Multi-step (Licht et al., 2006) 
Y402H He MBI6 and MBI7 (Francis et al., 2012) 
S890I He MBI7 (Tortajada et al., 2012) 
V1007L He MBI7 (Tortajada et al., 2012) 
E1172X He Multi-step (Manuelian et al., 2003) 
W1183L He1 Multi-step (Sanchez-Corral et al., 2002) 
V1197A He2 Anti-FH antibody column (Sanchez-Corral et al., 2002) 
R1210C He Anti-FH3 (Sanchez-Corral et al., 2002) 
R1210C He Anti-FH3 (Recalde et al., 2015) 
Table 52 Purification techniques to purify FH from serum reported in functional studies 
Variants were inherited in heterozygosity (He) or homozygosity (Ho) and purified for functional studies by a number of 
different techniques. 1the purified protein was a mixture of wildtype and mutant protein. 2 due to the other allele being null, 
the purified protein was of the V1197A only, 3further purification of the R1210C mutant protein covalently linked to albumin 
was performed by using an albumin-binding purification column. 
 
Theoretically, other purification methods could be tried to separate a mutant protein from 
wildtype. The effect on a mutant protein might be altered ligand binding. If heparin binding is 
affected, a heparin-affinity column could be used. Alternatively, an individual amino acid 
substitution may lead to a sufficient change in electrostatic properties that ion exchange could 
separate two variants. Finally, the generation of additional high-specificity monoclonal 
antibodies against other common polymorphisms such as I62V or even the disease-associated 
variant itself may ultimately separate a wildtype and mutant protein.  
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6.4.3 Limitations of Study 
My studies of 1 rare genetic variant in the N-terminal domain and 2 rare genetic variants in 
the C-terminal domain of CFH in the setting of a recombinantly expressed full length FH 
protein confirmed the previous observations from studies using short FH fragments. This 
suggests that data from previous demonstrating loss of function in short FH fragments can be 
extrapolated to a full length protein. Additional studies of mutant proteins in full length FH 
will strengthen this association and could include the use of FH purified from serum. Direct 
comparisons of mutant full length FH proteins from serum and recombinant expression 
should be performed to exclude the possibility that recombinant proteins, in Pichia may have 
additional modifications such as glycosylation that may confound results. 
The use of FH purified from patient serum also allele specific quantification if the patient is 
heterozygous for the Y402H polymorphism (Hakobyan et al., 2010). Modifications to the 
protein from serum, such as the binding of R1210C mutant to albumin can also be 
demonstrated. However, obtaining purified protein from serum does require access to 
patients, is invasive, and if in a child, presents as an additional ethical choice to ensure 
sufficient serum for preparation. 
 
6.4.4 Future Studies 
Studies of rare genetic variants that are not within the N-terminal and C-terminal domains of 
CFH are limited (Table 53). The polymorphic variants Y402H (Francis et al., 2012) and 
S890I/V1007L (Tortajada et al., 2012) were purified to homogeneity for functional studies 
that demonstrated no differences in complement regulatory function. Most recently, serum 
from patients carrying the variants Q950H and T956M were used in haemolysis assays 
(Szarvas et al., 2016). A loss of regulatory effect was detected for the Q950H variant, and 
confirmed in studies using both patient’s serum and recombinant full length FH (Mohlin et 
al., 2015). 
The functional testing and purification techniques described and discussed in this chapter are 
applicable to the study of MPGN and C3G-associated rare genetic variants that are not in the 
N- or C-terminal domains of CFH that were identified at the beginning of Chapter 5. Future 
functional studies using full length protein, both recombinantly expressed and purified from 
patient samples will improve the understanding of the role of FH in MPGN and C3G. 
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Variant SCR Recombinant 
FH 
Patient 
FH 
C3b/d 
binding 
Heparin 
binding 
Co-factor Decay Endothelial 
Cell Binding 
Haemolysis 
Assay 
Reference 
Y402H 7 SCR 6-8 Purified ↓1 ↓1 ND ↔2 ND ↔2, 3 
(Clark et al, 2006; Herbert et al., 2007; 
Francis et al., 2012) 
S772X 13 N Serum4 ND ND ND ND ND ↔5 (Szarvas et al., 2016) 
S890I 15 N Purified ↔ ND ↔ ND ND ↔6 (Tortajada et al., 2012) 
Q950H 16 SCR 1-20  Serum ND ND ↓ ND ND ↓ (Mohlin et al., 2015; Szarvas et al., 2016)  
T956M 16 N Serum ND ND ND ND ND ↔ (Szarvas et al., 2016) 
V1007L 17 N Purified ↔ ND ↔ ND ND ↔6 (Tortajada et al., 2012) 
Table 53 Studies of CFH variants not in the N- or C-terminal domains 
Functional testing of recombinant FH, FH from patient serum and FH purified from patient serum. Tests used in the studies of N- and C-terminal domain variants are summarised in this table. 
1in setting of SCR6-8, 2in setting of purified protein, 3as described in (Tortajada et al., 2009) 4low serum FH levels, 5as described by (Sanchez-Corral et al., 2004), 6Lysis initiated by serum from 
W1183L patient. 
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6.5 Summary 
Functional studies of rare genetic variants in CFH are important to determine their 
importance in disease. A high proportion of studies, especially those of variants in the N-
terminal domain are in the setting of short FH fragments. Whilst these studies have 
demonstrated clear differences in function, extrapolation of these effects to a full length 
protein is required. 
Rare genetic variants in CFH that been previously studied in short fragments of FH were 
expressed recombinantly in full length FH. Experiments to test the effect of 1 mutant protein 
with an abnormal N-terminal domain and 2 mutant proteins with an abnormal C-terminal 
domain were performed on the surface of sheep erythrocytes. These experiments identified 
functional defects in complement regulation. These findings correlate with previous studies 
using short FH fragments. 
The study of mutant FH proteins was extended to a novel hybrid FH/FHR3 protein identified 
in case of aHUS. In this study, mutant protein was purified directly from serum and 
functional defects were also demonstrated. 
Expression of recombinant mutant FH proteins and purification of mutant FH proteins from 
patient serum can be used for the future study of other MPGN/C3G-associated rare genetic 
variants in CFH. This will improve the understanding of the role of FH in MPGN/C3G. 
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Chapter 7 Discussion 
I had several main aims in this thesis. 
1. Identification of acquired and genetic abnormalities of AP in two cohorts of 
MPGN/C3G. 
2. Solving a long-standing conundrum in a case of familial MPGN. 
3. Determining the range of functional effects of rare genetic variants in the N-terminal 
domain of CFH in MPGN/C3G. 
4. Functional studies of rare genetic variants in full length FH to confirm the findings of 
previous functional studies performed in the regulatory domain of FH. 
7.1 Identification of Acquired and Genetic Abnormalities of AP in MPGN/C3G 
In this thesis, I have described a prospective and a retrospective cohort of patients with 
MPGN/C3G. Screening for rare genetic variants in C3, CFB, CFH, CFI and CD46 in these 
cohorts revealed a low prevalence of genetic abnormalities (8.2% - 17.9%). Compared to the 
prevalence rate of C3 nephritic factor identified in this prospective cohort, and the prevalence 
rate of other autoantibodies identified in both the prospective and retrospective cohorts, it is 
clear that the predominant abnormalities in these cohorts are acquired, suggesting that 
MPGN/C3G is largely an autoimmune phenomenon, comparable with previous cohorts with 
data on both acquired and genetic abnormalities (Servais et al., 2012; Iatropoulos et al., 
2016). 
 
7.2 Functional Studies of Rare Genetic Variants in CFH 
Whilst the prevalence of rare genetic variants in C3, CFH, CFH, CFI and CD46 identified in 
my cohorts of MPGN/C3G was low, one genetic variant was of particular interest as it 
associated with a case of familial MPGN. The variant R83S in the N-terminal region of CFH 
segregated with all family members with the renal phenotype. Functional studies using short 
recombinant fragments of FH comprising the N-terminal domains of FH confirmed that the 
mutant protein expressed resulted in complete loss of regulatory function and solved a long 
standing conundrum in the field of complement-mediated renal disease. 
I then reviewed all 43 rare genetic variants in MPGN/C3G identified in the literature and 
showed that many were functionally significant, including 17 that resulted in low FH levels 
and 4 (including my study of R83S) that resulted in a functionally defective mutant protein. 
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These abnormalities were all in keeping with the paradigm of the importance of fluid phase 
activation of complement in these diseases. I therefore undertook functional studies to 
confirm the significance of variants that had not been studied. 
I characterised a further 8 disease-associated rare genetic variants that had been identified in 
the N-terminal domain of CFH, of which 3 had been described in MPGN/C3G. The other 5 
had been described in aHUS and AMD, two other diseases that share complement risk factors 
with MPGN/C3G. It was evident that the functional effects of these genetic variants could be 
divided into two categories, those that resulted in complete loss of function, and those that do 
not. Initial interpretation of the results of these studies using short fragments of FH in the 
clinical context suggests that only those with complete loss of regulatory function can 
definitively be considered pathogenic. 
The variants that resulted in complete loss of function were not exclusively in MPGN/C3G. 
Of the two variants that resulted in complete loss of function, one (Q81P) was in a case of 
aHUS and the other (R53C) was found in cases of MPGN/C3G, aHUS and AMD. Functional 
studies of variants in CFH are therefore important in all of these diseases that share 
complement risk factors. Small effects on regulatory function were observed in the remaining 
variants, though in contrast to those that resulted in complete loss of function, the functional 
significance of these remains uncertain and their role in disease pathogenicity on their own is 
unlikely. 
Many of the functional studies in both MPGN/C3G and aHUS previously reported used short 
fragments of recombinantly expressed FH. A functional effect for many of these variants has 
been identified from functional studies including those of my own. To confirm that these 
effects can be extrapolated to full length protein, I used recombinantly expressed full length 
mutant proteins. 
In these studies, I demonstrated that the variant, R53H, in the N-terminal domain of FH, had 
complete loss of decay activity (and some loss of co-factor activity) therefore confirming the 
previous findings from studies of R53H in short fragments of FH (Pechtl et al., 2011). I also 
demonstrated that the variants, D1119G and S1191L/V1197A, in the C-terminal domain of 
FH had impairment of cell surface complement regulation by both decay and co-factor 
activity, again confirming the previous findings that both had impairment of cell surface 
complement regulatory activity (Ferreira et al., 2009). 
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The study of full length mutant FH proteins was extended to include a novel hybrid 
FH/FHR3 protein identified in case of aHUS. In this study, mutant protein was purified 
directly from serum and functional defects were also demonstrated. 
7.3 Future studies 
Further studies are required to improve our understanding of MPGN/C3G. These studies 
should include the following. 
 Longitudinal follow up of both MPGN/C3G cohorts to determine correlations of 
clinical outcomes with complement abnormalities. 
 Given that MPGN/C3G is largely an autoimmune phenomena, characterisation of 
these abnormalities, especially C3 nephritic factor and autoantibodies to FH in a large 
prospective cohort is required. 
 Functional studies of rare genetic variants in C3 and CFB  
 Functional studies of rare genetic variants in CFH - Studies that follow on directly 
from the work described in this thesis would involve the study of rare genetic variants 
that are not within the N- or C-terminal domains. Unlike those in the N- and C-
terminal functional domains, these variants have not been extensively studied. These 
could be performed using full length mutant proteins, either expressed recombinantly 
or purified from serum. 
7.4 Summary 
Work in this thesis has identified a large number of abnormalities of AP, both acquired and 
genetic in two cohorts of MPGN/C3G. The majority of these are acquired and supportive of 
MPGN/C3G as largely an autoimmune phenomenon. Rare genetic variants, though 
individually fewer were not insignificant as demonstrated in the functional studies of mutant 
proteins that abolish regulatory function due to variants in the N-terminal domain of CFH. 
However, not all such variants lead to complete loss of function thus highlighting the 
importance of functional studies. Furthermore, previous studies performed in short fragments 
of FH describing both N- and C-terminal variants in CFH have been replicated in studies 
using full length protein. 
In summary, the significance of rare genetic variants in CFH needs to be considered even in a 
cohort in which autoimmune abnormalities predominate. Future work to determine the 
functional and clinical significance of a larger number of acquired and genetic complement 
abnormalities of AP in MPGN/C3G is required.  
 202 
 
Chapter 8 Appendices 
8.1 Appendix 1 – Primers and DNA sequences 
Variant Forward Primer Reverse Primer 
R53C cccaggctatctataaatgcTgccctggatatagatctcttgg ccaagagatctatatccagggcAgcatttatagatagcctggg 
G69E ggtatgcaggaaggAagaatgggttgctcttaatccattaagg ccttaatggattaagagcaacccattctTccttcctgcatacc 
Q81P ggaaatgtcCgaaaaggccctgtgg ccacagggccttttcGgacatttcc 
R83S 
gggttgctcttaatccattaaggaaatgtcagaaaagTccctgtggaca
tcctggagatactcc 
ggagtatctccaggatgtccacagggActtttctgacatttccttaatgg
attaagagcaaccc 
D90G ggccctgtggacatcctggaggtactccttttggtacttttaccc gggtaaaagtaccaaaaggagtacctccaggatgtccacagggcc 
DelE122-G128 gtaatgaggggtatcaattgctatgtgacacagatggatggacc ggtccatccatctgtgtcacatagcaattgatacccctcattac 
D130N ggtgagattaattaccgtgaatgtAacacagatggatggacc ggtccatccatctgtgtTacattcacggtaattaatctcacc 
S159N N/A1 N/A 
A161S ggaaaaattgtcagtagtTcaatggaaccagatcggg cccgatctggttccattgAactactgacaatttttcc 
M162V cagtagtgcaGtggaaccagatcggg cccgatctggttccaCtgcactactg 
Table 54 Primers for site-directed mutagenesis 
Mutagenesis primers were HPLC-purified from Integrated DNA Technologies. The mutated base pair has been capitalised. 
1A clone of FH SCR1-4 in E.coli with the S159N mutation was a gift from Professor Alan Wright, University of Edinburgh. 
 
 Primer 
Forward cgggttattgtttataaatac 
Reverse gtcgacggcgctattcagatcctc 
Table 55 Primers for sequencing pPICZαB 
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8.2 Appendix 2 – Reagents 
Stock solutions 
10X YNB (13.4% yeast nitrogen base with ammonium sulphate without amino acids) 
134g of yeast nitrogen base (YNB) with ammonium sulphate and without amino acids was 
dissolved in 1000 mL of dH2O. Once completely dissolved, the solution was filter sterilised 
using a 0.22μm filter and stored at 4°C. 
 
500X B (0.02% Biotin) 
20mg biotin was dissolved in 100 mL of dH2O. Once completely dissolved, the solution was 
filter sterilised using a 0.22μm filter and stored at 4°C. 
 
10X D (20% Dextrose) 
200g of D-glucose was dissolved in 1000mL of dH2O. Once completely dissolved, the 
solution was filter sterilised using a 0.22μm filter and stored at 4°C. 
 
10X Methanol (5% methanol) 
50ml of methanol was diluted to a final volume of 1000ml of dH2O. The solution was filter 
sterilised using a 0.22μm filter and stored at 4°C. 
 
10X Glycerol (10% glycerol) 
100mL of glycerol was diluted to a final volume of 1000ml of dH2O. The solution was 
sterilised by autoclave and stored at 25°C. 
 
1 M potassium phosphate buffer, pH 6.0 
132mL of 1M K2HPO4 and 868 mL of 1M KH2PO4 were prepared and added together. The 
pH of the final solution was adjusted to 6.0 using phosphoric acid or KOH The solution was 
sterilised by autoclave and stored at 25°C. 
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YPD (Yeast Extract Peptone Dextrose Medium) 
10g yeast extract and 20g of peptone were dissolved in 900mL of dH2O. 20g of agar was 
added for making YPD agar plates. The solution was autoclaved for 20 minutes on liquid 
cycle. After autoclaving, 100mL of 10X D was added. The liquid medium was stored at room 
temperature. Prior to pouring into plates, YPD agar was allowed to cool to ~55°C before 
Zeocin™ was added at the required concentration. The YPD agar plates were stored at 4°C. 
 
LB (Luria-Bertani) medium  
10g tryptone, 5g yeast extract and 10g NaCl were added to 1000ml of dH2O. 15g of agar was 
added for making LB agar plates. The solution was autoclaved for 20 minutes on liquid cycle 
LB medium or agar was allowed to cool to ~55°C before Zeocin™ was added at the required 
concentration. The medium was stored at room temperature and LB agar plates stored at 4°C. 
For low salt LB, 5g instead of 10g NaCl was used. 
 
Buffered Minimal Glycerol (BMG) or Buffered Minimal Methanol (BMM) 
700mL of dH2O containing 1% casamino acids powder (Fisher Chemical) was autoclaved for 
20 minutes on liquid cycle. The solution was made up to 1L by the addition of 100 mL 1M 
potassium phosphate buffer, pH 6.0, 100mL 10X YNB, 2mL 500X B and 100mL 10X 
glycerol. For BMM, 100 mL 10X methanol was added instead of glycerol. The media was 
stored at 4°C. 
 
BMG and BMM containing 15N-ammonium sulphate as sole nitrogen source 
BMG and BMM were prepared from alternative 10X stock solution by dissolving 34g of 
YNB without ammonium sulphate and amino acids in 1000 mL of dH2O. Once completely 
dissolved, the solution was filter sterilised using a 0.22μm filter and stored at 4°C. From this, 
a 1X YNB without ammonium sulphate and amino acids solution was prepared, and 
supplemented with 2g of 15N-ammonium sulphate (Isotec) per litre of BMG required and 1g 
of 15N-ammonium sulphate (Isotec) per litre of BMM required. 
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Fermentation Basal Salt medium 
26.7ml of 85% phosphoric acid, 0.93g calcium sulphate, 18.2g potassium sulphate, 14.9g 
magnesium sulphate-7H2O, 4.13g potassium hydroxide, 25ml 100% glycerol and 10g of 
casamino acids powder were added to a final volume of 1L dH2O per litre of media required. 
 
PTM1 Trace Salts 
PTM1 Trace Salts (Sunrise Science Products) comprising 6.0g cupric sulphate-5H2O, 0.08g 
sodium iodide 3.0g manganese sulphate-H2O, 0.2g sodium molybdate-2H2O 0.02g boric 
Acid, 0.5g cobalt chloride, 20.0g zinc chloride, 65.0g ferrous sulphate-7H2O and 0.2g biotin 
were dissolved in 5.0ml of sulphuric acid and dH2O to a final of volume of 1L. Once 
completely dissolved, the solution was filter sterilised using a 0.22μm filter and stored at 
room temperature. 
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8.3 Appendix 3 - SDS-PAGE and Western Blotting 
Molecular weight marker Manufacturer 
PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa ThermoFisher Scientific 
Prestained Protein Marker, Broad Range (7-175 kDa) New England Biolabs Inc® 
Precision Plus Protein™ Dual Color Standards Biorad 
Table 56 Molecular weight markers for SDS-PAGE 
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Protein target FH SCR1-41 FH2 FH2 FB2 α- and β-chain of C3b3 
Size 30kDa 150kDa 150kDa 90kDa 40-110kDa 
System Biorad Novex Novex Novex Biorad 
Gel percentage 4-15% 6% 6% 6% 10% 
Serum dilution N/A 1:100 1:100 1:100 N/A 
Reduced or non-reduced Non-reduced Non-reduced Non-reduced Non-reduced Reduced 
Primary Antibody 
Polyclonal Goat anti-FH 
(Calbiochem) 
Polyclonal Goat anti-FH 
(Calbiochem) 
MBI6/ MBI7 Monoclonal 
Mouse anti-402Y or H in 
SCR7 of FH (Gift from 
Professor Claire Harris, 
Cardiff University) 
Polyclonal Goat anti-
FB (R and D Systems) 
Polyclonal Rabbit Anti-
C3 (Abcam) 
Concentration 1:14000 1:14000 1:2000 1:2000 1:5000 
Secondary Antibody 
Rabbit anti-Goat HRP 
(Calbiochem) 
Rabbit anti-Goat HRP 
(Calbiochem) 
Sheep anti-mouse IgG 
HRP (Jackson Immuno 
Research) 
Rabbit anti-Goat HRP 
(Calbiochem) 
Goat anti-Rabbit HRP 
(Abcam) 
Concentration 1:3000 1:3000 1:4000 1:3000 1:5000 
Table 57 Antibodies used to detect purified protein by Western blotting 
Specific experiemental conditions for Western blotting are shown. 1FH SCR1-4 was recombinantly expressed. 2FH and FB were deteted in serum. 3α- and β-chain of C3b detected following 
fluid-phase co-factor assay. N/A = not applicable, HRP = horse radish peroxidase. 
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8.4 Appendix 4 – Extinction Co-efficient of Proteins 
Protein Extinction co-efficient (M-1 cm-1) 
FH SCR1-4 47870 
FH 246800 
FH/FHR3 hybrid 272170 
Table 58 Extinction co-efficient to determine protein concentration from A280 
Extinction co-efficient calculated based upon amino acid sequence inputted into http://web.expasy.org/protparam/ - 
translate tool. Calculation of molar concentration of protein based upon formula of absorbance at 280nm (A280)/extinction 
co-efficient. 
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8.5 Appendix 5 – SNP Analysis in RaDaR Cohort 
  C/C C/G G/G Frequency of variant allele (G) Odds Ratio (95% CI) P (vs control) 
C3 All 40 27 5 0.257 1.28 (0.87-1.85) 0.22 
c.304C>G Ig-GN 7 1 0 0.067 0.24 (0.03-1.85) 0.17 
p. R102G Ig-MPGN 15 10 4 0.310 1.64 (0.94-2.88) 0.07 
rs2230199 DDD 2 10 1 0.462 3.14 (1.45-6.8) 0.004 
 C3GN 16 6 0 0.136 0.57 (0.24-1.37 0.21 
 Control1 2670 1459 171 0.209 
  
  C/C C/T T/T Frequency of variant allele (T) Odds Ratio (95% CI) P (vs control) 
C3 All 38 29 5 0.271 1.44 (1.00-2.09) 0.05 
c.941C>T Ig-GN 7 1 0 0.063 0.25 (0.03-1.96) 0.19 
p.P314L Ig-MPGN 16 11 2 0.259 1.36 (0.75-2.45) 0.31 
rs1047286 DDD 4 8 1 0.385 2.43 (1.10-5.36) 0.03 
 C3GN 11 9 2 0.295 1.63 (0.85-3.12) 0.14 
 Control1 2702 1436 162 0.205 
  
  C/C C/T T/T Frequency of variant allele (T) Odds Ratio (95% CI) P (vs control) 
CFB All 65 5 1 0.049 0.47 (0.22-1.03) 0.06 
c.94C>T Ig-GN 8 0 0 0.000 0.28 (0.02-4.66) 0.37 
p.R32W Ig-MPGN 27 2 0 0.034 0.33 (0.08-1.35) 0.12 
rs641153 DDD 10 1 1 0.125 1.32 (0.39-4.43) 0.66 
 C3GN 20 2 0 0.045 0.44 (0.11-1.82) 0.26 
 Control1 2206 476 27 0.098 
  
  G/G G/A A/A Frequency of variant allele (A) Odds Ratio (95% CI) P (vs control) 
CFB All 65 5 0 0.036 0.39 (0.16-0.95) 0.04 
c.95G>A Ig-GN 7 1 0 0.063 0.70 (0.09-5.34) 0.73 
p.R32Q Ig-MPGN 28 0 0 0.000 0.09 (0.01-1.51) 0.10 
rs12614 DDD 11 1 0 0.045 0.46 (0.06-3.41) 0.45 
 C3GN 19 3 0 0.107 1.27 (0.38-4.21) 0.70 
 Control1 2260 429 20 0.087 
  
  C/C C/T T/T Frequency of variant allele (T) Odds Ratio (95% CI) P (vs control) 
CFH All 25 21 7 0.330 1.22 (0.73-2.04) 0.45 
c.-331C>T Ig-GN 2 4 1 0.429 1.85 (0.61-5.60) 0.27 
 Ig-MPGN 7 11 5 0.457 2.08 (1.07-4.03) 0.03 
rs3753394 DDD 4 2 0 0.167 0.49 (0.10-2.33) 0.37 
 C3GN 12 4 1 0.132 0.46 (0.18-1.17 0.10 
 Control2 44 43 5 0.288 
  
  
 
2
1
0
 
  G/G G/A A/A Frequency of variant allele (A) Odds Ratio (95% CI) P (vs control) 
CFH All 49 20 3 0.186 0.80 (0.52-1.23) 0.31 
c.184G>A Ig-GN 4 3 1 0.313 1.59 (0.55-4.59) 0.39 
p.V62I Ig-MPGN 22 7 0 0.121 0.48 (0.22-1.06) 0.07 
rs800292 DDD 9 4 0 0.154 0.64 (0.22-1.85) 0.41 
 C3GN 14 6 2 0.227 1.03 (0.51-2.09) 0.93 
 Control1 2601 1489 210 0.222 
  
  T/T T/C C/C Frequency of variant allele (C) Odds Ratio (95% CI) P (vs control) 
CFH All 18 39 15 0.090 0.47 (0.26-0.85) 0.01 
c.1204T>C Ig-GN 5 3 0 0.188 0.37 (0.11-1.31) 0.12 
p.Y402H Ig-MPGN 5 18 6 0.517 1.73 (1.03-2.90) 0.03 
rs1061170 DDD 3 7 3 0.500 1.62 (0.75-3.49) 0.22 
 C3GN 5 11 6 0.523 1.77 (0.98-3.20) 0.06 
 Control1 1649 2014 637 0.382 
  
  A/A A/G G/G Frequency of variant allele (G) Odds Ratio (95% CI) P (vs control) 
CD46  All 10 18 10 0.500 1.62 (0.92-2.83) 0.09 
c.-652A>G Ig-GN 2 2 1 0.400 1.08 (0.29-3.99) 0.91 
 Ig-MPGN 0 11 5 0.656 3.09 (1.39-6.88) 0.006 
rs2796267 DDD 2 2 1 0.400 1.08 (0.29-3.99) 0.91 
 C3GN 6 3 3 0.375 0.97 (0.40-2.37) 0.95 
 Control2 30 34 12 0.382   
  A/A A/G G/G Frequency of variant allele (G) Odds Ratio (95% CI) P (vs control) 
CD46  All 11 21 6 0.434 1.31 (0.75-2.29) 0.34 
c.-366 A>G Ig-GN 2 2 1 0.400 1.14 (0.31-4.21) 0.84 
 Ig-MPGN 2 12 2 0.500 1.71 (0.80-3.67) 0.17 
rs2796268 DDD 2 2 1 0.400 1.14 (0.31-4.21) 0.84 
 C3GN 5 5 2 0.375 1.03 (0.42-2.49 0.16 
 Control 33 35 12 0.369 
  
  T/T T/C C/C Frequency of variant allele (C) Odds Ratio (95% CI) P (vs control) 
CD46  All 17 30 7 0.315 0.94 (0.58-1.51) 0.79 
c.*4070T>C Ig-GN 3 3 1 0.357 0.76 (0.24-2.34) 0.63 
 Ig-MPGN 6 15 2 0.413 0.96 (0.50-1.84) 0.90 
rs7144 DDD 2 4 2 0.500 1.36 (0.49-3.78 0.55 
 C3GN 6 8 2 0.375 0.81 (0.38-1.76 0.61 
 Control2 36 41 21 0.423 
  
Table 59 Association of common SNPs with MPGN and C3G 
In an analysis of 10 SNPs, statistical significance taken as P<0.005. Control data from 1European American population of evs.gs.washington.edu/, or 2(Fremeaux-Bacchi et al., 2005). 
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8.6 Appendix 6 – Less Common Polymorphisms in RaDaR cohort 
Disease Gene Variant Frequency1 
C3GN 
CD46 
CFB 
A353V 
K565E 
1.7% 
1.6% 
IC-MPGN CFB L9H 4.2% 
C3GN CFB L9H 4.2% 
IC-MPGN CFB G252S 3.9% 
DDD CFB G252S 3.9% 
IC-MPGN CD46 A353V 1.7% 
IC-MPGN CFB K565E 1.6% 
IC-MPGN CFB K565E 1.6% 
C3GN CFB K565E 1.6% 
Table 60 Polymorphisms reported at 1-5% of control cohort 
Genetic variants in C3, CFB, CFH, CFI and CD46 identified in RaDaR cohort with 1frequency of 1-5% as reported in 
European American population of evs.gs.washington.edu/. 
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8.7 Appendix 7 – Lipodystrophy Genes 
Gene Name Symbol Reference 
Partial lipodystrophies associated genes 
Lamin A/C LMNA (Cao and Hegele, 2000) 
Peroxisome proliferator-activated receptors γ  PPARG (Hegele et al., 2002) 
Zinc metalloproteinase STE24  ZMPSTE24 (Agarwal et al., 2003) 
Perilipin  PLIN1 (Gandotra et al., 2011) 
Nuclear lamina protein lamin B2  LMNB2 (Hegele et al., 2006) 
Protease subunit, beta type 8  PSMB8 (Agarwal et al., 2010) 
Total lipodystrophy associated genes 
Seipin  BSCL2 (Magre et al., 2001) 
Lysophosphatidic acid acyltransferase  AGPAT2 (Agarwal et al., 2002) 
Caveolin1  CAV1 (Kim et al., 2008) 
Polymerase I and transcript release factor  PTRF (Hayashi et al., 2009) 
Table 61 Lipodystrophy-associated genes 
Taken from (Wong et al., 2014). The genes listed above have been associated with partial and complete lipodystrophies. 
Whole exome sequencing was performed to screen these genes however no genetic variants were identified which segregated 
with lipodystrophy in the family. 
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8.8 Appendix 8 – Rare Genetic Variants in CFH in MPGN and C3G 
Variant SCR Disease He/Ho Type1 or 2 Reference 
P26S  1 C3GN He 2 Unpublished, Newcastle 
R53C 1 C3GN He 2 (Servais et al., 2012) 
R53C 1 MPGN Ho 2 (Servais et al., 2012) 
R53C 1 MPGN1 He 2 (Janssen van Doorn et al., 2013) 
P76X 1 C3GN He 1 (Servais et al., 2007) 
L77X 1 C3GN He 1 (Servais et al., 2012) 
R78G 1 C3GN Ho 2 (Iatropoulos et al., 2016) 
R83S2 1 MPGN He 2 (Wong et al., 2014) 
P88T 2 MPGN Ho 13 (Alfandary and Davidovits, 2015; Iatropoulos et al., 2016) 
DelG122-E128 2 C3GN He 2 (Servais et al., 2012) 
R127L 2 MPGN Ho 13 (Dragon-Durey et al., 2004) 
R127C 2 C3GN He NK (Iatropoulos et al., 2016) 
D130N 2 C3GN He 2 (Servais et al., 2012) 
V143I 2 DDD He 1 (Servais et al., 2012) 
A161S 3 DDD He 2 (Servais et al., 2012) 
IVS 11+54 N/A C3GN He 2 (Servais et al., 2012) 
S199G / E1172X  4/20 DDD He5 NK Unpublished, Newcastle 
I216T 4 MPGN1 He 1 (Gnappi et al., 2012) 
DelK2242 4 C3GN Ho 2 (Licht et al., 2006) 
R232X  4 C3GN He 1 Unpublished, Newcastle 
R232X 4 DDD He 1 (Servais et al., 2012) 
G334A  6 MPGN He 2 Unpublished, RaDaR 
C431S  7 C3GN He 16  Unpublished, Newcastle 
C431S 7 DDD Ho 13 (Dragon-Durey et al., 2004; Servais et al., 2012) 
N516K 9 DDD He NK (Zhang et al., 2012) 
C597R 10 C3GN Ho 13 (Servais et al., 2012) 
  
 
2
1
4
 
C597R 10 MPGN1 Ho 13 (Servais et al., 2012) 
V609I  10 MPGN He NK Unpublished, Newcastle 
V609I  10 C3GN He NK Unpublished, Newcastle 
P621Y 10 MPGN1 Ho 12 (Vaziri-Sani et al., 2006)- 
G650V 11 C3GN He 2 (Servais et al., 2007) 
G650V  11 MPGN He 2 Unpublished, RaDaR 
C673R 11 DDD He 1 (Servais et al., 2012) 
C673S 11 MPGN Ho 13 (Dragon-Durey et al., 2004) 
F717L2 12 MPGN He 2 (Servais et al., 2012) 
M725X 12 C3GN He NK (Sethi et al., 2012a) 
N767KfsX 13 aHUS7 He 1 (Boyer et al., 2008) 
V837I / E1145D 14/19 DDD He5 NK (Zhang et al., 2012) 
H878Y 15 MPGN He 2 Unpublished, Newcastle 
A892V 15 MPGN He 2 Unpublished, RaDaR 
Y899X 15 aHUS7 Ho 1 (Boyer et al., 2008) 
Q950H 16 C3GN He NK (Iatropoulos et al., 2016) 
T956M 16 DDD He NK (Zhang et al., 2012) 
T956M 16 MPGN He NK (Sethi et al., 2011) 
T956M 16 C3GN He NK (Iatropoulos et al., 2016) 
Y1008X 17 C3GN Ho 13 (Iatropoulos et al., 2016) 
C1043S 17 MPGN1 He 1 (Servais et al., 2012) 
W1096R2 18 DDD Ho 13 Unpublished, Newcastle 
R1210V 20 C3GN He 2 (Servais et al., 2012) 
R1210C 20 C3GN He 2 (Servais et al., 2007) 
R1210C 20 DDD He NK (Iatropoulos et al., 2016) 
Table 62 Rare genetic variants in CFH in cases of MPGN/C3G 
Rare genetic variants in CFH identified in cases of MPGN/C3G from literature and cohort studies described in this thesis. The rare genetic variants in CFH for individual patients or pedigrees 
identified are represented in Figure 79. SCR = short consensus repeat, He = heterozygous, Ho = homozygous, NK= not known, N/A = not applicable.. 1Later developed aHUS, 2Familial, 
3Complete FH deficiency,4IVS11+5 = splice change, 5Could be compound heterozygous,6Known type 1 mutation, but normal FH levels in this case, 7Later developed C3GN in transplant. 
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8.9 Appendix 9 – Rare Genetic Variants in N-terminal Domain of CFH in aHUS 
Variant SCR Disease Type Reference 
R28Ifs5X 1 aHUS 1 (Warwicker et al., 1998) 
T30Nfs10X 1 aHUS1 1 (Bresin et al., 2013) 
I32X 1 aHUS 1 (Kavanagh et al., 2013) 
R53H 1 aHUS 2 (Pechtl et al., 2011) Unpublished, Zipfel 
R53S 1 aHUS U (Rodriguez de Cordoba et al., 2014) 
R53C 1 aHUS1 2 (Fakhouri et al., 2010b) 
S58A 1 aHUS U (Rodriguez de Cordoba et al., 2014) 
W71R 1 aHUS 2 Unpublished, Newcastle 
R78G 1 aHUS 2 (Pechtl et al., 2011) (Noris et al., 2010) 
Q81P 1 aHUS1 2 (Fakhouri et al., 2010b) 
V111E 2 aHUS U (Bresin et al., 2013) 
Y118IfsX4 2 aHUS 1 (Bresin et al., 2013) 
I124Mfs12X 2 aHUS 1 (Dragon-Durey et al., 2004) 
R127H 2 aHUS 1 (Falcao et al., 2008) 
W134R 2 aHUS U (Bresin et al., 2013) 
P139S 2 aHUS U (Factor H HUS Mutation Database, 2016) 
S159N 3 aHUS 2 Unpublished Newcastle cohort 
A161S 3 aHUS1 2 (Fakhouri et al., 2010b) 
A161S 3 aHUS 2 Unpublished, Newcastle 
A161S 3 aHUS 2 (Loirat and Fremeaux-Bacchi, 2011) 
M162V 3 aHUS 2 (Fremeaux-Bacchi et al., 2013) 
R166L 3 aHUS U (Chaudhary et al., 2014) 
W198$ 3 aHUS 2 (Szarvas et al., 2016) 
G218E 4 aHUS1 1 (Fakhouri et al., 2010b) 
R232X 4 aHUS 1 Unpublished, Newcastle 
Y235S 4 aHUS U (Rodriguez de Cordoba et al., 2014) 
C247G 4 aHUS U (Factor H HUS Mutation Database, 2016) 
P258L 4 aHUS 1 (Rodriguez de Cordoba et al., 2014) 
Table 63 Rare genetic variants in N-terminal domain of CFH in aHUS 
Rare genetic variants in N-terminal domain of CFH in aHUS identified in literature and unpubilshed from Newcastle 
Complement Genetics cohort. Type = Type 1 or Type 2 mutation, U = unknown. 1Pregnancy-associated. 
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8.10 Appendix 10 – Rare Genetic Variants in N-terminal Domain of CFH in AMD 
Variant SCR Variant SCR 
p.L3V1 1 p.R166W 3 
p.P26S 1 p.R166Q 3 
p.T46A 1 p.E167Q 3 
p.R53C4 1 p.A173G1 3 
p.R53H 1 p.R175Q1 3 
p.S58A 1 p.R175P 3 
p.G69E2 1 p.C192F 3 
p.D90G3 2 p.S193L1 3 
p.T91S 2 p.W198X 3 
p.R127H 2 p.V206M 3 
p.C129Y 2 p.I216T1 4 
p.D130N 2 p.G218X 4 
c.428-2A>G1 Splice acceptor  3 p.I221V 4 
p.S159N 3 p.R232Q 4 
p.A161S1 3 p.M239T 4 
Table 64 Rare genetic variants in N-terminal domain of CFH in AMD and Drusen 
Rare genetic variants in N-terminal domain of CFH in AMD identified in literature All cases reported in (Triebwasser et al., 
2015) unless indicated. Two additional splice site changes were also reported in (Triebwasser et al., 2015) within the N-
terminal domain of CFH.  1(Duvvari et al., 2015), 2(Raychaudhuri et al., 2011), 3(Yu et al., 2014), 4reported in both 
Triebwasser et al and Yu et al. SCR = short consensus repeat. 
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